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2 SUMMARY 
 
 
Expression of GDNF-Family ligands and their receptors by immune cells 
 
GDNF (Glial cell line-Derived Neurotrophic Factor) and NTN (Neurturin) are two of the 
four members of the GDNF family ligands (GFLs) and are potent survival and 
developmental factors for the kidney as well as the peripheral and central neurons. 
Persephin (PSP), a third family member, behaves only as survival factor for central 
neurons. 
GDNF and NTN signaling is mediated by a two-component receptor containing a ligand 
specific binding component, GFRα-1 (higher GDNF affinity) and GFRα-2 (higher NTN 
affinity) respectively, and the common signal transducing component, RET. PSP signals 
only through the binding to GFRα-4 and RET. 
The aim of this study was to investigate possible mutual interactions between the nervous 
and immune system mediated by GFLs and their receptors. 
While GDNF, the prototype of its family, was not expressed by any of the studied human 
immune cells, the related molecule NTN, was found to be expressed by T and B cells and 
monocytes as seen by RT-PCR, Western blot and immunocytochemistry. Additionally, 
PSP was found in peripheral blood mononuclear cells (PBMCs) by RT-PCR.  
The RET gene, expressed in all the studied immune cells, contains 21 exons and encodes a 
tyrosine kinase receptor. Multiple splice variants of this gene have been described. Various 
cell subsets were found to express distinct RET 3’ or 5’-isoforms. In T and B cells, the 
expression of the 3’-end RET isoforms, where CD4+ and CD8+-T lymphocytes show 
different expressions patterns, was regulated by cell activation.  
At the 5’-end however, a new isoform that lacks exon 5, resulted in a partial deletion of the 
receptor’s extracellular part. The latter was detected only in CD8+-T cells (non-activated 
and activated cells) and in non-activated B cells. Interestingly, monocytes expressed full 
length RET mRNA indicating their responsiveness to GFLs.  
Immune cells also expressed the GDNF and NTN binding components: named GFRα-1 
and GFRα-2. Whereas the GFRα-1 receptor was mostly detected on monocytes, GFRα-2 
was abundantly expressed on both, monocytes and lymphocytes. Several GFRα-2 isoforms 
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 6 
were detected in various cell types, the most abundant, which lack exons 2 and 3, was 
observed in T cells and monocytes. The predicted protein therefore loses its N-terminal 
cysteine-rich domain and one of the N-glycosylation sites, a region not critical for the 
binding of NTN and interaction with RET. 
Several experiments were performed to find out the functional effects NTN or GDNF 
might have on immune cells. The expression of the activation markers, HLA-DR, CD38, 
CD40, CD69, and CD86 was not modulated neither was the proliferation nor production of 
IL-4 and IFN-γ. However, TNF-α was found to be regulated by both NTN and GDNF: 
when GDNF or NTN was added to PBMCs five or six days after activation by LPS+IFN-γ 
or by ConA, a reduced amount of TNF-α was observed after 24 hours. Data from diverse 
experiments suggested that the decrease in TNF-α was due to an increased uptake or 
consumption rather than a reduced production. 
In summary, this study shows that all subsets of human immune cells express the 
ligand NTN, up-regulated after cell activation, and probably PSP mRNA, as well as the 
receptor GFRα-1 and predominantly GFRα-2 with protein upregulation seen upon cellular 
activation; that multiple isoforms of the signaling component RET were constitutively 
expressed and then regulated by cellular activation. Whether the transmembrane receptor 
levels differ upon activation remains unclear and as well as NTN and GDNF modulating 
the uptake and/or consumption of TNF-α. These findings suggest that immune cells 
communicate with each other and with the nervous system via GFLs. 
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ZUSAMMENFASSUNG 
 
 
GDNF (glial cell line-derived neurotrophic factor) und NTN (Neurturin), die zwei zuerst 
beschriebenen Liganden der GDNF-Familie, fungieren als Überlebens- und 
Entwicklungsfaktoren für definierte Populationen von zentralen und peripheren Neuronen. 
GDNF ist darüber hinaus für die Nierenentwicklung erforderlich. Für die Vermittlung ihrer 
biologischen Wirkung benutzten GDNF und NTN einen Rezeptor, der aus zwei Ketten 
besteht: Die Signal-transduzierende Komponente RET wird sowohl von GDNF als auch 
von NTN benutzt. RET wird von 21 Exonen kodiert und kommt in multiplen Spleiß-
Varianten vor. Für die Liganden-Spezifität ist eine zweite Rezeptorkomponente 
verantwortlich, ein Mitglied der GFR-Familie. GFRα-1 bindet präferentiell GDNF, 
während GFRα-2 NTN stärker als GDNF bindet.  
Ziel dieser Arbeit war es, mögliche wechselseitige Interaktionen zwischen dem Nerven- 
und Immunsystem durch die GDNF-Familie zu untersuchen. Zu diesem Zweck wurde 
zunächst die Expression von GDNF, NTN und ihrer Rezeptoren in gereinigten Immunzell-
Subtypen untersucht. Dabei zeigte sich, dass der Prototyp dieser Liganden-Familie, GDNF, 
von keiner der untersuchten Immunzellen exprimiert wurde. Hingegen wurde das 
verwandte NTN von T-Zellen, B-Zellen und Monozyten exprimiert wie mit RT-PCR, 
Western Blot und Immunzytochemie gesehen wurde. Transkripte für das zu NTN und 
GDNF verwandte Persephin (PSP) wurden in Monozyten und mononukleären Zellen des 
peripheren Blutes gefunden. Der Transmembran-Rezeptor RET wurde von allen 
untersuchten Immunzell-Subtypen exprimiert. B-Zellen und T-Zellen exprimierten 
unterschiedliche Isoformen von RET, sowohl im extrazellulären Liganden-bindenden als 
auch im intrazellulären Signal-transduzierenden Teil. Die Expression der Isoformen von 
RET wurde zudem in T-Zellen und B-Zellen noch stark durch Aktivierung reguliert. In 
CD8+-T-Zellen wurde auch eine bislang noch nicht beschriebene Spleiß-Variante am 5` 
Ende beobachtet. Im Gegensatz zu T-Zellen und B-Zellen exprimierten Monozyten nur die 
volle Länge von RET. 
Auch die Liganden-bindenden Ketten GFRα-1 und GFRα-2 wurden von Immunzellen 
exprimiert wie mit RT-PCR und FACS gesehen wurde. GFRα-2 war deutlich abundanter 
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als GFRα-1. Von GFRα-2 wurden verschiedene Isoformen in Immunzellen gefunden. In 
der in T-Zellen und B-Zellen am stärksten exprimierten Isoform ist Exon 2 und 3 nicht 
enthalten. Dem resultierenden Protein fehlen die N-terminale Cystein-reiche Domäne und 
eine N-Glykosylierungsstelle, eine Region, die allerdings für die Bindung von NTN und 
die Interaktion mit RET entbehrlich ist. 
Mögliche Effekte von GDNF und NTN auf Immunzellen wurden untersucht. Dabei zeigte 
sich, dass GDNF und NTN an der Regulation von TNF-α beteiligt sind. Wenn GDNF oder 
NTN nach 5 oder 6 Tagen zu LPS+IFN-γ stimulierten Blutzellen oder zu ConA aktivierten 
T-Zellen gegeben wurde, dann war nach weiteren 24 h der TNF-α-Gehalt im Überstand 
reduziert. Weitere Experimente wiesen daraufhin, dass diese Reduktion des TNF- α-
Gehalts auf eine verstärkte Aufnahme oder Verbrauch zurückzuführen ist. Proliferation, 
Expression von Aktivierungsmarkern (HLA-DR, CD38, CD40, CD69, CD86) oder 
Produktion von IFN-γ und IL-4 wurden durch GDNF und NTN nicht beeinflusst.  
 Zusammenfassend zeigt diese Arbeit, dass Immunzellen den neurotrophen Faktor 
NTN produzieren und Rezeptoren für GDNF und NTN besitzen. Multiple Isoformen der 
Signal-transduzierenden Kette RET wurden exprimiert und durch Aktivierung reguliert. 
NTN und GDNF regulierten in aktivierten T-Zellen und Monozyten die Aufnahme oder 
den Verbrauch von TNF-α. Diese Befunde weisen daraufhin, dass Immunzellen 
miteinander und auch mit dem Nervensystem mit Hilfe der GDNF-Familie interagieren 
können.
Introduction 
 
 
 9
3 INTRODUCTION 
3.1. GDNF FAMILY LIGANDS  
3.1.1. General description of GFLs 
Glial cell line-Derived Neurotrophic Factor (GDNF) is the first member of a growing 
family of proteins named “GDNF family ligands (GFLs)” or “GDNF family of 
neurotrophic factors”.  The family consists of GDNF (Lin et al., 1993), Neurturin (NTN) 
(Kotzbauer et al., 1996), Artemin (ART) (Baloh et al., 1998; Masure et al., 1998), and 
Persephin (PSP) (Mildbrandt et al., 1998) all of which are basic secretory proteins, 
biologically active as homodimers. GFLs are structurally distant members of the 
transforming growth factor-β superfamily (TGF-β) (Unsicker, 1996) due to seven-
conserved cysteine residues (Cys) located in the same relative spacing in the mature 
protein. Both of the aforementioned groups (TGF-β and GFLs) belong to the “cysteine 
knot growth factor superfamily” (McDonald and Hendrickson, 1993). 
GFLs are produced in the form of a precursor, namely preproGFL. The signal sequence is 
cleaved upon secretion, and activation of the proGFL probably occurs by proteolytic 
cleavage. They seem to bind heparan-sulphate side chains of extracellular-matrix 
proteoglycans, which might restrict their diffusion and raise their local concentration 
(Hamilton et al., 2001). 
The gene regulation of GFLs, the mechanisms of secretion and the activation of GFL 
precursors are not yet well understood. The specific proteases that cleave GFL precursors 
have not been identified. Interestingly, recent evidence indicates that secreted pro-
neurotrophins are biologically active (pro-NGF) (Lee et al., 2001). 
The amino acid sequence homology between members of the GFLs is between 40 and 50% 
(NTN to GDNF: 43%, PSP to GDNF: 50%, PSP to NTN: 40%), and less than 20% with 
other members of the TGF-β superfamily (Saarma, 2000). 
Similarities between GFLs functions can be summarized as follows: GDNF, NTN and 
ART exert important roles for the survival of mesencephalic dopaminergic (DA) neurons 
and spinal cord motor neurons (MN), as well as for peripheral sympathetic, neural crest- 
and placode-derived sensory and enteric neurons. However, PSP supports only the survival 
of central neurons but not of peripheral neurons.  
Introduction 
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The RET, GDNF and GFRα-1 knock-out mice showed similar phenotype, consisting in 
renal agenesis and colon aganglionosis, demonstrating their importance for the 
development of the kidney and the enteric nervous system (ENS) (Schuchart et al., 1994, 
Pichel et al. 1996, Enomoto et al. 1998). 
 
3.1.2. GDNF-Family Ligand receptor complex  
Each ligand (GDNF, NTN, ART and PSP) requires the presence of two receptors on the 
target cell to induce the activation of intracellular signaling pathways (Airaksinen and 
Saarma, 2002). 
1) GFRα -1/4 surface receptors (GDNF family receptors α-1/4) are the ligand-
binding components; they are small proteins anchored by a glycosyl-
phosphatidylinositol (GPI)-link to the outer plasma membrane. 
2) RET, the transmembrane tyrosine kinase receptor, signals through the 
autophosphorylation of its multiple intracellular tyrosine (Tyr) residues, which 
are also potential docking sites for adaptor proteins. 
The following signaling model was proposed: first, a homodimeric member of the GDNF 
family binds to the corresponding surface receptor GFRα-(1 to 4), allowing the subsequent 
interaction of the GFL/GFRα-1 to 4 complex with two molecules of RET, inducing its 
homodimerization, autophosphorylation and further activation of signaling pathways to the 
nucleus (Treanor et al., 1995; Trupp et al., 1996). This process occurs in lipid raft domains 
within the membrane (Saarma, 2001). 
All ligands share the same transmembrane receptor RET; however, each ligand binds a 
preferred GFRα surface receptor: GDNF signals preferentially via the GFRα-1 receptor; 
NTN via GFRα-2; ART through GFRα-3 and PSP through GFRα-4. However, cross talk 
between the different ligands and receptors has also been described in vitro (Sanicola et al., 
1997) and in vivo (Baloh et al., 1997; Sanicola et al., 1997; Trupp et al., 1998). For 
instance, GDNF binds with high affinity to GFRα-1 and with low affinity to either GFRα-
2 or GFRα-3 (Airaksinen et al., 1999). Although GFRα-3 does not bind GDNF directly, it 
is able to interact with GDNF only in the presence of RET (Baloh et al., 1997). NTN and 
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ART may cross-talk weakly with GFRα-1, while PSP, on the other hand, has only been 
reported binding to GFRα-4 (Masure et al. 2000), see Figure 1. 
 
  
 
 
Figure 1: GDNF family ligands and receptors interactions. RET can bind to all the GFRα receptors 
(indicated by black arrows) and each GFRα receptor has a preferred ligand. The latter is only the case in the 
absence of RET, whereas in its presence the GFRαs can interact with 2 or 3 GDNF family ligands (dashed 
arrows). GFRα proteins are attached to the plasma membrane by a GPI anchor located in raft membranes. 
Four Tyr residues present on the intracellular part of RET serve as docking sites for adaptor proteins (red 
circles). Yellow arrows represent possible independent signaling pathways, which can signal in the absence 
of RET. Only one alternative pathway, triggered by the phosphorylation of the Src family kinase (SFK), has 
been described after the binding of GDNF to GFRα-1 (from Airaksinen and Saarma, 2002). 
Although RET alone does not bind directly any of the GFLs, it is capable of modifying the 
interactions between the ligands and their GFRα receptors. Thus, in the absence of RET, 
each receptor binds only to a single ligand, whereas in the presence of RET, the GFRα 
receptors become more promiscuous and can interact with 2 or 3 different GFLs. Ca2+ ions 
SFK ?  ?  ? 
NTN GDNF ART PSP 
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bind to one of the four extracellular cadherin-like domains (CLD) of RET and are required 
for RET activation by GFLs. 
A RET independent signaling pathway has been described for GDNF once bound to 
GFRα-1 in a lipid raft. In this case, kinases of the Src family are activated and signal to the 
nucleus. 
 
 
3.2. Interactions between the CNS, PNS and the immune system  
Until recently, the central nervous system (CNS) and immune system (IS) were thought to 
operate independently of each other. Recent data have changed this view. Various 
paradigms about the dynamic inter-relationships of both systems have arisen from studies 
examining the events initiated by stressors (Maier et al., 1994) that activate neural circuits 
in the brain, leading to activation of brain-outflow pathways to the periphery, such as the 
hypothalamic-pituitary-adrenal axis and sympathetic nervous system. In turn, the 
hormones and transmitters released bind to receptors expressed by immune cells, altering 
immune functions (Maier and Watkins, 1998). This activity is bi-directional. Products of 
activated immune cells feed back to the brain to alter neural activity. 
Neurotrophins (NTs), named nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), are proteins that were 
shown to have different effects on the nervous system, such as enhancement of neuronal 
survival, development and maintenance of CNS and PNS, regulation of neurotransmitter 
release, dendritic growth, neuronal regeneration and survival in response to injury and 
degeneration (Levi-Montalcini, 1987; Sendtner et al., 1992; Thoenen, 1995; Lewin and 
Barde, 1996; Sawai et al., 1996; Barde, 1997; Semkova and Krieglstein, 1999). 
Additionally, expression of NTs by immune cells has been also reported: NGF and its 
receptor TrkA are expressed in activated CD4+-T cell clones (Ehrhard et al., 1993b; 
Santambrogio et al., 1994); NGF is expressed by B cells (Torcia et al., 1996), macrophages 
and microglia (Elkabes et al., 1996; Heese et al., 1998), mast cells (Leon et al., 1998), 
eosinophils (Solomon et al., 1998), and basophiles (Burgi et al., 1996). mRNA of 
neurotrophins is expressed in spleen and thymus (Laurenzi et al., 1994) and in inflamed 
tissues. In our laboratory, it was demonstrated that activated T cells, B cells, and 
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monocytes produce BDNF in vitro and in inflammatory brain lesions (Kerschensteiner et 
al., 1999). Human hematopoietic cells (Chevalier et al., 1994) and stimulated PBMCs 
express Trk receptors (Ehrhard et al., 1993a; Ehrhard et al., 1994; Besser and Wank, 1999). 
NTs are able to modulate certain functions of the IS: NGF increases lymphocyte 
proliferation rate (Thorpe and Perez Polo, 1987) and differentiation of immune cells 
(Matsuda et al., 1988; Otten et al., 1989), stimulates immunoglobulin (Ig) production, and 
induces mast cell degranulation (Mazurek et al., 1986). Both NT-3 and BDNF induce 
proliferation and phagocytic activity of microglia (Elkabes et al., 1996). Myelin reactive T 
cells secrete effector molecules that mediate tissue destruction, but also produce 
neurotrophic factors, providing support to aid neuronal survival (Kerschensteiner et al., 
1999; Moalem et al., 1999; Hohlfeld et al., 2000). The ability of neuroantigen-reactive T 
cells to infiltrate the CNS might be used to deliver molecules that augment a recovery 
response to degenerative, malignant or traumatic processes (Rapalino et al., 1998; Becher, 
2000). Autoimmune T cells express NGF, BDNF, NT-3, and NT-4/5 when reactivated by 
their specific antigen in the injured CNS, suggesting a neuroprotective effect on the 
autoimmune damaged tissue (Schwartz et al., 1999; Hohlfeld et al., 2000; Moalem et al., 
2000; Stadelmann et al., 2002; Kerschensteiner et al., 2003). 
Besides the beneficial effects of NTs secreted from both systems, they have also been 
implicated in sickness and pain (Snider and McMahon, 1998; Benett, 1999; Shu and 
Mendell, 1999; Watkins and Maier, 1999). Hyperalgesia or exaggerated pain is triggered 
by pro-inflammatory cytokines released by activated macrophages, stimulating peripheral 
nerves that signal to the brain through the neighboring paraganglia, in which microglia and 
astrocytes release neuroexcitatory substances creating exaggerated pain responses. 
Since most NTs exert functions in both systems, establishing neuro-immune 
communications, it is possible that also GFLs could have similar effects. However, few 
and contradictory reports have been published concerning the expression and/or functions 
of GFLs and their receptors in human immune and hematopoietic cells.  
A putative role of RET in the regulation of hematopoietic cells has been suggested by the 
presence of RET in lympho-hematopoietic tissues of mice and rats, including fetal liver, 
thymus, spleen and lymph nodes (Avantaggiato et al., 1994; Tsuzuki et al., 1995), as well 
as in two human leukemia cell lines (Takahashi et al., 1985; Tahira et al., 1990; Takahashi 
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et al., 1991). Subsequently, RET expression was shown in some myelomonocytic, B cell 
and T cell leukemia/lymphoma cell lines (Gattei et al., 1997; Nakayama et al., 1999). 
In contrast, transcripts of GFRα-1, GFRα-2 and GFRα-3 neither are found in THP-1 and 
HL-60 leukemia cells expressing RET nor in normal human peripheral blood cells 
(Nakayama et al., 1999). 
Bone marrow (BM) hemopoietic cells express only RET, whereas BM stromal cells 
express GFRα-1, GFRα-2 and GDNF. It was speculated that GFRα on the surface of BM 
stromal cells function like soluble GFRα, and thus, the interaction between BM 
hemopoietic cells and stromal cells may induce the formation of a functional GDNF/RET 
complex involved in maturation of myelomonocytic cells in the BM microenvironment 
(Nakayama et al., 1999).  
Despite these preliminary indications, expression of RET in human lympho-hematopoietic 
cells has not been investigated in detail so far.  
The aim of this study was to investigate possible interactions between the nervous system 
and the immune system mediated by members of the GFLs, as well as their receptors: RET 
GFRα-1 and GFRα-2.  
 
 
3.3. GDNF 
3.3.1. Description and characteristics 
GDNF was purified and characterized by Lin (Lin et al., 1993) from the supernatant of a 
rat glial cell line (B49) as a potent growth factor as well as survival factor for embryonic 
substantia nigra DA neurons (which degenerate in Parkinson’s disease). 
GDNF is processed and secreted as a mature protein of 134 amino acids that contains two 
N-linked glycosylation sites. It is a homodimer (disulfide-linked dimer) with a molecular 
mass of ~32 to 45 kDa, and under reducing conditions of ~18 to 22 kDa. Subsequently, it 
was found that GDNF was also a potent survival factor for spinal motoneurons (Henderson 
et al., 1994), and for sympathetic neurons. 
However, the main function of GDNF is related to development, migration and survival of 
neural crest cells, which migrate to the kidney and to the enteric nervous system (ENS).  
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3.3.2. The GDNF gene 
The human GDNF gene contains three exons and two introns. The second exon encodes 
the first 143 bp of the coding sequences that translates the prepro-region of the protein. 
The 3’-end region of this exon possesses an alternative splice site, resulting in an internal 
deletion of 78 bp. At the protein level, this deletion results in a loss of 26 amino acids in 
the prepro-region, leading to two identical isoforms (Woodbury et al., 1998). The third 
exon contains the majority of the coding sequences, the remainder of the prepro-region and 
all the amino acids found in the mature polypeptide. 
The GDNF gene is highly regulated; its promoter region contains putative cis-elements 
that may account for the complex spatiotemporal pattern of expression and for rapid up-
regulation by environmental stimuli. 
3.3.3. GDNF knock-out mice 
The importance of GDNF was revealed by GDNF knockout mice (GDNF-/-), which 
displayed defects in the developing kidneys and lacked the ENS due to failed migration of 
neural crest cells (Moore et al., 1996; Pichel et al., 1996; Sanchez et al., 1996). These mice 
showed complete renal agenesis owing to lack of induction of the uretheric bud, an early 
step in kidney development. These mice die shortly after birth due to renal failure, and do 
not have enteric neurons, causing pyloric stenosis and dilation of duodenum.  
In the nervous system, the total number of DA neurons is normal. Only a small deficit in 
sensory, sympathetic and motoneurons has been detected. 
The phenotype of GDNF-/- mice is similar to both, RET-/- and GFRα-1-/- mice, suggesting 
that they act upon similar signaling pathways. 
3.3.4. Signaling 
RET-dependent signaling of GDNF: GDNF induces different signaling pathways when 
acting through the GFRα-1/RET receptor complex (Trupp et al., 1999; Pezeshki et al., 
2001); some of these pathways include PLCγ/AKT, RAS-MAPK-ERK (inducing 
phosphorylation of CREB), and JNK (Jun N-terminal kinase) (Airaksinen et al., 1999). 
RET-independent signaling of GDNF via GFRα molecules: The GFRα-1 surface 
receptor located in lipid rafts together with an unknown transmembrane protein recruits 
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and activates Src-type kinases upon GDNF binding to GRFα receptor. Src kinases, in turn, 
phosphorylate PLCγ, leading to the production of IP3 and release of intracellular Ca2+. 
In the absence of RET, GFRα-1 failed to activate AKT and RAS-MEK-ERK cascade, but 
activated a Src-like kinase that allowed ERK-independent phosphorylation of CREB 
(Pezeshki et al., 2001). Depending on the cell type, ligand-induced clustering of GPI-
anchored proteins may activate different signaling pathways. GDNF induced Fos 
activation in cells expressing GFRα-1 but lacking RET (Trupp et al., 1998). 
3.3.5. Expression and physiological functions 
GDNF exhibits an extensive and complex spatiotemporal pattern of expression.  
GDNF is essential as a differentiation, migration and growth factor in developing kidneys 
and the enteric nervous system (Sanchez et al., 1996). 
Developmental and neonatal GDNF mRNA expression has been found at several sites in 
rat (Scharr et al., 1993) and in mouse CNS (Suter-Crazzolara and Unsicker, 1994): e.g. 
cerebral cortex, hippocampus, thalamus, striatum, cerebellum, olfactory bulb, superior 
cervical ganglia, dorsal root ganglia (DRG) and spinal cord. GDNF, NTN and their 
receptors were found in rat glial cultures (type-1 and type-2 astrocytes), and in glial 
precursors (Franke et al., 1998). TPA-treatment increased their levels (Remy et al., 2001), 
and following exposure to glutamate agonists, GDNF was a strong survival factor for 
astrocytes (Ho et al., 1995). 
Low GDNF expression is maintained throughout life, particularly in the brain (Stromberg 
et al., 1993). In human adult CNS, a widespread distribution of GDNF protein was 
demonstrated (Kawamoto et al., 2000) in neuronal somas, dendrites and axons. It was also 
found in astrocytes (Moretto et al., 1996) and in microglia of the neocortex and white 
matter, hippocampus, basal forebrain, basal ganglia, hypothalamus, thalamus, 
mesencephalon (including SN), pons, medulla oblongata, cerebellum and spinal cord. 
In the periphery, the expression of GDNF is widespread in many organs (Trupp et al., 
1995): e.g. kidneys, skin, stomach, lungs, bone, heart, liver, spleen, blood (Suter-
Crazzolara and Unsicker, 1994), peripheral nerves (Schwann cells), skeletal muscle 
(Springer et al., 1995) and reproductive tract: ovary but not in testis (Widenfalk et al., 
2000). 
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GDNF in the CNS promoted the survival, induced differentiation and increased the high-
affinity DA uptake of SN dopaminergic neurons in vitro (Lin et al., 1993) and in vivo 
(Hudson et al., 1995). Retrograde axonal transport of GDNF from the DA terminal region 
to the SN demonstrated its trophic effects on DA neurons in the adult brain (Tomac et al., 
1995). GDNF also exerted a trophic effect on noradrenergic neurons (Arenas et al, 
1995), and prevented neuronal degeneration when applied prior to the neurotoxic insult (6-
OHDA) (Lapchak et al., 1997a). Similar effect was seen in cholinergic neurons located in 
the septo-hippocampal pathway, important for locomotor activity (Lapchak et al., 1997b). 
GDNF may act in a paracrine-like fashion for the regulation of somatotrophic cell growth 
and in other cell functions, since its expression was found in the anterior pituitary-cell 
types: gonadotrophs, corticotrophs and the somatotrophs (Urbano et al., 2000). 
GDNF enhanced the development and differentiation of Purkinje cells (cerebellar 
neurons), which are the principal output cells of the cerebellum (Mount et al., 1995). 
Approximately 50% of spinal cord motoneurons (MN) degenerate and die at a time when 
they are establishing synaptic connections with their target muscles. The survival of 
developing MN depends on the access to trophic molecules (such as BDNF or NGF). 
During this period, GDNF has a dose-dependent effect on the survival of MN cultures 
from embryonic (day 14) rat (Henderson et al., 1994) or embryonic (day 5) chick spinal 
cords (Oppenheim et al., 1995; Houenou et al., 1996). GDNF is 75 fold more potent than 
other NTs in supporting survival of motoneurons. 
An age-dependent response to GDNF of peripheral sensory neurons, such as 
sympathetic, parasympathetic, cutaneous sensory and enteroceptive neurons has been 
reported (Buj-Bello et al., 1995). DRG neurons and MN are able to retrogradely transport 
radiolabelled GDNF (Matheson et al., 1997) from the periphery to the spinal cord. 
Additionally, during the post-natal life, GDNF has a more potent trophic effect than NGF 
on sensory neurons from the DRG (Snider and Wright, 1996; Molliver et al., 1997). 
GDNF is present within the axons and in surrounding Schwann cells of peripheral nerves 
(Scharr et al., 1993), which highly express the full length and the truncated GDNF mRNA 
(Springer et al., 1995). 
At neuromuscular junctions, transgenic over-expression of GDNF led to an increase in 
the number of motor axons innervating muscle fibers at the time when axons are being 
eliminated (Nguyen et al., 1998). Subcutaneous GDNF injections during the post-natal life 
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increased the number of axons converging at neuromuscular junctions (Keller-Peck et al., 
2001). Over-expression of GDNF in skeletal muscle produced hyper-innervation of 
neuromuscular junctions with abnormal motor endplates (Zwick et al., 2001). Probably, 
one role of GDNF in post-natal MN is to promote terminal axon branching and synapse 
formation. 
Elevated expression of the truncated GDNF isoform was found in normal human skeletal 
muscle (Springer et al., 1995). GDNF mRNA in muscle may not be entirely muscle-
derived, but rather derived from peripheral nerve segments sheathed by proliferating 
Schwann cells infiltrating the fascicles. 
GDNF could promote MN survival acting as a target-derived neurotrophic factor (Suzuki 
et al., 1998a) through retrograde transport to the motoneurons (Yan et al., 1995). 
GDNF in lympho-hematopoietic system probably plays a role in terminal (Gattei et al., 
1997) or intermediate differentiation (Nakayama et al., 1999) of myelomonocytic cell 
maturation in the BM microenvironment. BM stromal cells expressed GDNF, as well as 
GFRα-1 and GFRα-2; thus the interaction between hematopoietic cells expressing RET 
and stromal cells may form a functional GDNF/GFRα-1 complex. The involvement of 
GDNF in the regulation of normal and neoplastic monocytic cells was also supported by 
the developmental relationships between glial cells and the monocyte/macrophage system, 
and by the high expression of these factors in non-neural tissues, including hematopoietic 
organs such as liver and spleen (Treanor et al., 1995; Trupp et al., 1995). 
GDNF in embryogenic kidney is localized in the metanephric mesenchyme at early 
stages, and is repressed in the induced mesenchyme when epithelial conversion occurs 
(Hellmich et al., 1996). GDNF stimulated branching morphogenesis in the kidney and 
induced ectopic uretheric buds from the nephric duct (Sainio et al., 1997). 
GDNF may function as a paracrine morphogen secreted by cells of mesenchymal and 
neuroectodermal origin to modulate epithelial cell functions, such as migration during 
development and post-natal life in kidneys (Sainio et al., 1997) and in the ENS (Pichel et 
al., 1996; Sanchez et al., 1996). In vitro, GDNF promotes migration of human corneal 
epithelial cells, which express the receptors GFRα-1 and RET, indicating that GDNF is a 
chemoattractant factor for epithelial cells (You et al., 2001). 
GDNF possess the ability to regulate spermatogonia renewal and differentiation during 
male spermatogenesis (Meng et al., 2000). 
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3.3.6. Regulation of GDNF expression 
Signaling through multiple secondary messenger systems could regulate synthesis and 
release of GDNF in neuroblastoma and glioma cell lines (Verity et al., 1999). In glial cells, 
fibroblast growth factor (FGF) family members (-1,-2,-9) stimulated GDNF release as a 
consequence of re-entry into the cell cycle; pro-inflammatory cytokines: TNF-α, TNF-β, 
IL-1β and LPS also elevated GDNF expression. In contrast, in neuroblastoma cells, the 
same cytokines and LPS repressed GDNF release. TNF-α and IL-1β exerted inhibitory 
effects at the level of protein synthesis, post-translation modifications, or release of GDNF. 
Several stimuli could elevate GDNF release from neuroblastoma cells without changing 
mRNA levels, such as direct application of cAMP, activators of adenyl cyclase, inhibitors 
of phosphodiesterase activity, and prostaglandins (PGA2, PGE2 and PGI2) that elevated 
intracellular cAMP levels, suggesting a regulated secretion of GDNF protein. A 
requirement for regulated release is the pre-existence of intracellular stores. GDNF has 
been also found in chromaffin granules (Krieglstein et al., 1998). 
3.3.7. GDNF during pathological conditions 
Parkinson’s disease is characterized by degeneration of SN dopaminergic neurons in the 
midbrain that innervate the caudate nucleus and the putamen, forming the nigro-striatal 
dopaminergic system (Adams and Victor, 1993). Therefore, GDNF that could potentially 
prevent this degeneration and increase the functional activity of the remaining DA neurons, 
is of clinical interest and has been tested in several animal models (Gash et al., 1995; 
Kearns and Gash, 1995; Sauer et al., 1995; Tomac et al., 1995; Cass, 1996; Gash et al., 
1996; Schultz et al., 1996; Lapchak et al., 1997; Date et al., 1998; Lapchak et al., 1998a; 
Lapchak et al., 1998b; Rosenblad et al., 2000). Due to these successful results, a 
multicenter clinical study of Parkinson’s disease started in 1996, consisting of either 
GDNF or placebo intraventricular administration for one whole year. At the end, some 
patients entered the open-labeled phase, receiving GDNF therapy monthly. However, three 
years later, clinicopathological findings of a GDNF-treated patient, who died after seven 
months of treatment, were published, indicating that intraventricular GDNF treatment 
neither improved clinical Parkinsonism nor reduced dopaminergic degeneration. The 
conclusion was that the intracerebroventricular route of GDNF delivery might be 
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suboptimal in humans, suggesting the need for other delivery techniques for GDNF 
administration (Kordower et al., 1999). 
Shaker mutant rats, an animal model for spinocerebellar ataxias (cerebellar disease) with 
degeneration of cerebellar Purkinje cells were treated with GDNF, which caused a delay in 
the degeneration of many but not all Purkinje cells (Tolbert et al., 2001), while only 
supporting the survival of spatially related Purkinje cells. Degenerated cells after treatment 
were not responsive to GDNF due to lack of GFR-α receptors (Burazin and Gundlach, 
1999). Increased amounts of GDNF were also detected in the cerebellum of patients with 
multiple system atrophy compared to control patients (Kawamoto et al., 2000). 
Epileptogenesis can be studied in animal models, such as the one caused by injection of 
kainic acid (Martin et al., 1995) or kindling-evoked recurring seizures (Kokaia et al., 
1999). After induction of seizures, an increase in mRNA expression of GDNF, NTN and 
its receptors was observed in different regions of the brain. Thus, GDNF and NTN may 
modulate seizure susceptibility. 
GDNF exhibited potent neuroprotective effects against brain infarction induced by 
middle cerebral artery occlusion and then reperfusion (Wang et al., 1997), and gave 
protection against the subsequent edema (Abe and Hayashi, 1997a; Abe et al., 1997b). 
GDNF protected against delayed neuronal dead induced in the hippocampus by transient 
forebrain ischemia (Miyazaki et al., 1999), which was related to transient increases of 
hippocampal GDNF, GFRα-1 and RET, as well as cortical GFRα-2 mRNA levels (Kokaia 
et al., 1999; Arvidsson et al., 2001). 
Glioblastoma and gliosarcoma expressed GDNF and GFRα-1 protein at concentrations 
up to five times higher compared to normal tissue. GDNF could act as an autocrine or 
paracrine factor for gliomas in vivo, suggesting an involvement of GDNF for their growth 
and differentiation (Wiesenhofer et al., 2000). 
GDNF can rescue neonatal rat facial MN from axotomy-induced cell death and atrophy. 
90% of facial MN degenerate after peripheral nerve axotomy; however, all MN survived 
and exhibited normal soma morphology after GDNF treatment. Therefore, GDNF can be a 
physiological and pharmacological trophic factor for spinal MN (Henderson et al., 1994). 
After sciatic nerve lesions in adult animals, GDNF mRNA levels increased in Schwann 
cells and in denervated muscles. Thus, GDNF produced by muscle could act as a target-
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derived neurotrophic factor for MN (Springer et al., 1995; Trupp et al., 1995), which took 
up and retrogradely transported GDNF from a terminal field on muscles. 
After axotomy, Schwann cells proliferated in the distal stump of a transected peripheral 
nerve; this coincided with the up-regulation of the GDNF-full length mRNA and RET 
mRNA observed distal to the nerve site injury, and on the satellite cells of the affected 
DRG (Hammarberg et al., 1996; Bär et al., 1998). If a significant amount of GDNF protein 
is synthesized in injured nerves after trauma and becomes available to primary sensory, 
sympathetic and MN, it could have important survival and regenerative effects on these 
groups of peripheral neurons (Ramer et al., 2000). The rapid appearance of cytokines in 
injured nerve tissue suggests that TNF-α and IL1-β may in part regulate injury-induced 
glial GDNF synthesis/release.  
Locally administered GDNF prevented 50% of cell death in adult mice after avulsion-
induced cell death, and induced hypertrophy of surviving MN (Li et al., 1995). 
In peripheral neuropathies, GDNF can be transported retrogradely in a receptor-mediated 
fashion: spinal MN express GDNF receptors, thus, skeletal muscle-derived GDNF exerts a 
trophic function on these neurons, which had been disconnected from their target muscle 
after nerve-fiber lesion. GDNF might enhance axonal sprouting, contributing to re-
innervation (Lie and Weis, 1998). 
GDNF, GFRα-1 and RET mRNAs were examined in sural nerve biopsies from normal 
controls and from various peripheral neuropathies (vasculitis, ischemic, acute and chronic 
inflammatory demyelinating neuropathies, and others). GDNF and GFRα-1 mRNA levels 
were elevated to variable extents in the diseased nerves compared to controls, but 
independent of the type of disease. GDNF mRNA was related neither to axonal or 
demyelinating pathology, nor to the presence of inflammatory cells. In contrast, an 
increase in GFRα-1 mRNA expression was correlated with the extent of axonal pathology, 
and was also proportional to the nerve invasion by T cells and macrophages. The 
proportional relationship between GFRα-1 levels and the extent of inflammatory cell 
invasion could indicate that these cells may express GFRα-1 mRNA (Yamamoto et al., 
1998). RET mRNA expression was not detected in normal or diseased nerves. 
 
Introduction 
 
 
 22 
Biopsies from normal human skeletal muscle and from muscular diseases, such as 
polymyositis (PM, an inflammatory autoimmune muscle disease) and Duchenne muscular 
dystrophy (DMD, a genetic muscle disease) were studied (Suzuki et al., 1998b). In both 
diseases, muscle fibers undergo massive necrosis with focal lyses of the plasma membrane; 
satellite cells surrounding necrotic fibers are activated and differentiated into myogenic 
cells. Finally, regenerating post-mitotic myoblasts fuse to multinucleated myotubes, 
similar to immature muscle fibers. GDNF was present in the periphery of normal 
myofibers and was up-regulated only in regenerating muscle fibers in both diseases. 
Muscle contusion also induced up-regulation of GDNF and GFRα-1 mRNAs in Schwann 
cells of intramuscular nerves in damaged muscle fibers (Kami et al., 1999). 
 
Neurogenic atrophy of skeletal muscles is caused by peripheral neuropathy or by 
degeneration of MN (i.e.: Amyotrophic Lateral Sclerosis: ALS). In ALS, denervation is 
incomplete combined with different stages of atrophy, being partially compensated by 
collateral reinervation and muscle fiber hypertrophy, all of them present at the same time. 
In muscle biopsies from patients with motor neuropathy, the full-length GDNF mRNA 
was increased, but four weeks after denervation, both isoforms showed similar expression. 
Muscle biopsies taken from ALS patients showed that both GDNF isoforms were elevated 
in all post-mortem spinal cords of end-stage disease patients. High levels of GDNF were 
found in muscles with high number of partially atrophic, recently denervated fibers, 
indicating an increased demand of GDNF from MN, probably related to excessive 
collateral nerve sprouting. In contrast, a down-regulation in the muscular expression of 
GDNF mRNA was found in end-stages of ALS, due to a reduction in the number of 
muscle fibers, and replacement of them by connective tissue (Corse et al., 1995; 
Grundstrom et al., 1999). Increased levels of GDNF protein were found in 12 out of 15 
ALS-cerebrospinal fluid samples compared to controls.  
Taken together, the increased expression of GDNF mRNA in muscle of ALS indicates that 
the capacity to synthesize GDNF is enhanced in ALS (Grundstrom et al., 2000). 
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Figure 2: Expression of GDNF, NTN, RET, GFRα-1 and GFRα−2 in the neuromuscular system. The 
scheme shows the spinal cord, the dorsal root ganglia (DRG) and ventral root ganglia (VRG), peripheral 
nerves, neuromuscular junction and muscles. Skeletal muscles express GDNF and NTN, both can be 
retrogradely transported to the ventral horn of the spinal cord (motoneurons) where the receptors RET, 
GFRα-1 and GFRα-2 are expressed and bind GFLs. Schwann cells ensheathing the axons of peripheral 
nerves also express GDNF. 
The relation between perineural invasion of tumor cells and expression of GDNF, GFRα-
1 and RET was investigated in patients with bile duct carcinoma (Iwahashi et al., 2002). 
High expression levels of GDNF were found in normal epithelial cells of the bile duct, 
whereas GFRα-1 and RET proteins were undetectable in the same cells. In peripheral 
nerve tissues surrounding the bile duct, strong expression of GFRα-1 and moderate 
expression of RET and GDNF was observed. In specimens of bile duct carcinoma, 
expression of GDNF was down-regulated during its development. GDNF in tumor cells, as 
well as GFRα-1 and RET expression in peripheral nerves may play a role in perineural 
invasion of bile duct carcinoma through chemoattraction among these molecules. 
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3.4. NEURTURIN 
3.4.1. Description and characteristics 
Neurturin (NTN) was discovered due to the fact that conditioned medium of Chinese 
hamster ovary cells could support the long-term survival of sympathetic neurons from the 
superior cervical ganglion (SCG). This survival factor was purified and a novel protein, 
with a molecular weight of 25 kDa and similar structural characteristics of GDNF was 
described (Kotzbauer et al., 1996). The prepro-NTN contains 195 amino acids and the 
mature peptide 100 amino acids. Its sequence shares 42% similarity with the mature 
GDNF, containing the seven-conserved Cys residues spaced similarly as other member of 
the TGF-β superfamily. 
The mRNA sequence for prepro-NTN is encoded by two exons containing 594 base pairs. 
The intron begins at position 169. The coding sequence for the mature protein is located in 
exon 2, between nucleotides 286 and 591 (Heuckeroth et al., 1997). 
NTN is a trophic factor that promotes the survival of numerous neuronal populations 
including peripheral parasympathetic, nodose and DRG sensory neurons, as well as central 
midbrain DA neurons. 
3.4.2. NTN knock-out mice 
NTN-/- mice are viable and fertile but have defects in the ENS, including reduced 
myenteric plexus innervations and reduced gastrointestinal motility. The phenotype shows 
periorbital abnormalities, with eyelid droopiness, crusting drainage around the eye, and 
reduced tear production, resulting from defects in the lachrymal gland parasympathetic 
innervation, which also affects the submandibular salivary gland. Parasympathetic neurons 
have a reduced size and diminished fiber density, indicating that NTN is a trophic factor 
for them. GFRα-2-expressing cells in the trigeminal ganglia, DRG, cilliary ganglion and 
submandibular salivary gland are also depleted (Heuckeroth et al., 1999). 
3.4.3. Signaling 
Like other members of the GFLs, NTN signals through the RET tyrosine kinase and also 
requires a GPI-linked surface receptor, GFRα-2. Binding of NTN induces 
autophosphorylation of RET and subsequent activation of different signaling pathways 
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(Airaksinen et al., 1999), such as MAPK pathway, which is activated in sensory cervical 
ganglia neurons, as well as the PI3-K pathway (Creedon et al., 1997). 
NTN also activated RET through the binding to GFRα-1 in fibroblasts transfected with 
GFRα-1 but not with GFRα-2 (Baloh et al., 1997). However, a similar RET-activation was 
not observed when neurons were transfected with GFRα-2 (Buj-Bello et al., 1997). In 
addition, cell-free studies failed to show specific binding of NTN to GFRα-1, even at NTN 
concentrations that should activate RET. These results indicated that the RET-independent 
action of GFRα-1 was highly selective for GDNF, but not for NTN (Pezeshki et al., 2001). 
NTN and GFRα-2 expression patterns are in some cases complementary, but not in others, 
suggesting multiple modi operandi in relation to RET and GFRα-1. For example, NTN co-
localized with RET and GFRα-1, but not with GFRα-2 in uretheric buds of developing 
kidney. 
However, the similarity of potency and efficacy of NTN and GDNF on DA neurons was 
difficult to explain with the low expression of GFRα-2 on these neurons. Probably, NTN 
signals via low levels of GFRα-2 on the surface of DA neurons, or NTN might signal in 
vivo through GFRα-1. Alternatively, GFRα-2 expressed by cells in the vicinity of nigral 
DA neurons may be presented to nigral dopaminergic neurons either by cell-cell contact or 
by diffusion of soluble GFRα-2. 
3.4.4. Expression and physiological functions 
NTN expression is developmentally regulated in the nigrostriatal system, exhibiting potent 
actions on the survival and function of midbrain DA neurons, with efficiencies similar to 
GDNF, being sequentially expressed in mature nigral DA neurons (Horger et al., 1998). 
NTN mRNA expression was found in mouse CNS in the postnatal cerebral cortex, 
striatum, brain stem, pineal gland and in the developing pituitary gland. 
Low levels of NTN mRNA are expressed in astrocytes (Franke et al., 1998; Remy et al., 
2001). 
During development, NTN is expressed in the smooth muscle layer of the intestines, in 
smooth muscle of the urether, and in bronchiole. In salivary glands NTN showed an 
epithelial expression, whereas GFRα-2 is located in the surrounding tissue. 
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NTN and GFRα-2 are also found in developing sensory organs, in Sertoli cells and in the 
epithelium of the oviduct, whereas germ cells express only GFRα-2. 
In neonatal animals, NTN mRNA is strongly detected in blood, the heart, the brain, 
seminiferous tubules of the testis, in the uterus, but less in the ovaries (Widenfalk et al., 
2000). However, in adult tissues NTN expression is stronger in heart and less in blood, 
brain or ovaries (Creedon et al., 1997). 
In adult rats, NTN is expressed in smooth muscle of penile blood vessels, corpus 
cavernosum, and in several intrapelvic organs, whereas GFRα-2 and RET mRNA are 
expressed in the penile neurons of the pelvic ganglia. NTN acted as a target-derived 
survival factor for penile erection-inducing postganglionic neurons, being specific 
transported from the axon terminals to neuronal soma (Laurikainen et al., 2000). 
NTN is a trophic factor for parasympathetic and postmitotic enteric neurons. To form 
the ENS, neural crest cells migrate from the vagal and sacral regions of the spinal cord to 
the gastrointestinal tissue. While migrating, these cells undergo many rounds of 
proliferation to produce enough neurons and glial cells to populate the ENS. Post-mitotic 
neurons extend axonal processes to create a network of cells that regulate motility, 
sensation and mucosal secretion in the gut. GDNF-/- mice have intestinal aganglionosis, as 
a result of insufficient proliferation of ENS precursor cells. NTN-/- mice have a reduction 
in the ENS-nerve fibers and abnormal gastrointestinal motility, with minimal reduction in 
the enteric neuron number; thus, NTN is important as a trophic factor rather than migration 
factor for postmitotic myenteric neurons. 
3.4.5. Regulation of expression of NTN 
GDNF signaling via the RET/GFRα-1 complex is required early for proliferation and 
migration of the neuronal precursors of the parasympathetic cranial ganglia: 
submandibular, sphenopalatine and otic. NTN exerts its effects subsequently during 
development and is important for the maintenance of these neurons. This switch in ligand 
dependency during development was partly governed by the altered expression of GFRα, 
as demonstrated by the predominant expression of GFRα-2 in parasympathetic neurons 
after ganglia formation (Enomoto et al., 2000). Synthesis of NTN was maintained 
throughout the cell death period. In contrast to stable levels of NTN and GFRα-2, the 
down-regulation of GDNF and GFRα-1 suggested a novel mechanism by which multiple 
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neurotrophic factors and their receptors contribute to neural differentiation and survival 
(Hashino et al., 2001). NTN also regulated heat sensitivity in a subpopulation of 
unmyelinated nociceptors. 
3.4.6. NTN under pathological conditions 
GFLs signaling exert a neuroprotective role after brain insults as shown after the 
administration of recombinant GFLs to the brain in animal models. GDNF, NTN and ART 
could reduce death of DA neurons following lesions of the nigrostriatal pathway (Tseng et 
al., 1998; Bjorklund et al., 2000; Rosenblad et al., 2000). In vivo, a single administration of 
NTN led to a threefold increase in nigral cells survival after intrastriatal injection of 6-
OHDA (Horger et al., 1998). 
Seizure activity regulated gene expression for NTN, similarly to GDNF; therefore NTN 
could also modulate seizure susceptibility (Kokaia et al., 1999). 
NTN was expressed in human neuroblastoma cell lines, but its function is not yet known 
(Hishiki et al., 1998). 
 
 
3.5.  PERSEPHIN 
3.5.1. Description and characteristics 
Persephin (PSP) was identified as a new member of the GDNF family ligands using 
degenerate PCR and homology cloning. PSP showed 40–50% amino acid homology to 
GDNF and NTN (Mildbrandt et al., 1998). The human PSP gene contains 468 nucleotides 
coding the prepro-protein of 156 residues; the mature protein is encoded by 96 amino 
acids. The PSP gene contains one intron that begins at position 153. RT-PCR revealed a 
short and a long isoform, which were identical except for the 88 bp intron sequence 
continued in the longer version. Similar to NTN, PSP contains a long C-G rich region 
(Jaszai et al., 1998). 
Analysis of various tissues showed that PSP mRNA was inefficiently spliced, since spliced 
and unspliced mRNA species were found at equal levels. The relative abundance of the 
unspliced mRNA suggested that the regulation of PSP mRNA processing may be an 
important means of regulating the production of PSP protein in some tissues. 
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3.5.2. PSP knock-out mice 
PSP-/- mice showed normal development and behavior. No abnormalities were seen in the 
intestinal tract, ENS, kidney, liver, gonads, heart or skeletal muscle. Several tests for 
red/white blood cells, chemistry dysfunction, and chemical panel were performed on blood 
collected from adult mice of +/+, +/-, and -/- PSP genotypes; however, no significant 
differences between groups were observed. These findings suggested that PSP is not a 
survival or growth factor for CNS or peripheral tissues. The only abnormality found was 
hypersensitivity to focal cerebral ischemia or stroke (Tomac et al., 2002). 
3.5.3. Signaling 
PSP can bind only to the surface receptor GFRα-4, and then to RET receptor located on 
the lipid rafts (Airaksinen et al., 1999; Lindahl et al., 2001; Airaksinen and Saarma, 2002). 
3.5.4. Expression and physiological functions 
PSP mRNA was detected in the SNC in the cortex, hippocampus, striatum, 
mesencephalon, and cerebellum. In peripheral tissues it was found in heart, kidney, liver, 
skin, skeletal muscles, DRG, spinal cord, and MN (Jaszai et al., 1998). However, higher 
levels were found in embryonic than in adult tissues. 
PSP, like GDNF and NTN, promoted the survival of midbrain DA neurons in culture. It 
also promoted uretheric bud branching during developing stage. On the contrary, PSP had 
no survival-promoting effect on any peripheral neuron, including SCG, sensory neurons in 
DRG, and enteric neurons (Mildbrandt et al., 1998). 
3.5.5. PSP under pathological conditions 
PSP prevented degeneration of dopaminergic neurons after toxic stimulus in vivo, and 
supported the survival of MN in vitro and in vivo after sciatic nerve axotomy. In spinal 
cord motoneuron cultures, high doses of PSP enhanced glutamate transport inhibitor (Ho et 
al., 2000). Exogenous and endogenous PSP were critical components of neuroprotection 
mechanisms against ischemic brain injury induced via glutamate 
excitotoxicity/dysfunction (Tomac et al., 2002). 
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3.6. RET Tyrosine kinase receptor 
3.6.1. Description and characteristics 
RET was originally identified as an oncogene activated by DNA rearrangement (Takahashi 
et al., 1985), (RE-arranged during Transfection). The product of the Ret proto-oncogene is 
a cell surface and transmembrane receptor with an intracellular tyrosine kinase domain. 
The same author (Takahashi and Cooper, 1987) showed that this gene encoded a protein 
homologous to a tyrosine kinase, and reported the first sequence of a RET cDNA derived 
from the THP-1 human leukemia cell line (Takahashi et al., 1988). The sequence coded for 
a protein of 1114 amino acids (Takahashi et al., 1989). 
Subsequently, it was reported that alternative polyadenylation and mRNA splicing could 
generate at least five distinct 3’-ends (Tahira et al., 1990). These isoforms were predicted 
to encode RET proteins with two distinct intracellular C-terminal ends. The second 
isoform encoded a smaller protein of 1072 amino acids. These two proteins, containing 
either 1072 or 1114 amino acids differ from each other in their 9 and 51 C-terminal amino 
acids respectively. Those sequences were completely unrelated, designated as the short or 
RET-9 (9 amino acids) and the long or RET-51 (51 amino acids) isoforms of the RET 
protein. Further analysis demonstrated a third RET transcript that encoded a protein with 
an alternative 43 amino acids C-terminal, also called the middle isoform or RET-43 
(Myers et al., 1995). The intracellular domain of RET contains 14 Tyr residues; RET-9 
lacks two Tyr at the C-terminus.  
The structure of the extracellular region of the RET exhibits four domains, each of about 
110 residues, containing the consensus motif of the cadherin sequence (CLD) and a Ca2+-
binding site located between two domains (starting at amino acid position 272), which is 
required for RET binding to GDNF but not for GDNF binding to the GFRα-1. Ca2+-
binding helps to linearize and rigidify the structure and to promote dimerization of CLDs. 
This region also contains a cysteine–rich motif (Cys) located between amino acids 516 and 
635, corresponding to nucleotide sequences of exons 8 to 11 (Anders et al., 2001). 
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Overall, the RET protein contains an extracellular domain composed by a NH2 region, 
including four CLD-1/4 domains and a Cys-rich motif; a transmembrane domain; and an 
intracellular domain formed by two tyrosine kinase domains, an inter-kinase domain, and 
the COOH-terminal region, as depicted in the next figure: 
 
 
Figure 3: Scheme of the amino terminal and extracellular domain 
of the RET protein.  
This scheme displays the relation between amino acid sequences and 
numbers of exons translated into the extracellular domain of the human 
RET protein. The amino terminal region of RET is depicted, including 
the four cadherin-like domains: CLD-1 to CLD-4, the Ca2+ binding site 
(starting at amino acid 272), and the cysteine-rich domain (Cys-rich). 
Exons encoding for each domain are numbered on the right side: CLD-
1: amino acids 28 to 155 (exons 2 and 3). CLD-2: amino acids 166 to 
271 (exons 3 and 4). CLD-3: amino acids 273 to 387 (exons 4 and 6). 
CLD-4: amino acids 401 to 516 (exons 6 and 8). 
EXTRACELLULAR 
Figure 4: Scheme of the full length of the human RET 
protein representing the extracellular, the transmembrane 
and the intracellular domains.  
The scheme shows from the upper part to the bottom: the amino 
terminal region (NH2), the Ca2+-binding motif (yellow circle), 
four cadherin-like domains 1 to 4 (CLD-1, CLD-2, CLD-3, 
CLD-4), the cysteine rich region (Cys); the transmembrane 
domain (TM) and the intracellular part composed by the tyrosine 
kinase domains (TK1 and TK2) and the carboxyl terminus 
(COOH). Red circles represent Tyr residues acting as docking 
sites for adaptor proteins (modified from Anders et al. 2001). 
 TM 
INTRACELLULAR 
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3.6.2. The RET gene 
The human RET oncogene was mapped to chromosome 10q11.2 (Ishizaka et al., 1989). 
This gene contains 21 coding exons (Kwok et al., 1993; Myers et al., 1995). The first exon 
contains the translation start site and codes for most of the amino terminal signal sequence; 
the extracellular domain is encoded by the first 10 exons. A cadherin related sequence is 
located about 480 amino acids upstream of the transmembrane domain. Seven copies of a 
motif responsible for Ca2+ mediated homophilic binding are present within the 
extracellular domain. The transmembrane domain is encoded by a single exon (exon 11). 
The cytoplasmic domain is encoded by the next 9 exons, which encode the two-tyrosine 
kinase domains and the C-terminus. The following scheme, Figure 5 shows the relation 
between exon structure and predicted domains of the RET protein, as well as the location 
of primers utilized for detecting spliced isoforms located at both ends of the gene, i.e. at 
the 5’-end and at the 3’-end regions. 
 
 
 
Figure 5: Correlation of the exon structure of the RET oncogene and the functional domains of the 
predicted protein. Solid black boxes indicate the exons. Dotted lines refer the exons to the corresponding 
domains found in the RET protein, which are represented as following: the amino terminal signal (NH2) 
sequence (S), Ca2+ mediated binding motifs (hatched boxes), the cadherin like-domains (CLD), the cysteine 
rich region (Cys), the transmembrane domain (TM), the tyrosine kinase domains (TyrK 1 and TyrK 2), the 
inter-kinase domain (IK), and the COOH-terminal. Sites for alternative splicing at the 5’-end region are 
shown as exons inside of lined squares (red and blue). Primers used to amplify the isoforms hybridized in 
exons 2-3 (forward: orange arrow) and in exon 6 (purple arrow). Dotted squares represent altered sites in the 
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protein after splicing. Differential splicing at the 3’-end region results in transcripts encoding three isoforms 
that differ with respect to their C-terminal amino acid sequences. Head arrows to the left represent location of 
reverse primers for each isoform: blue arrow corresponds to the short isoform (RET-9) in intron 19; red 
arrow represents the long isoform (RET-51) in exon 20; green arrow shows the middle isoform (RET-43) 
located in exon 21. Arrow to the right (yellow) represents the forward primer. (Taken and modified from 
Kwok et al., 1993 and Myers et al., 1995). 
3.6.2.1. RET splicing isoforms of the human gene 
Extensive splice variants in the mRNA regions encoding the extracellular domain and the 
carboxyl terminal part of the RET protein provide high diversity, variation in the half life 
and in nuclear localization, and are predicted to affect the ligand-interacting properties or 
downstream signaling of the protein, respectively. 
Alternative splicing of the primary transcript occurs at the 5’- or at the 3’-end regions; 
splice sites located at the 5’-end region encode RET proteins exhibiting differences at the 
amino-terminus (NH2) and in the extracellular domain, due to having a truncated 
extracellular ligand-binding domain. 
The splice variants at the 3’-end region of mRNA encode at least three different carboxyl 
terminal amino acid sequences, and therefore differences in the intracellular domain. 
The RET exons 8 – 18, encoding the cysteine–rich, the transmembrane, and the major 
tyrosine kinase domains seem not to be subjected to alternative splicing. The 
transcriptional and post-transcriptional mechanisms of RET mRNA processing may 
contribute to the differential expression of RET protein in some carcinomas compared to 
non-neoplastic tissues (Carson and Walter, 1998; Fluge et al., 2001). 
The 5’-end coding region of the RET gene: 
Three alternatively splice isoforms due to exon skipping in the 5’-end region of the RET 
gene, that encodes the extracellular domain of the RET protein were described. Skipping 
occurs with the combination of exon 2 to exon 4, 5 or 6 (Lorenzo et al., 1995; Ivanchuk et 
al. 1997): 
Full length mRNA (FL): exon 2 linked to exon 3 
3-RET mRNA: exon 3 spliced out 
3,4-RET mRNA: exons 3 and 4 spliced out 
3,4,5-RET mRNA: exons 3, 4 and 5 spliced out 
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The FL mRNA is expressed three times more abundantly than the 3- and 3,4-RET mRNA 
isoforms in fetal human brain and kidney (Lorenzo et al., 1995). 
3,4,5-RET mRNA isoform is the least abundantly expressed, only 10% of the amount of 
the full length transcript. All four RET mRNA isoforms are expressed in thyroid cells 
(from MTC) and in SHSY-5Y neuroblastoma cells. However, they are not tumor-specific, 
because they are also expressed in normal human adult tissues, such as thyroid, adrenal 
gland, kidney and brain. 
3- and 3,4,5-RET mRNA isoforms maintain the published open reading frame and are 
predicted to encode RET proteins with deletions in the extracellular domain within the 
putative ligand-binding domain; they differ from FL in their ability to interact with the 
ligands since the cadherin domains are partially or completely removed. Relative to the 
published open reading frame (ORF), the 3- and 3,4,5- mRNA isoforms maintain the ORF 
and encode proteins, lacking aa. 113 to 209 and 113 to 354, respectively, Figure 6. 
However, 3,4-mRNA does not maintain the published ORF. In this message, exon 5 is 
translated in another frame that has a stop codon within exon 5, at nucleotide 1204. The 
predicted protein contains the published exon 2 and 3 ORF plus 63 amino acids from the 
alternate frame of exon 5 at the C-terminus. This protein terminates before the TM domain, 
and would encode a soluble form of RET (next figure).  
 
 
              
Figure 6: Putative proteins encoded by the RET mRNA isoforms located at the 5’-end region. (1) Full 
length RET protein. (2) 3-RET: exon 3 spliced out. (3) 5-RET: exon 5 spliced out. (4) 3,4-RET: exons 3 and 
4 spliced out or soluble isoform. (5) 3,4,5-RET: exons 3, 4 and 5 spliced out. NH2: amino terminus. COOH: 
carboxyl terminus. CLD-1 to 4: cadherin-like domains. Cys: cysteine-rich domain. TM: transmembrane 
(1) (2) (3) (4) (5) 
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domain. TK1 and TK2: intracellular tyrosine kinase domains. The predicted proteins do not differ in the 
COOH terminus (modified from Lorenzo et al. 1995 and Ivanchuk et al., 1997). 
Another variant, lacking exon 5 (Figure 6 (3)) has not been described; however in this 
work it was detected in some human immune cells by RT-PCR. This isoform would 
encode a protein with a smaller CLD-3 domain (see Results).  
 
Recently, another publication describing the expression of alternative splicing isoforms of 
RET in normal thyroid tissue and in papillary carcinoma reported new variants at the 5’-
end region of the gene. Four RET splicing events were found in this region. The open 
reading frames were all in-frame with the RET tyrosine kinase domain (Fluge et al., 2001). 
In the region encoding the Cys-rich, transmembrane, and Tyr kinase domains no 
alternative splicing has been detected. 
The splice variants located between exons 1 and 8 are the following: 
Ret 1-8 mRNA: exons 2, 3, 4, 5, 6 and 7 are spliced out 
Ret 2-8 mRNA: exons 3, 4, 5, 6 and 7 are spliced out 
Ret 3-8 mRNA: exons 4, 5, 6, and 7 are spliced out 
 
The 3’ end coding region of the RET gene: 
The RET gene may encode 10 different 3’-termini producing three coding variants and 
four polyadenylation sites (Tahira et al., 1990; Myers et al., 1995; Ivanchuck et al., 1998). 
RET-9 or short isoform is generated when exon 19 continues directly downstream with 
nine further codons, which lie within intron 19. 
RET-51 or long isoform is expressed when exon 19 is spliced directly to exon 20, 
encoding 51 absolutely different amino acids at the COOH. 
RET-43 or middle isoform occurs when exon 19 splices directly to exon 21. Exon 19 is 
followed by additional 43 codons downstream before a stop codon is reached. 
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The genomic organization of the 3’-end region of the human RET gene is represented: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: A) Genomic organization of the 3’-end region of RET showing intron and exon arrangement. 
Primers used in this study and their orientations are indicated by arrows. Boxes indicate coding sequences: 
RET–9 (short isoform), RET–51 (long isoform) and RET–43 (middle isoform), while lines represent 
untranslated regions. They differ in their amino acid composition, and length at the carboxyl terminus. B) 
Schematic representation of transcripts analyzed (taken from Ivanchuk et al., 1998). 
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Next scheme shows the nucleotide sequence of the isoforms located at 3’-end of RET: 
 
              Exon 19                 |Intron 19 
..CCTCCCTT CCACATGGAT TGAAAACAAA CTCTATGTAG AATTTCCCAT GCATTTACTA  3360 
                                       G  R   I  S  H   A  F  T     
GATTCTAGCA CCGCTGTCCC CTTTGCACTA TCCTTCCTCT CTGTGATGCT TTTTAAAAAT  3420 
R  F stop 
GTTTCTGGTC TGAACAAAAC CAAAGTCTGC TCTGAACCTT TTTATTTGTA AATGTCTGAC  3480 
TTTGCATCCA GTTTACATTT AGGCATTATT GCAACTATGT TTTTCTAAAA GGATGTGAAA  3540 
3541  -  3960 (not shown) 
CACCTTCAGG ACGGTTGTCA CTTATGAAGT CAGTGCTAAA GCTGGAGCAG TTGCTTTTTG  4020 
AAAGAACATG GTCTGTGGTG CTGTGGTCTT ACAATGGACA GTAAATATGG TTCTTGCCAA  4080 
AACTCCTTCT TTTGTCTTTG ATTAAATACT AGAAATTTTT TCTGTTTCCT AACTTCATCA  4140 
4141  -  4680 (not shown)                      |Exon 20 
TTTGGTTCTT CAGTGCAGAA CAAATGATCT GTTTTCATTT TTAGGCATGT CAGACCCGAA  4740 
                                                G  M   S  D  P  N 
CTGGCCTGGA GAGAGTCCTG TACCACTCAC GAGAGCTGAT GGCACTAACA CTGGGTTTCC  4800 
  W  P  G   E  S  P   V  P  L  T   R  A  D   G  T  N   T  G  F  P  
AAGATATCCA AATGATAGTG TATATGCTAA CTGGATGCTT TCACCCTCAG CGGCAAAATT  4860 
  R  Y  P   N  D  S   V  Y  A  N   W  M  L   S  P  S   A  A  K  L 
                        |Intron 20 
AATGGACACG TTTGATAGTT AACATTTCTT TGTGAAAGGT AATGGACTCA CAAGGGGAAG  4920 
  M  D  T   F  D  S  stop  
AAACATGCTG AGAATGGAAA GTCTACCGGC CCTTTCTTTG TGAACGTCAC ATTGGCCGAG  4980 
4981 - 6120 (not shown) 
          |Exon 21 
GTGGTCACAG ATGCACAACA CTCCTCCAGT CTTGTGGGGG CAGCTTTTGG GAAGTCTCAG  6180 
           D  A  Q  H   S  S  S   L  V  G   A  A  F  G   K  S  Q  
CAGCTCTTCT GGCTGTGTTG TCAGCACTGT AACTTCGCAG AAAAGAGTCG GATTACCAAA  6240 
 Q  L  F   W  L  C  C   Q  H  C   N  F  A   E  K  S  R   I  T  K  
ACACTGCCTG CTCTTCAGAC TTAAAGCACT GATAGGACTT AAAATAGTCT CATTCAAATA  6300 
 T  L  P   A  L  Q  T   stop   
CTGTATTTTA TATAGGCATT TCACAAAAAC AGCAAAATTG TGGCATTTTG TGAGGCCAAG  6360 
AATGATAGTC TTACTAAATG CAGAAATAAG AATAAACTTT CTCAAATTAT TAAAAATGCC  6600 
TACACAGTAA GTGTGAATTG CTGCAACAGG TTTGTTCTCA GGAGGGTAAG AACTCCAGGT  6660 
CTTTTTTTGT AATCAAGGTG ACTAAGAAAA TCAGTTGTGT AAATAAAATC ATGTATC     6957 
 
Figure 8: Sequence of the RET 3’-end terminus. The sequence begins at the 3’-end of exon 19 at bp 3337 
according to Takahashi et al. (1988, 1989). Base position numbering after exon 19 through to the final 3’ 
polyadenylation site includes all UTR and coding sequences and therefore does not agree with Takahashi. 
Coding sequences are underlined and colored and amino acids are shown below. Sequences related with 
polyadelylation are dotted-underlined and italicized. Polyadenylation sites are indicated by an asterisk (*) 
above the nucleotide preceding the poly A sequence. Stop codons are indicated. Nucleotide sequences from 
each isoform are marked with letters of different colors: RET-9 in blue, RET-51 in red and RET-43 in green 
(from Myers et al., 1995). 
*
* 
* 
* 
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3.6.2.2. Functional differences between proteins encoded by the three isoforms 
located at the 3’-end region of c-RET gene:  
Differences between the aforementioned isoforms have not yet been well defined and only 
few studies have demonstrated some specific characteristics in developing kidneys and in 
the ENS. RET-9 and RET-51 are necessary for specific temporal and spatial RET 
functions. The long isoform, RET-51, is essential for normal RET function, since the last 
two additional Tyr are implicated in autophosphorylation of RET and are docking sites for 
adaptor proteins. RET-9 and RET-43 do not encode these Tyr residues, suggesting 
differences in regulation or interactions. RET-43 is expressed in normal fetal and adult 
kidney, as well as in a neuroblastoma cell line. 
RET-51 may contribute to cell differentiation and shaping of mature kidney because it only 
appears 8.5 weeks after onset of gestation rather than during the induction of this tissue. 
On the other hand, RET-9 and RET-43 expression in kidneys are higher from 7 through 24 
weeks of gestation (Myers et al., 1995; Ivanchuck et al., 1998). 
Mono-isoformic mouse strains showed that only signaling by RET-9, in the absence of 
RET-51, is sufficient for normal embryonic development and post-natal life. In contrast, 
signaling by RET-51, in the absence of RET-9, resulted in developmental defects of the 
excretory system and ENS. RET isoforms have distinct properties, thus RET-51 is 
important during embryogenesis, whereas RET-9 is necessary and sufficient for normal 
development of ENS and the excretory system (de Graaff et al., 2001). 
As mentioned, RET-51 contains two additional Tyr residues (Tyr1092 and Tyr1096), 
Tyr1096 forms a docking site for the adaptor protein Grb2 and activates the PI3-K and the 
MAP-K signaling pathways (Besset et al., 2000). The differential actions of RET-9 and 
RET-51 could be due to their specific C-terminal ends. The two isoforms diverge in 
sequence one amino acid after Tyr1062, a residue essential for binding of the adaptor 
protein Shc and the assembly of signaling complexes. Because amino acid flanking Tyr-
residues can determine the efficiency of active complex formation and intracellular 
signaling, it is possible that in RET-51, Tyr1062 is a less efficient docking site for binding 
to Shc (Lorenzo et al., 1997; Ishiguro et al., 1999). 
RET-9-specific amino acids at the C-terminus that are absent in RET-51 may have 
signaling properties that have to be delineated. Differential signaling by both isoforms 
could result from the segregation of RET-9 and RET-51 in distinct membrane sub-
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domains, influencing their interactions with downstream components, receptors or ligands 
(de Graaff et al., 2001). 
RET-51 but not RET-9 becomes phosphorylated upon binding by NGF. Probably, because 
both isoforms might be localized differently and NGF-dependent RET activation occurs 
specifically in sub-cellular compartments (Weiss et al., 1997). Recruitment of RET by 
NGF could be part of an antagonistic interaction between NGF and GFLs, which would 
allow NGF to gain control over GFL-mediated signaling by regulating the functional 
properties of RET (Tsui-Pierchala et al., 2002). 
3.6.3. c-RET re-arrangements 
Diverse mutations of the c-RET gene cause different human genetic diseases (Takahashi, 
2001) due to the oncogenic potential of RET. 
a) Activating mutations of c-RET gene are found in sporadic human thyroid carcinomas, 
such as papillary thyroid carcinoma (PTC) and in familiar medullar thyroid carcinoma 
(familiar MTC, 25% of all cases), in multiple endocrine neoplasia type 2 syndrome (MEN-
2) and in sporadic phaeochromocytoma (Eng et al., 1994). A MEN-2 syndrome consists of 
three clinical varieties: MEN-2A, MEN-2B and familial MTC, all characterized by MTC 
and the variations depend on the presence of phaeochromocytoma, parathyroid hyperplasia 
or developmental abnormalities, affecting lineages of neural crest ectoderm (Santoro et al., 
1990; Mulligan et al., 1994). Most of the MTCs express RET, and its ligands GDNF and 
GFRα-1, as well as NTN and GFRα-2, and binds preferentially to tumor cells adjacent to 
the stroma rather than normal thyroid tissues, suggesting that this complex is an important 
step in MTC development (Frisk et al., 2000). 
In 25% of PTCs, the 3’ tyrosine kinase domain of RET is fused to the 5’-terminal region of 
other genes inducing dimerisation and tyrosine activity (Grieco et al., 1990). 
a.1) Mutations in the extracellular cysteine-rich domain of RET have been 
detected in MEN-2A leading to the formation of constitutively active RET homodimers 
(Romeo et al., 1994). 
a.2) Mutations in the intracellular parts of c-RET found in MEN-2B produce a 
mutant RET kinase with changed substrate specificity, but this activity can be modulated 
by GFLs. The expression of MEN-2B in human neuroblastomas alters cell adhesion in 
vitro, enhances metastatic behavior in vivo, and activates the JNK pathway (Marshall et al., 
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1997). A 2-point mutation in TyrK-1 has been described and induces FMTC. A 1-point 
mutation in the TyrK-2 domain causes MEN-2B (Airaksinen et al., 1999). 
b) Inactivating mutations of RET cause Hirschsprung disease (HRSD), characterized by 
the absence of intramural ganglion cells in the hindgut, which results in aganglionic 
megacolon (Eng et al., 1997; Santoro et al., 1999; Takahashi, 2001).  
b.1) HRSD is associated with other mutations of RET such as heterozygous 
deletions, frame-shifts, non-sense, and missense mutations, which are scattered throughout 
the whole gene (Romeo et al., 1994; Sakai et al., 2000) and some of them induce apoptosis 
(Bordeaux et al., 2000). 
b.2) A mutation of tyrosine 905 to phenylalanine (Y905F) impairs the kinase 
activity and abolishes the transforming activity of RET-MEN2-A. 
3.6.4. RET knock-out mice 
RET-/- mice died soon after birth due to kidney agenesis and absence of enteric nervous 
system below the stomach. They did not display gross defects in the brain. 
RET-/- embryos lacked 100% of sympathetic superior ganglion neurons, and had a reduced 
number of a subpopulation of other sensory neurons (Schuchart et al., 1994). 
The hematopoietic system was not analyzed in these animals. 
3.6.5. Expression and distribution 
In the CNS, RET was detected in the cerebellum, forebrain, olfactory bulb, sub-thalamic 
nucleus, hippocampus and other limbic structures (Nosrat et al., 1997; Trupp et al., 1997). 
RET was higher expressed in neurons compared to astrocytes (Remy et al., 2001). 
RET was strongly expressed in the spinal cord and was restricted to axons in normal and in 
avulsed DRG (Bär et al., 1998). Also, it was present in noradrenergic neurons (SCG) 
providing sympathetic innervation for the neck and cranial organs. 
In embryonic kidneys RET was expressed along the nephric duct and in the newly formed 
uretheric bud (Pachnis et al., 1993), but became restricted to the growing tips of the bud as 
branching morphogenesis progressed (Tang et al., 1998). 
Outside of the CNS, RET was found in the spleen, thymus, lymph nodes, salivary gland, 
and in the adrenal medulla (Belluardo et al., 1999). It was present in normal thyroid gland 
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(Forander et al., 2001), and was mostly restricted to the neural crest-derived C cells 
(Bunone et al., 2000), as well as several other neural crest-derived cell lines. 
RET protein was found in the ganglia of human normal colon (Martucciello et al., 1995). 
In the testis, RET, as well as GFRα-1 and GFRα-2, were distributed in overlapping 
patterns (Widenfalk et al., 2000). 
All four isoforms encoded by alternative splicing at the 5’-end of the gene were expressed 
in adult thyroid, adrenal, kidney and brain tissues (Lorenzo et al., 1995). 
3.6.6. Signaling 
The c-RET oncogene encodes a receptor tyrosine kinase that functions as a signaling 
molecule of the multicomponent receptor system for all members of the GFLs (Durbec et 
al., 1996; Airaksinen and Saarma, 2002). Receptor tyrosine kinases (RTKs) are 
transmembrane proteins mediating cell-cell signaling. The intracellular domain is activated 
by ligand interaction with the extracellular domain, inducing its dimerisation and 
autophosphorylation leading to the activation of intracellular signal pathways with 
phosphorylation of cytoplasmic substrates (Schlessinger, 2000; Grimm et al., 2001). 
Upon ligand binding, RET forms dimers and becomes phosphorylated at specific 
cytoplasmic tyrosine residues. Tyr autophosphorylation is required for the catalytic activity 
of RET and for downstream signaling, activated by all members of the GFLs. In addition, 
Ca2+ ions are necessary for the complex receptor formation of RET, indicating the 
importance of the CLD present in the extracellular domain (Nozaki et al., 1998). 
GDNF/NTN-dependent RET activation triggers various intracellular signaling pathways 
via the phosphorylation of Tyr905, Tyr1015, Tyr1062 and Tyr1096 (Coulpier et al., 2002), 
which are docking sites for the adaptor proteins Grb7/Grb10 (Asai et al., 1996), 
phospholipase-Cγ  (PLCγ) (Borello et al., 1996), Shc/ENIGMA (Arighi et al., 1997), 
DOK4/5 and Grb2 (Liu et al., 1996; Xing et al., 1998). Tyr1062 in the COOH terminus is 
the binding site of at least 5 different docking proteins: Shc, DOK4/5 (down-stream of Tyr 
kinase 4/5), FRS2 (fibroblast growth factor receptor substrate 2), IRS1/2 (insulin receptor 
substrate 1/2) and Enigma, which is phosphorylation-independent. 
RET also activates Ras-MAPK (Worby et al., 1996), PI3K (Van Weering et al., 1998), and 
JNK (Xing et al., 1998). 
Introduction 
 
 
 41
GDNF and NTN could trigger PLCγ-dependent Ca2+ release changing the intracellular free 
Ca2+ concentration that activates signal transduction cascades, such as those that regulate 
gene expression (Airaksinen et al., 1999). 
Stimulation of RET in cis or in trans by GDNF in a complex with GPI-anchored or soluble 
GFRα-1, respectively, triggers different signaling pathways inside and outside the rafts 
(Figure 9), although both types of stimulation activates different RET Tyr phosphorylation 
sites with indistinguishable kinetics (Coulpier et al., 2002). 
 
 
 
Figure 9: Intracellular RET-binding proteins and downstream signaling pathways activated by GDNF 
family ligands. Distinct GFLs inside and outside of lipid rafts showing different intracellular RET-binding 
proteins (blue) and activated downstream signaling pathways (gray) when RET tyrosine kinase (TK) is 
stimulated. A) in rafts (yellow) by GFL in a complex with GFRα in cis; or B) outside rafts by a soluble 
GFL-GFRα complex in trans. Docking proteins: FRS2, DOK4/5, IRS1/2, GAB1, GAB2-associated binding 
protein 1; GRB (growth factor receptor-bound protein), MAPK, PH (plextrin homology), PI3K, and PLC 
(from Airaksinen and Saarma, 2002). 
In the absence of ligand, most GPI-anchored GFRα molecules are in lipid rafts; some are 
weakly bound to RET, while most RET is outside the rafts. GFLs may induce GFRα 
dimerisation. The enhanced affinity of the GFL-GFRα complex to RET attracts RET to the 
rafts and promotes its dimerisation. RET stimulation in trans by GFL bound to soluble 
GFRα outside the rafts activates signaling pathways that are mediated by soluble adaptors 
such as Shc recruiting RET to lipid rafts and triggering raft-specific signaling. 
A B 
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3.6.7. Physiological functions of RET 
RET display a major role as growth and survival factor, as well as regulator of migration, 
differentiation and proliferation of neural crest cells. For example, RET was necessary for 
migrating neuroblasts that colonize the colon (Martucciello et al., 1995), migration of RET 
and GDNF-expressing neurons into the developing gut endoderm, to generate the enteric 
neurons of the intestinal tract; as well as being a survival factor for a variety of central and 
peripheral neurons (Schuchart et al., 1994),  
In the embryonic kidney, RET-expressing uretheric bud epithelial cells grew towards the 
metanephric mesenchyme, which expressed GDNF. These epithelial cells were able to 
migrate towards a localized source of GDNF, indicating chemoattraction at the cellular 
level. For this reason, RET played an important role in the induction and development of 
the metanephric kidney (Pachnis et al., 1993), and also regulated uretheric bud outgrowth 
and branching (Tang et al., 1998). 
A reciprocal signaling loop between the uretheric bud epithelium and the stromal 
mesenchyme was dependent on RET and vitamin A. Vitamin A-dependent signaling 
molecules secreted by stromal cells might control RET expression in the uretheric bud, 
subsequently uretheric bud signals dependent on RET controlled stromal cell patterning 
(Batourina et al., 2001). 
Activated RET pathways promoted dysplasic cells to become metastatic and were then 
able to invade surrounding tissue, probably due to cytoskeletal and focal adhesion 
rearrangements and lamellipodia formation. These migrating cells were attracted to 
localized sources of GDNF, as in some neuroblastoma tumors (Marshall et al., 1997). 
Hematopoiesis is a regulated process in which a small population of self-renewing basic 
progenitors generates an offspring of differentiated end cells with specific activities 
(Morrison et al., 1995). This process is controlled by several growth factors and cytokines, 
some of them exerting their functions through the binding to high-affinity RTKs, which are 
differentially expressed on many hematopoietic cells (Ehrhard et al., 1993a; Galli et al., 
1994; Small et al., 1994). A putative role of RET in the regulation of hematopoietic cells 
was suggested by the presence of RET transcripts and protein in lympho-hematopoietic 
tissues of mice and rats, including fetal liver, thymus, spleen, and lymph nodes 
(Avantaggiato et al., 1994; Tahira et al., 1988); it was also present in two myeloid 
leukemia cell lines of human origin (HL-60 and THP-1) (Takahashi and Cooper, 1987; 
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Takahashi et al., 1989; Takahashi et al., 1991). Levels of RET and GFRα-1 mRNA were 
analyzed in purified normal and malignant cells of myeloid and lymphoid lineages 
mirroring various stages of differentiation, and in the BM microenvironment (Gattei et al., 
1997). The results showed low levels of RET mRNA in early CD34+ hematopoietic 
progenitors that increased with maturation along the myelomonocytic lineage, being up-
regulated in circulating neutrophils and in resting or activated monocytes from peripheral 
blood. Findings in human myelomonocytic cell lines were consistent with the pattern 
found in normal cells, since a progressive increase of RET mRNA was present in cells 
representing early to late stages of granulocytic and monocytic differentiation. RET 
expression was maturation-associated in human myelopoiesis, suggesting a possible role in 
the regulation of intermediate and mature myelomonocytic cells. However, purified normal 
T cells from human peripheral blood, tonsil and thymus did not express RET mRNA, even 
after cellular activation. 
In human normal and malignant B cells on different stages of maturation, RET mRNA was 
sporadically detected in SIg+B cell tumors. These results were in agreement with results 
obtained from mouse B cells. RET was only expressed at early stages of B cell 
differentiation, being down-regulated after the expression of surface immunoglobulins. 
Accessory cells of the BM microenvironment provided a physiologic source of GFRα-1 
for RET-expressing hematopoietic cells as seen with human BM aspirate (Gattei et al., 
1997) and mouse tissue (Nakayama et al., 1999). Human BM stromal cells, BM fibroblasts 
and other stromal cells did not express RET but expressed GFRα-1. Thus, GDNF may 
induce terminal differentiation of monocytic leukemia cells, because of enhanced 
maturation of monocyte/macrophage precursors from normal BM CD34+cells in the 
presence of soluble GFRα-1 (Gattei et al., 1997 and 1999). The last reports also showed a 
higher RET expression in blood from patients with monocytic acute myeloid leukemia 
(AML). A statistically significant association was found between the amount of RET and 
the expression of surface molecules: β2 integrins, ICAM-1/CD54, CD56, CD4 and CD14, 
were commonly expressed at high levels by blasts cells of monocytic AMLs. An inverse 
correlation between RET and CD34+ on blasts of the stem cells was observed, which is 
usually lacking in monocytic leukemia (Gattei et al., 1999). 
The association of elevated levels of RET with AMLs of monocytic phenotype, that were 
associated with cell infiltration of gingiva, skin, central nervous system, kidney and other 
Introduction 
 
 
 44 
extra-haemopoietic sites and the presence on blast cells of several adhesion molecules, 
could indicate that cells characterized by a prominent migratory capacity, such as neural 
crest cells, embryonic cells in developing nervous tissues and kidneys, monocytes, 
neutrophils and dermatotropic T cells expressed high levels of RET. Accordingly, RET-
mediated intracellular signaling in non-hemopoietic cells resulted in modifications of cell 
adhesive properties, cell scattering and increased metastatic potential, in agreement with 
the notion that signal transduction through RTK synergized with integrin-mediated 
changes in cell adhesion and migration (Miyamoto et al., 1996). 
Since GDNF was highly expressed within the CNS, spinal cord, skin and other organs 
infiltrated by monocytic AML, probably RET-GDNF interactions may favor leukemia cell 
migration through these tissues. The stromal and endothelial components of these organs 
may represent the source of receptors GFRα and ligands available for interaction with 
RET-expressing blasts in AML, as well as with tissue granulocytes and monocytes during 
inflammatory and wound healing processes (Gattei et al., 1999). 
A similar study was performed in monocytes obtained from peripheral blood and in 
leukemia cell lines (Nakayama et al., 1999). RET was highly expressed in intermediate 
mature myeloid cells and was down-regulated during terminal maturation. Hemopoietic 
cells from mouse BM expressed only RET among the genes examined (GDNF, NTN, 
GFRα-1 and GFRα-2), whereas bone marrow adherent cells (BMAC) or stromal cells 
expressed GFRα-1, GFRα-2 and GDNF but not RET. These results demonstrated that 
promyelocytes and myelocytes highly expressed RET rather than mature neutrophils and 
monocytes, although transcripts were also detected in mature cells. In addition, RET 
expression decreased during differentiation of HL-60 and THP-1 cells in vitro, suggesting 
that c-RET might play a role at an intermediate stage of myelomonocytic maturation rather 
than at its terminal stage.  
BM hemopoietic cells (macrophages) expressed only RET, whereas BMAC expressed 
GFRα-1 and GFRα-2. As previously reported (Treanor et al., 1995; Jing et al., 1996; Klein 
et al., 1997; Nozaki et al., 1998), soluble GFRα was able to mediate GDNF or NTN 
signaling in cells that expressed RET but not GFRα. According to these results, both 
groups (Gattei et al., 1997 and 1999; Nakayama et al., 1999) have speculated that GFRα-1 
on the cell surface of BM stromal cells might function like soluble GFRα receptor. 
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During development the survival of almost all sympathetic neurons in SCG depended on 
NGF and its receptor TrkA. GFLs (except PSP) also can act on SCG neurons. In addition 
to the GFLs dependent route, RET may be activated by NGF signaling via a novel indirect 
mechanism, which contributed to the post-natal maturation of SCG neurons. The 
mechanisms linking NGF/TrkA to RET activation remain unclear. This finding leads to the 
conclusion that growth factors and their receptors interact to form a net of trophic signaling 
routes that guide the development of SCG neurons, thus RTKs could be sensitive to ligand-
dependent and ligand-independent mechanisms (Weiss et al., 1997). 
The functions of neurotrophic factors from different families provided evidence for a 
hierarchy of TrkA and RET interactions in the SCG, showing that GDNF could antagonize 
the growth promoting effects of NGF on sensory neurons (Linnarsson et al., 2001). It was 
also reported that NGF activated RET (Tsui-Pierchala et al., 2002) in vitro and in vivo in 
rodent SCG neurons, by a mechanism independent of GFLs and GFRα receptors. NGF-
dependent RET phosphorylation regulated soma size and metabolism but not survival of 
maturing post-natal sympathetic neurons (Dechant, 2002). 
3.6.8. RET under pathological conditions 
The higher expression of the RET gene was detected mainly in neuroblastomas (tumors of 
neuroectodermal origin) among the tumors from the neural crest cells (Ikeda et al., 1990), 
as well as in phaeochromocytoma and in medullar thyroid carcinomas.  
Some human leukemia cells also expressed high levels of RET, i.e., HL-60 and THP-1 
(Takahashi et al., 1991). 
The expression of oncogenic re-arranged versions of c-RET in PTC derived from thyroid 
follicular cells was demonstrated, as well as the presence of RET transcripts in some 
follicular thyroid carcinoma lymph node metastases. RET could be active in thyroid 
follicular cells (Bunone et al., 2000). 
After transient forebrain ischemia, RET mRNA expression was induced in the 
hippocampus, mainly 12 hours after artery occlusion. Its expression was reduced by local 
GDNF-pretreatment, suggesting that GDNF could modulate RET expression, and also 
some signaling pathways that contribute to brain injury induced by ischemia (Arvidsson et 
al., 2001; Miyazaki et al., 2002). 
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3.7. GDNF FAMILY RECEPTORS-α 
3.7.1. General characteristics 
The GFRα family of proteins is composed of a highly conserved group of co-receptors 
required for the binding of the GFLs and the subsequent activation of RET transmembrane 
receptor. GFRα proteins are linked to the plasma membrane through a cluster of small 
amino acids, namely glycosyl phosphatidylinositol (GPI) anchor (Brodbeck et al., 1998; 
Ferguson et al., 1999), and they are located within lipid rafts, which are structures resistant 
to cold detergent lyses (Muniz and Riezman, 2000; Ilangumaran et al., 2000). Structurally 
GFRαs possess three globular cysteine-rich domains (D1, D2, D3), except for GFRα-4 
which has only two (Lindahl et al., 2000). GFLs bind to the second domain of GFRα 
receptors that is also crucial for RET binding (Scott and Ibanez, 2001). 
The four GFRα genes are similar in structure and organization of exons. They share 30–
45% amino acid identities and have similar arrangements of conserved Cys residues. 
The cleavage by an unknown phospholipase or protease produces soluble forms, which are 
able to capture the ligand from the extracellular environment for subsequent assembly into 
a functional receptor complex on the cell membranes carrying the appropriate signaling 
subunits (Paratcha et al., 2001). In addition, GFRαs can negatively modulate levels of RET 
phosphorylation in the absence of ligand; thus, GFR-α receptors could increase the signal-
to-noise ratio in response to the ligands (Ibanez, 1998). 
“GFRα-X” is used for GDNF Family Receptor Alpha-X, where “X” denotes an Arabic 
numeral to be assigned based on the date of publication of the receptor. The term “alpha” 
served to clarify that these molecules are part of a multicomponent receptor complex 
(Nomenclature Committee, 1997). 
All GFRα members retain the signal sequence that is required for GPI-anchoring and is 
found in the final coding exon of each gene (Vanhorne et al., 2001). 
GFRα receptors can mediate activation of RET when expressed on the cell surface 
(activation in cis), or when presented in soluble form, immobilized on the cell matrix or in 
neighboring cells (activation in trans). GFRαs are often expressed in the absence of RET 
(i.e., in Schwann cells, or several areas of adult brain) suggesting that RET is not always 
required for signaling, or they may interact with RET in soluble forms. 
Introduction 
 
 
 47
3.8. GFRα-1 
3.8.1. Description and characteristics 
GFRα-1 is the surface receptor component of the GDNF/GFRα-1/RET signaling complex. 
It is a glycolipid-linked extracellular protein attached to the cell membrane by a GPI-
linkage, without having an intracellular signaling domain. Its structure contains 30 Cys 
residues with similar spacing and arrangement to other members of this family. GFRα-1 
contains 465 aa with a signal peptide at the amino terminus, with 20–23 hydrophobic aa at 
the carboxyl-terminus and 3 glycosylation sites (Treanor et al., 1995; Jing et al., 1996; 
Sanicola et al., 1997; Eng et al., 1998).  
In the human GFRα-1 gene, exon 1 and the largest parts of exons 2 and 11 are not 
translated. The translation start site is located 247 nucleotides downstream the start of the 
second exon.  
Two isoforms of GFRα-1 have been described in murine and in human tissues. The shorter 
variant has a deletion of 15 bp, which is contained within the entire exon 5. Both isoforms 
are able to bind GDNF and activate RET with high affinity and specificity (Eng et al., 
1994; Sanicola et al., 1997; Angrist et al., 1998). 
3.8.2. GFRα-1 knock-out mice 
GFRα-1 deficient mice displayed deficits in the kidneys, the ENS, the spinal cord and in 
sensory neurons. They had complete bilateral renal and urethral deficits.  
The neural crest-derived enteric neurons belonging to the myenteric and submucosal plexi 
were absent in the intestine and colon of these mice, similar to GDNF-/- and RET-/- mice.  
GFRα-1-/- mice exhibited small losses of lumbar spinal (24%) and trigeminal nucleus MN 
(22%), but not of facial MN. They did not show a reduction in the density of DA 
projections in the striatum and had normal noradrenergic neurons in the locus coeruleus. 
Minimal or no losses of neurons were observed in a number of peripheral ganglia, which 
were severely affected in both c-RET and GDNF-/- mice, suggesting that while 
physiological interactions exist between GFRα-1 and GDNF in renal and in ENS 
development, significant cross talk between GDNF and other GFRα must also occur in 
peripheral ganglia (Enomoto et al., 1998). Adrenal glands, gonads, remaining abdominal 
and thoracic tissues appear to be normal (Calacano et al., 1998). 
Introduction 
 
 
 48 
3.8.3. Signaling 
GDNF bound specifically and with high affinity to GFRα-1 mediating activation of RET. 
Cells expressing GFRα-1 on the surface treated with GDNF rapidly stimulated RET 
autophosphorylation in a dose- and time–dependent manner. RET was also activated by 
treatment with GDNF and soluble GFRα-1 in cells lacking GFRα-1, because GFRα-1 
does not need to be anchored to the cell membrane in order to interact with RET (Jing et 
al., 1996). GFRα-1 had some affinity for RET in the absence of ligand, suggesting that 
pre-formed complexes of GFRα/RET were also present on the cell surface. 
The GDNF dose required to trigger a biological effect varies widely among different cell 
types, suggesting the existence of both high and low affinity GDNF receptors. 
Modes of action of GFRα-1 in the activation of c-RET molecules in trans: 
? Released and soluble GFRα-1 molecules can bind GDNF in the extracellular space and 
present it in trans to RET expressing cells located at a distance providing a trophic 
signal with excellent spatial resolution. 
? Released GFRα-1 can be immobilized to the extracellular matrix by passive adsorption 
and present GDNF. 
? GPI-anchored GFRα-1 molecules on standby cells can bind GDNF and present it in 
trans to RET receptor on adjacent cells by cell-cell contact (Paratcha et al., 2001). 
3.8.4. Expression and physiological functions 
GFRα-1 mRNA was present in defined brain areas: in midbrain DA neurons (SN and 
ventral tegmental areas), olfactory tubercle, hippocampus (Nosrat et al., 1997), cortex 
(occipital lobe), medial geniculate, caudate nucleus and the habenula (Trupp et al., 1996; 
Sanicola et al., 1997), and in rat-cultured microglia (Honda et al., 1999). 
Schwann cells expressed GFRα-1 but not RET (Treanor et al., 1995). 
In peripheral embryonic rat tissues, GFRα-1 expression showed high levels in fetal 
intestine and kidneys (Sanicola et al., 1997). In the rat thyroid tissue, GFRα-1 expression 
was widespread. In contrast, RET was expressed in a subpopulation of cells in the 
follicular epithelium and in the interfollicular spaces (Belluardo et al., 1999). 
GFRα-1 protein was found on the membrane of capillary endothelial cells. GDNF 
activated the brain-blood barrier function of these cells in the presence of cAMP. Since 
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GDNF was secreted from astrocytes sheathing capillary endothelial cells in the brain 
cortex, GDNF/GFRα-1 may enhance the function of the tight junctions of the brain blood 
barrier and could also support neuronal survival (Igarashi et al., 1999). 
GDNF activated by GFRα-1 and RET in corneal epithelial cells induced phosphorylation 
of Ras and FAK, followed by activation of MAPK to initiate gene transcription, and FAK-
dependent phosphorylation of paxillin to initiate cell migration (You et al., 2001). 
Immature adrenal medullar cells expressed GFRα-1 mRNA that increased upon GDNF 
treatment, promoting transformation of chromaffin cells into a neuronal-like phenotype 
(Forander et al., 2001). 
3.8.5. GFRα-1 under pathological conditions 
GFRα-1 and GDNF were expressed in human gliomas in vivo. However, it is unknown 
whether human astroglioma can produce GDNF and its receptors during the process of 
malignant transformation (Wiesenhofer et al., 2000). 
GFRα-1 mRNA expression was elevated to variable levels in peripheral nerve biopsies 
from patients with various inflammatory neuropathies when compared to control subjects 
(Yamamoto et al., 1998). The increased levels of expression correlated well to the extent of 
axonal degeneration. The infiltration of T cells and macrophages is one of the important 
factors in the process of nerve injury and repair, especially in vasculitic and inflammatory 
neuropathies. Macrophage invasion into the nerve fascicles occurred in acute stages of 
axonal degeneration (Kiefer et al., 1998). The GFRα-1 mRNA expression was 
proportionally elevated to the extent of macrophage invasion as well as to the extent of 
axonal degeneration, suggesting that cytokines or other factors secreted by the 
macrophages and T cells may enhance the GFRα-1 expression. 
As reported before, GDNF and GFRα-1 mRNAs, but not RET were up-regulated in 
Schwann cells of damaged nerves after axotomy. Nerve sprouting was induced and guided 
by processes that extended from Schwann cells to denervated muscles.  
Schwann cells produced GFRα-1 that captured and concentrated GDNF in a cell-anchored 
GDNF/GFRα-1 complex that acted as a guide to attract re-growing motor axons extended 
from MN expressing RET to muscle cells. GDNF and GFRα-1 expressed by Schwann 
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cells of injured adult peripheral nerves probably play a role in nerve regeneration (Trupp et 
al., 1997; Naveilhan et al., 1998). 
GFRα-1 and RET mRNA levels in MN were up-regulated following muscle contusion. 
This rapid and prominent up regulation may be important for regeneration of intramuscular 
motor nerves damaged by muscle contusion (Kami et al., 1999). 
GFRα-1 and RET played a role in the regulation of GDNF signaling pathways in response 
to electroconvulsive seizures (ECS), because after acute and chronic ECS, levels of GFRα-
1 mRNA in the dentate gyrus were increased. This in turn elevated GDNF expression, 
which could have beneficial effects on neuronal function/survival after seizures (Chen et 
al., 2001). 
GFRα-1 was expressed in all bile duct carcinoma samples, indicating that carcinogenesis 
leads to aberrant expression of GFRα-1 (Iwahashi et al., 2002). 
 
 
3.9. GFRα-2 
3.9.1. Description and characteristics 
GFRα-2 is the preferred surface receptor for the ligand NTN (Baloh et al., 1997; Buj-Bello 
et al., 1997; Sanicola et al., 1997).  
Structural features essential for GFRα-1 function have been preserved in GFRα-2: a) a 
signal peptide for secretion at the N-terminus; b) three potential N-glycosylation sites 
located in similar positions; c) 30 conserved cysteine residues, and d) a stretch of 17 
hydrophobic aa at the C-terminus preceded by a group of three small amino acids 
indicative of a typical cleavage-binding site for a GPI linkage. The protein contains 464 aa, 
having a molecular weight of 52 kDa and 47% identity to GFRα-1 (Wang et al., 1998). 
3.9.2. The GFRα-2 gene 
Using the human GFRα-1 sequence to search for homologues with the BLAST and 
BLASTN algorithms, the GFRα-2 gene was identified (Wang et al., 1998). The complete 
reading frame was encoded by nine exons (1526 bp) which were all translated (Baloh et 
al., 1997).  
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The nucleotide positions, as well as the splice isoforms have been described in mice 
(Wong et al., 1998) and in humans (Vanhorne et al., 2001; Wong et al., 2002). GFRα-2a 
corresponds to the full length mRNA. GFRα-2b lacks exon 2 (315 bp) and the deduced 
amino acid sequence is identical to GFRα-2 full length except for a 105 amino acid 
deletion at the N-terminus. The signal peptide cleavage site in GFRα-2b is located 20 
amino acids downstream from the initiation of translation. GFRα-2c lacks exon 3 (84 bp). 
GFRα-2b and GFRα-2c have a deletion of eight Cys residues and a single glycosylation 
site at the N-terminus.  
Another isoform described in human tissues (Vanhorne et al., 2001) resulting from the lack 
of exons 2 and 3 (399 bp) is the Exon 1-4 mRNA splice variant. The transcript encodes a 
protein of 331 amino acids that would not contain the N-terminal Cys-rich domain, lacking 
three N-terminal α helices of the protein and at least one N-glycosylation site. The deleted 
protein region is not critical for binding of NTN and RET to GFRα-2, and does not 
determine the specificity of interactions, ligand binding or signaling capabilities of GFRα 
and GDNF family ligands (Scott and Ibanez, 2001). 
 
 
Figure 10: Predicted proteins encoded by the alternative splice isoforms of the GFRα-2 gene. GFRα-2a 
(F.L) has three globular domains. The difference between GFRα-2a and GFRα-2c is that the latter lacks a 
single glycosylation site at the N-terminus. GFRα-2b has a deletion of 105 amino acids at NH2 terminus and 
therefore also lacks the glycosylation site. Exon 1-4 variant does not contain the first Cys-rich domain, 
because a total of 331 aa are not translated (modified from Airaksinen et al., 1999 and Vanhorne et al., 2001). 
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The first globular Cys-rich domain (D1) was not necessary for ligand specificity. Ligand-
independent interaction with RET resides in the central domain of GFRαs (D2) within a 
distinct and smaller region required for ligand binding (Scott and Ibanez, 2001). 
3.9.3. GFRα-2 knock-out mice 
GFRα-2-/- mice are viable and fertile, but display dramatic growth retardation. Organs, 
which normally express high levels of GFRα-2, appear normal in morphology. However, 
the neuronal deficits led to dry eyes due to a reduction in tear secretion and increase 
blinking rate. In the gut, there was a decrease in the frequency, intensity, and synchrony of 
the gut contractile activity. These animals share a similar eye phenotype and deficits in the 
enteric and parasympathetic nervous system as NTN-/- mice, indicating a functional 
interaction between NTN and GFRα-2 in vivo. The cholinergic innervation of the 
lachrymal and salivary glands, as well as the small bowel was almost absent. They 
displayed deficits in fiber density of substantia P-positive neurons of the small intestine 
(Rossi et al., 1999). 
3.9.4. Signaling 
GFRα-2 was able to bind NTN with high affinity and GDNF with lower affinity in vitro 
(Cik et al., 2000), and both complexes signal through RET tyrosine phosphorylation 
(Baloh et al., 1997; Sanicola et al., 1997). GFRα-2 was unable to signal in the absence of 
RET (Pezeshki et al., 2001). 
The signaling pathways activated after the ligand-receptor complex is formed were 
described in the section about RET signaling (3.6.6). 
3.9.5. Expression and physiological functions 
Within the brain (mouse, rat and human), the highest levels of GFRα-2 mRNA were found 
throughout the cerebral cortex, olfactory bulb, amygdaloid nuclei, superior/inferior 
colliculus, cerebellum and thalamus. Moderate levels were found in the hypothalamus and 
in the pre-optic area (Sanicola et al., 1997; Wang et al., 1998). 
In mouse organs, GFRα-2 mRNA was present in developing sensory organs, in the gut 
myenteric intestinal plexus and in the gonads, being required for growth and proliferation 
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of neural crest cells. GFRα-2 was also expressed in the penile neurons in the major pelvic 
ganglia (Laurikainen et al., 2000). 
In mouse (Widenfalk et al., 1997) and in rat tissues (Wang et al., 1998) GFRα-2 mRNA 
was expressed in the brain, spleen, placenta (Sanicola et al., 1997) and lungs (Naveilhan et 
al., 1998). Moderate to low levels were detected in kidneys, thymus, stomach and small 
intestine. GFRα-2 mRNA was not detectable in skeletal muscles or liver.  
GFRα-2 also played a critical role in the parasympathetic innervations of the lachrymal 
and salivary glands through cholinergic neurons. 
Astrocytes from rat glial cells expressed high amounts of GFRα-1 and GFRα-2 mRNA. 
Expression of GFLs and their receptors was not restricted to neurons and may be 
implicated in oligodendrocyte development (Remy et al., 2001). Enriched mature 
oligodendrocytes also expressed RET, GFRα-1 and GFRα-2 mRNA (Strelau and Unsicker, 
1999). 
3.9.6. GFRα-2 under pathological conditions 
Cortical GFRα-2 mRNA transiently increased in the post-ischemic phase of local ischemic 
insults, as well as GFRα-1 and RET mRNAs, indicating that changes of GFL receptors 
could enhance neuroprotective and neuroregenerative responses, due to both endogenous 
and exogenous GFLs (Arvidsson et al., 2001). 
Levels of GFRα-2 mRNA and GFRα-1, but not GDNF, were elevated after acute and 
chronic ECS implying that the regulation of the GFRαs may mediate adaptive responses of 
the GDNF system to acute and chronic stimulation (Chen et al., 2001). Epileptogenesis, in 
the hippocampal kindling model, was suppressed in GFRα-2-/- mice, thus providing 
evidence that GFRα-2 signaling was involved in mechanisms regulating the development 
and persistence of kindling epilepsy (Nanobashvili et al., 2000).  
GFRα-2 polymorphism variants occurred naturally and did not contribute to the HRSD 
phenotype (Vanhorne et al., 2001). 
Table 1 shows the distribution of GFLs and receptors in the nervous system and in 
peripheral organs. 
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GDNF GDNF NTN NTN RET RET GFRα1 GFRα1 GFRα2 GFRα2 
Tissue 
Embryo Adult Embryo Adult Embryo Adult Embryo Adult Embryo Adult 
Olfactory bulb ++ + _ _  ++   ++ +++ 
Cingulate cortex    _      ++ 
Cortex cerebri + + _ _ _ _ + + ++ +++ 
Striatum ++ + _ _ _ _ + + _ _ 
Septum    _      ++ 
Dentate gyrus   _ _  +   + ++ 
DA neurons SN - - ++ _ +++ +++ +++ +++ _ _ 
Pituitary gland   ++ ++     ++ + 
Pineal gland    +       
Amygdale  +  _  +  + + ++ 
Thalamus ++ + _ _ ++ + ++ ++ + ++ 
Reticular thalamic N    _     + ++ 
Zona incerta    _     +++ +++ 
Hypothalamus +  _ _ + + ++  ++ ++ 
Cerebellum ++ + _ _ + / ++ ++ +++ ++ ++ + 
Brainstem ++ - _ _ ++ ++ ++ ++ ++ ++ 
Trigeminal ganglia _ + _ + +++ +++ ++ +++ ++ +++ 
Spinal cord, gray m. + + post. H _ _ +++ ++ +++ ++ ++ + 
Dorsal root ganglia ++ - / + _ _ +++ +++ +++ +++ +++ +++ 
Autonomic ganglia _  _  +++  +  ++  
Peripheral nerve  + _     +++   
Skeletal muscle _ ++ _ + _ _ + _ _ _ 
Inner ear   ++      +  
Olfactory mucosa   ++      ++  
Skin _  +++ ++ _ _ _ _ + _ 
Salivary glands   ++      + ++ 
Lung  - / + + ++  _  _ + ++ 
Myocardium + _ + _ _ _ + _ + _ 
Heart vessels    _      _ 
Intestine ++ _ ++ +++ ++ ++ ++ _ + _ 
Kidney +++ _ ++ + +++ _ +++ + _ _ 
Adrenal glands + _ _ ++ _ _ _ +++ _ - / + 
Thyroid _ _   + + + ++   
Testis +++ + ++ +++ _ _ _ +++ _ +++ 
Oviduct / Ovary  - / +++  - / +++  - / +  - / -  - / - 
Thymus _ _ + + - / + _ _ _ _ ++ 
Liver _ - / + ++ + _ - / + ++ + + _ 
Spleen  +   + +   ++ +++ 
 
Table 1: This table describes the localization of GDNF, NTN, RET, GFRα-1 and GFRα-2 in mouse, rat and 
human nervous system and in several peripheral tissues. The mRNA or protein expression usually changes 
from the development through the adult life (Suter-Crazzolara and Unsicker, 1994; Nosrat et al., 1996; 
Nosrat et al., 1997; Sanicola et al., 1997; Widenfalk et al., 1997; Naveilhan et al., 1998; Wang et al., 1998; 
Belluardo et al., 1999; Golden et al., 1999). 
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3.10. MYOBLASTS 
Part of this work involved studying the expression of GDNF, NTN and their receptors on 
human myoblasts in culture. These experiments were carried out in collaboration with Dr. 
G. Chevrel.  
At sites destined to form striated muscles, mononuclear, mesenchymal-like cells with 
precise phenotypic markers accumulate, permitting the discrimination of muscles from 
other, and non-muscle precursors. 
Myoblasts are defined as post-mitotic, spindle shaped, mononuclear cells capable of 
synthesizing contractile proteins and capable of fusion with other myoblasts. They are the 
immediate descendents of presumptive myoblasts, which can neither fuse nor synthesize 
muscle-specific gene products. Subsequent to myoblast cell fusion, long, cylindrical, 
multinucleated or syncytial cells are formed, termed myotubes. These cells exhibit central 
nucleation and peripherally disposed myofibrils, which confers a tube-like appearance. 
Alongside these initial, or primary, myotubes are longitudinally oriented myoblasts, which 
subsequently fuse to form secondary myotubes. Initially, the primary myotubes and their 
associated myoblasts and secondary myotubes are coupled by gap junctions and share a 
common basal lamina. As the muscle mature, secondary myotubes acquire their own basal 
lamina and become independent fibers. Primary and secondary myoblasts may synthesize 
different isoforms of myosin and have different developmental requirements for 
innervation. 
Once the myonuclei shift from a central to a subsarcolemmal position, the muscle cells are 
termed myofibers to distinguish them developmentally from the more embryonic 
myotubes. The appearance of central nucleation within otherwise normal adult muscle is a 
sign of muscle regeneration within a tissue. 
At some point, the presumptive myoblasts aggregate and cease migration. The cells enter a 
prolonged G1 period of the mitotic cell cycle and initiate the transcription of genes 
characteristic of the terminally differentiated muscle cells. If unfused, such cells are termed 
myoblasts; upon cytoplasmic fusion, they are termed myotubes. The migrated presumptive 
myoblasts express many of the cytoskeletal and contractile proteins characteristic of other 
non-muscle mesodermal cell types. 
It is accepted that the contractile muscle fiber is a terminally differentiated cell type. In 
vertebrates, muscle regeneration in response to trauma or injury is affected by a reverse 
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cell population of satellite-undifferentiated stem cells, which are closely aligned along the 
fiber between the basal lamina and the sarcolema. The satellite cells proliferate and 
populate the laminar sheath of the degenerating fiber, and recapitulate the process of fusion 
and differentiation observed in embryonic muscles. The irreversibility of the differentiated 
end state of the muscle fibers may reflect the structural limitations imposed by its 
prospective function (Engel AG in Myology, 1986). 
 
Previous studies have reported that GDNF was expressed in skeletal muscles as a target-
derived neurotrophic factor. However, the action of GDNF on normal or pathological 
muscles of humans is unknown.  
RT-PCR analyses showed that normal muscles expressed mostly truncated GDNF mRNA; 
on the contrary, muscles from polymyositis (PM) and Duchenne type muscular dystrophy 
(DMD) expressed the full length form (Li et al., 1995; Suzuki et al., 1998). The expression 
pattern of GDNF mRNA isoforms in amyotrophic lateral sclerosis was also different from 
controls (Yamamoto et al., 1998). On the other hand, the GFRα-1 mRNA expression did 
not change significantly in diseased muscles and RET mRNA was detected neither patients 
nor in control subjects. 
The expression of GDNF and its receptors has not been studied in human myoblasts in 
culture. In light of the possible role of GDNF in normal and pathological conditions in 
muscles, we were interested in studying the expression and regulation of this factor in 
myoblasts under inflammatory stimuli.  
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4 OBJECTIVES 
There is evidence that neurotrophins (NGF, NT-3, NT-4/5, and BDNF) exert functions in 
both the nervous and immune system.  
The aim of this study was to understand the expression and functions of the GDNF family 
ligands and their receptors on immune and hematopoietic cells, since few reports have 
been published about this issue.  
Most publications have given attention to RET receptor, and among them some have 
reported the presence of RET mRNA and protein in the lympho-hematopoietic tissues, 
such as fetal liver, thymus, spleen and lymph nodes (Avantaggiato et al., 1994; Tsuzuki et 
al., 1995), in human leukemia cell lines (Tahira et al., 1990; Takahashi et al., 1991), and in 
B and T cell leukemia/lymphomas and myelomonocytic cells (Gattei et al., 1997; 
Nakayama et al., 1999). RET may be a functional regulator of hematopoietic cells. 
In addition, transcripts of GFRα-1, GFRα-2 and GFRα-3 were found neither in leukemia 
cell lines expressing RET nor in normal human peripheral blood cells. BM hemopoietic 
cells expressed only RET whereas bone marrow adherent cells (BMAC) or stromal cells 
expressed GFRα-1, GFRα-2 and GDNF. 
Moreover, GFLs is a new family of trophic factors that are structurally related to the TGF-
β superfamily, which is a prominent family of cytokines. 
The complex distribution patterns of GDNF, RET and GFRα-1 and the relation of these 
patterns to those of NTN and GFRα-2 suggest that the GFLs and their receptors are 
required for both, the developing and adult organism, within and outside the nervous 
system. These relationships may be analogous to those for the neurotrophins and their 
receptors, as they also exert important functions in the IS and in the NS. 
Therefore, we decided to investigate possible interactions between the nervous and the 
immune system mediated by members of the GDNF family ligands, GDNF, NTN and PSP, 
and their receptors: GFRα-1, GFRα-2 and RET.  
To address this issue, the expression of these molecules was studied at the mRNA and at 
the protein level in sub-types of peripheral blood mononuclear cells: CD4+ and CD8+-T 
lymphocytes, CD19+B lymphocytes and CD14+ monocytes. Afterwards, to establish the 
potential functions of GDNF and NTN on immune cells, several functional experiments 
were also performed in this study. 
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5 MATERIALS AND METHODS 
5.1. BUFFERS and REAGENTS 
Phosphate buffered saline (1xPBS) 
9.1 mM Na2HPO4 (Dibasic sodium phosphate) 
1.7 mM NaH2PO4 (Monobasic sodium phosphate) 
150 mM NaCl. Adjust pH to 7.4 with NaOH (Sodium hydroxide pellets) 
 
Wash buffer (Western blot): PBS + 0.05% Tween-20 (polyoxyethylene-sorbitane monolaurate) 
 
PFA – 4% 
 Paraformaldehyde 4% (w/v) in PBS, pH: 7.3 
 Dissolve PFA in water with a drop of NaOH, add PBS after complete dissolution 
 
Tris buffered saline (1xTBS) 
10 mM Tris-HCl, pH: 8.0 
150 mM NaCl. Add distilled H2O to 1 liter 
 
Carbonate coating buffer 
0.025 M sodium bicarbonate 
0.025 M sodium carbonate, pH = 8.2 
 
Lysis Buffer: RIPA Buffer 
1xPBS 
1% Nonidet P-40 
0.5% Sodium deoxycholate 
0.1% SDS 
Add proteases and phosphatases inhibitors at time of use from, as follows: 
- PMSF [10 mg/ml] in isopropanol: add at 10 µl/ml RIPA 
- Aprotinin: add at 30 µl/ml RIPA 
- Leupeptine: add at 30 µl/ml RIPA 
- Sodium orthovanadate 100 mM, add at 10 µl/ml RIPA 
 
MOPS - SDS Running Buffer (20x) 
MOPS (3-(N-morpholino) propane sulfonic acid) 104.6 g 
Tris Base       60.6 g 
10% SDS        100 g 
EDTA      3 g 
Ultra pure water     to 500 ml; pH = 7.7 
 
MES - SDS Running Buffer (20x) 
MES (2-(N-morpholino) ethane sulfonic acid) 97.6 g 
Tris Base       60.6 g 
10% SDS        100 g 
EDTA      3 g 
Ultra pure water     to 500 ml; pH=7.3 
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Loading Buffer: LDS (4x) 
Tris Base   0.682 g  EDTA   0.006 g 
Tris HCL   0.666 g  Serva Blue G250 0.0075 g 
Sucrose   4 g   Phenol Red  0.0025 g 
SDS   0.8 g   Ultra pure Water to 10 ml 
 
Transfer buffer (20x) 
60 ml H2O 
10 ml MeOH 
10 ml 20x transfer buffer 
 
Molecular weight marker 
Rainbow Color Marker (Amersham): 250 kDa, 160 kDa, 105 kDa, 75 kDa, 50 kDa, 
35 kDa, 20 kDa, and 15 kDa. 
 
FACS buffer (staining buffer) 
Dulbecco’s PBS 
1% heat-inactivated FCS 
0.1% (w/v) sodium azide. Adjust buffer pH to 7.4 – 7.6 
 
Fixation Buffer 
Dulbecco’s PBS 
4% (w/v) paraformaldehyde 
Add the paraformaldehyde to PBS  
Adjust buffer pH to 7.4-7.6. Store at 4°C, protected from light 
 
Permeabilization Buffer 
Dulbecco’s PBS 
1% heat-inactivated FCS 
0.1% (w/v) sodium azide 
0.1% (w/v) saponin (Sigma). Adjust buffer pH to 7.4 - 7.6 
 
Propidium Iodide  
[1 mg/ml] + PBS 
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5.2. CELL PREPARATIONS 
All experiments were performed using two different cells preparations: human cell lines 
used as positive or negative controls (5.2.1), and freshly isolated human peripheral blood 
mononuclear cells (PBMCs), from which different cell types were obtained (5.2.2).  
PBMCs were separated into CD4+ and CD8+-T lymphocytes (Ly), CD19+-B lymphocytes 
and CD14+-monocytes using different methods described in the following sections. 
Immune cells were used either non-activated or activated with specific mitogens, 
antibodies or cytokines, depending on the cell type and on the experiments. 
The purity of the isolated cell types was >95% as determined by fluorescence-activated 
cell sorter scan (FACS) analysis (Becton-Dickinson FACSCalibur). 
Supernatants (SN) were removed at different time intervals after stimulation and analyzed 
for protein concentrations. Cell subtypes were used at different time points to prepare 
mRNA, total protein lysate or to perform FACS experiments, proliferation assays, etc. 
 
5.2.1. Cell line cultures 
Under sterile conditions, different human cell lines were cultured in 75cm2 Falcon flasks, 
with 5%-10% fetal calf serum (FCS) (Gibco®), either in RPMI (Gibco®) or in DMEM 
medium + penicillin (50-100 U/ml)/streptomycin (50-100 µg/ml), and were grown in 37°C 
incubators (95% humidity, 5% CO2) (Current protocols of Immunology, 2001). 
When adherent cells reached approximately 80% of confluence, cells were washed in PBS, 
then detached with trypsine, and split into two flasks. 
5.2.2.1. Cell types: 
3T3- fibroblasts transfected with rat-GDNF (from Dr. A. Fluegel, Max-Planck-Institute for 
Neurobiology, Germany)  
3T3- fibroblast transfected with rat-NGF (from Dr. A. Fluegel) 
293 cells (primary human embryonic kidney cells transformed with sheared human 
adenovirus type 5 DNA, epithelial morphology) 
HeLa cells (human, cervix, epithelial adenocarcinoma) 
HL-60 cells (human, leukemia, intermediate myeloid promyelocytic cell type) 
Jurkat cells (human, leukemia, T cell type) 
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K-562 cells (human, leukemia, early myelo-erytroblasts cell type)  
Myoblasts (human normal fetus, from Dr. Lochmüller, Genzentrum, Munich and Ludwig-
Maximilians-University, Munich) 
SHSY-5Y cells (human neuroblastoma cell line) 
TE671 cells (human rabdomyosarcoma cell line) 
TGW cells (human neuroblastoma cell line, given by Dr. M. Takahashi, Tokyo University, 
Japan) 
 
5.2.2. Isolation of peripheral blood mononuclear cells from fresh blood 
Peripheral blood mononuclear cells (PBMCs) were isolated from either fresh blood or 
from Buffy coat using the method of Bøyum: density centrifugation on Lymphoprep®, 
which is a mixture of sodium metrizoate and polysaccharide. The polysaccharide in this 
solution causes the erythrocytes to aggregate and settle to the bottom of the tube along with 
granulocytes. The density of the sodium metrizoate (1077 g/l) is such that lymphocytes, 
monocytes and platelets remain at the interface between the plasma and Lymphoprep® 
layers. This separation of cellular components is enhanced by low speed centrifugation, at 
room temperature (RT). 
 
5.2.2.1. Gradient method using Lymphoprep®: 
Ficoll-Hypaque density gradient centrifugation 
Human fresh blood (collected in a 9 ml Sarstedt EDTA tube) diluted with an equal volume 
of PBS or 10 ml Buffy coat + 25 ml PBS were carefully layered on top of 15 ml of 
Lymphoprep® in a 50 ml Falcon tube. Red blood cells were centrifuged through the 
Lymphoprep® cushion at 1,600 rpm, for 20 min, at RT. PBMCs were concentrated in a 
white ring. The fluid above the PBMCs was discarded and PBMCs transferred to a new 50 
ml Falcon tube. From then on, the cells were kept on ice or at 4°C. PBMCs were washed 
with PBS once, 10 min, 1,200 rpm, at 4 °C, and the pellet was resuspend in 10 ml of sterile 
RPMI 1640 + 5% FCS + antibiotics. Cells were counted and plated either at 2x105 cells/100 
µl medium/well in a 96 well plate or at 2x106 cells/ml medium/well in a 24 well plate. 
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5.2.3. Isolation and activation of sub-types of immune cells from PBMCs 
Immunomagnetic cell isolation using Ab-coated-beads is a reliable method for positive 
selection of immune cells, such as: CD4+ and CD8+-T lymphocytes, CD14+ cells 
(monocytes) and CD19+ cells (B Ly). Dynabeads® are uniform, magnetizable polystyrene 
beads coated with a primary mAb specific for a single membrane antigen that is 
predominantly expressed on the each subset of human immune cells. During a short 
incubation period, only positive cells (for each CD molecule) bind to Dynabeads® and 
subsequently, the rosetted cells can be isolated and washed by using a magnet.  
Negative selection also can be used to separate cell sub-types. Each kit contains a highly 
optimized Antibody Mix and Depletion Dynabeads® to deplete all kinds of cells, except 
the ones that are needed. Selected cells remain free of both, surface Ab and beads. 
5.2.3.1. Isolation of T Lymphocytes 
T lymphocytes are divided into two classes. One class differentiates into cells that activate 
other cells such as B cells and macrophages through the secretion of cytokines; these cells 
are CD4+-T cells (helper/inducer lymphocytes). The second class is the CD8+-T cells 
(cytotoxic lymphocytes) that among other functions kill cells infected with viruses. 
Lymphocytes are small, with few cytoplasmic organelles and much of the nuclear 
chromatin inactive. They have no activity until they encounter an antigen, necessary to 
trigger their proliferation and functional differentiation. 
a) Positive isolation of CD4+-T lymphocytes (Dynal) 
? 10 ml Buffy Coat or 30-40 ml fresh blood were used to isolate PBMCs, as 
described in “Gradient method using Lymphoprep®” 
? CD4+-T cells were isolated with the magnetic beads selection method according to 
manufacturer′s instructions (catalogue # 111.05) 
? During the next day, Dynabeads® were detached from the selected CD4+-T cells in 
culture. The content of the wells was collected into a new tube and washed 3 times, 
placing the tube on magnet. SN containing CD4+-T cells was kept, beads discarded 
? Isolated cells were cultured at 2x105 CD4+-T cells/100 µl RPMI/5%FCS medium. 
They were activated after 6 hr in culture. 
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b) Positive isolation of CD8+-T lymphocytes (Dynal) 
? Followed the same procedure as described in 5.1.2.1, changing amount and type of 
magnetic coated-beads anti-CD8+ (catalogue # 111.07) 
? The purity of the selected sub-sets obtained using this method was higher than 
93%, confirmed by FACS analysis using mAbs (see “Purity of cells”). 
c) T cells blasts from PBMCs 
PBMCs incubated with ConA for a long period induces strong and rapid T cell 
proliferation. After four days in culture, monocytes and B cells die and more than 95% 
of the cell population are activated T cell blasts.  
? To obtain activated T cell blasts (CD3+-T cells) 200,000 PBMCs/100µl medium 
were treated with ConA and incubated for at least 96 hr, at 37°C 
? IL-2 was added in order to keep T cell blasts proliferating. 
d) Non-activated T cells from whole blood 
Activation with ConA leads to morphologic and phenotypic changes in T cells. To 
obtain non-activated, resting T cells from whole blood, a direct isolation RosetteSep® 
procedure was used. This technique uses bi-functional Abs that are bound in bi-specific 
Ab complexes, which are directed against cell surface Ag on human hemopoietic cells 
(CD16, CD19, CD36, CD56) and glyphorin A on red blood cells. The cross-linked 
cells (granulocytes, monocytes, B cells and NK cells) precipitate with the erythrocytes, 
leaving the T cells in the low-density band of the gradient procedure: 
? Peripheral blood should be diluted in PBS. Mixed well 
? Added 50µl of RosetteSep Ab cocktail/ml of whole blood, incubated at RT 
? Protocol was same as for “Isolation of PBMCs from fresh blood”. 
e) T cell activation 
PBMCs can be differentially activated depending on the mitogen or cytokine added to 
the culture. In this manner, it is possible to activate a selected group of cells, which will 
proliferate, differentiate and regulate expression of some molecules (cytokines, CD 
molecules). To activate 200,000 PBMC/100 µl medium/well: 
1. Polyclonal activation with Lectins (polyvalent carbohydrate-binding proteins): 
1.1. ConA (Sigma): final concentration [10 µg/ml] 
1.2. PHA (Sigma): final concentration [10 µg/ml] 
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1.3. PMA + Ionomycine (Sigma) 
 PMA: final concentration [3 ng/ml] 
 Ionomycine: final concentration [300 ng/ml] 
2. Mouse anti-human CD3 Ab (DAKO): final concentration [1 µg/ml] 
3. Interleukine-2 (IL-2) (Promocell): final concentration [100 U/ml] 
 
5.2.3.2. Isolation of B Lymphocytes 
B-lymphocytes bear diverse receptors on their surface that allows them to recognize 
different antigens. These receptors are diverse in their antigen specificity, but an individual 
lymphocyte is equipped with receptors that will recognize only one particular Ag. 
a) Positive isolation of CD19+ B cells (Dynal) 
? Use the same procedure described in 5.1.2.1, changing the amount and type of 
magnetic beads for anti-CD19+ coated beads (Catalogue # 111.03) 
? On the next day, collected and discarded detached magnetic beads, as described 
? Cultured isolated cells: 200,000 cells/100 µl RPMI/5% FCS medium 
? Activated them after 6 hr resting in culture. 
b) Negative isolation of CD19+ B cells (Dynal) 
? PBMCs were isolated as described in Gradient method 
? CD19+ B lymphocytes were isolated according to manufacturer′s instructions, in 
which “1 Test” means 10x106 PBMCs 
? For 1 test: added 20 µl of Blocking Reagent and 20 µl Ab-Mix 
? Cultured 2x105 cells in 100 µl RPMI/5%FCS in a 96 wells/plate, at 37°C 
? Activated B cells next day 
c) B cell activation  
1. SAC (Staphylococcus Aurous Cowan 1 antigen) (Calbiochem) 
Dilution: 1:7,500 
2. mαh CD40 (Pharmingen) +  gαh IgM (Jackson Imm.) 
final concentration [10 µg/ml]      + final concentration [10 µg/ml] 
3. PWM (Pokeweed mitogen) (Sigma): final concentration [5 µg/ml] 
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5.2.3.3. Isolation of monocytes 
Macrophages are one of the two types of phagocyte in the immune system and they are 
distributed widely in body tissues, being part of an innate immunity. They are the mature 
form of monocytes, which circulate in the blood and differentiate continuously into 
macrophages upon migration into the tissues (Janeway, 1999). 
a) Positive isolation of monocytes (Dynal) 
? PBMCs were isolated as described in 5.1.2.1 
? CD14+ cells were isolated with the magnetic beads selection method according to 
manufacturer′s instructions (catalogue # 111.11) 
? Beads were engulfed by monocytes. It was not necessary to discard them 
? Cultured monocytes: 2x106 cells in 1 ml RPMI/10%FCS, at 37°C, 5% CO2 
? They were activated next day 
b) Monocyte negative isolation (Dynal) 
? Isolated PBMCs, as described before  
? CD14+ monocytes were isolated according to the manufacturer’s instructions, in 
which “1 Test” means 10x106 PBMCs. It yielded ~ 1-2 x 106 monocytes 
? Added Blocking Reagent (human γ-globulin to block monocyte Fc receptors) and 
Antibody Mix mixed and incubated for 10 min, at 2-8°C 
? Added washed Depletion Dynabeads® to PBMCs, incubated 15 min, at 4°C with 
gentle rotation 
? Cultured 2x106 cells in 1 ml RPMI/10%FCS in a 24 wells/plate, at 37°C, 5% CO2. 
Cells were activated the following day 
c) Monocyte activation  
Both isolation procedures described above yielded activated monocytes, either through 
the binding of coated beads to CD14 molecule (LPS receptor) in the case of positively 
isolated cells, or through the activation of Fc receptors in the negative isolation 
procedure. After 24 hr in culture, they are resting cells again and can be activated. 
1. LPS (055-B5) (Lipopolysaccharides from E. coli) (Sigma):  
final concentration [300 ng/ml]  
2. IFN-γ (Interferon-gamma) (Roche): final concentration [100 U/ml] 
3. TNF-α (Tumor Necrosis Factor-α) (Roche): final concentration [50-100 U/ml] 
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4. GM-CSF (Granulocyte–Macrophage Colony Stimulating Factor) (R&D): 
Final concentration [250 ng/ml] 
 
5.2.3.4. Human fetal myoblasts: 
Normal human fetal myoblasts were cultured in DMEM + 15% containing 50 µg/ml fetuin, 
1 ng/ml basic fibroblasts factor, 10 ng/ml epidermal growth factor, 10 µg/ml insulin, 0.4 
µg/ml dexamethasone, 50 ng/ml amphotericin B and 50 µg/ml gentamicin. Adherent 
myoblasts were detached from the culture flask with Versene (Gibco BRL). Myoblasts 
cultures contained more than 95 % CD56+ cells as determined by fluorescence-activated 
cell sorter scan (FACS) analysis.  
a) Myoblasts activation: 
1. IFN-γ (Interferon-gamma) (Roche) 
2. IL-1β (Interleukine-1β) (Sigma) 
 
5.2.4. Purity of selected sub-sets 
Because each isolated sub-type of immune cells expresses at least one specific CD 
molecule on its surface, it was possible to do FACS analysis using a fluorochrome-
conjugated antibody specific for each cell surface antigen.  
Extracellular staining determined the purity of selected sub-sets in each experiment, using 
directly labeled mouse mAbs against human CD4, CD8, CD14 and CD19 molecules. The 
analysis were performed 24 or 48 hours after selection of CD4+ and CD8+-T cells, B cells 
and monocytes, both resting and activated. Directly labeled mouse isotype controls 
matching with the Ab’s isotype were always included. 
The extracellular staining was performed either using two labeled Abs at the same time 
(each labeled with different fluorochromes) or separated Abs, i.e., mαhCD4-PE with 
mαhCD8-FITC and corresponding isotype IgG1-PE and IgG1-FITC. 
In order to analyze only viable cell populations, Propidium Iodide (Sigma) or Via Probe 
(B-D) were used to identify and discard dead cells. 
FACS protocols are described in Section 5.8 (FACS analysis). 
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5.2.4.1. Antibodies and Ig controls 
(a) Isotype controls: 
Mouse IgG1-FITC labeled (PharMingen) 
Mouse IgG1-PE labeled (B&D) 
Mouse IgG2a-FITC labeled (Dako) 
(b) Anti-human CD antibodies: 
Mouse IgG1-α-human CD3-FITC labeled (B&D) 
Mouse IgG1-α-human CD4-FITC labeled (Biosource) 
Mouse IgG1-α-human CD4-PE labeled (PharMingen) 
Mouse IgG1-α-human CD8-FITC labeled (ImmunoTech) 
Mouse IgG2a-α-human CD14-FITC labeled (PharMingen) 
Mouse IgG1-α-human CD14-PE labeled (B&D) 
Mouse IgG1-α-human CD20-PE labeled (PharMingen) 
Samples were analyzed on a FACSCalibur (B&D ) using CellQuest software. 
 
 
 
5.3. PROLIFERATION ASSAYS 
Proliferation assays measure the incorporation of radioactively labeled thymidine (3H 
methyl-thymidine) into the DNA of proliferating cells after mitogen activity. 
Only proliferating cells take up methyl-thymidine from the culture medium. After some 
days in culture, labeled cells were harvested onto a glass fiber filters that bind DNA. The 
radioactivity bound to the filter was measured for one minute in a β-Counter. 
5.3.1. Protocol 
? On day zero, PBMCs or any of the sub-sets were plated in 96 well plates, 200,000-
cells/well 200 µl medium and stimulated with an activator, mitogen or antigen 
? On different time-points (24, 48, 72 and 96 hr) cells were labeled by adding 20 µl 
(14800 Bq) of 3H-thymidine (37 MBq/ml, 1:50 dilution) to the medium 
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? After 18 hr of labeling, cells were harvested onto a filter. Proliferating cells were 
measured by [3H] thymidine incorporation in a gas scintillation counter for one 
minute (Matrix 9600 Direct beta Counter, Packard) 
? All tests were performed in triplicate 
5.3.2. Human myoblast proliferation 
For the measurement of myoblasts proliferation, cells were plated into flat-bottomed 
microwells at 5,000 cells/well and incubated with cytokines during 48 hr.  
To activate human myoblasts, 100 pg/ml of IL-1β or 100 U/ml of IFN-γ were used. 
After cytokine induction, myoblasts were washed and detached with Versene. 
Myoblasts proliferation was also measured by [3H] thymidine incorporation. 
 
 
 
5.4. ENZIME LINKED IMMUNOSORBENT ASSAY (ELISA) 
ELISA was employed to measure concentrations of cytokines or other soluble proteins 
(neurotrophic factors). Ags removed from the solution by capture Abs. A biotinylated 2nd 
Ab recognizing a different epitope of the same antigen was used to detect bound Ags. 
Bound 2nd Ab-biotin was quantified through a color reaction catalyzed by Avidin-HRP. 
5.4.1. ELISA – GDNF 
(GDNF Emax™ ImmunoAssay System. Promega) 
? Plates were coated with 100 µl/well of α-GDNF coating Ab, 10 µl diluted in 
carbonate coating buffer. Wells were sealed and incubated ON, at 4°C 
? Contents were flicked out of the wells and the plate tapped upside down 3 times 
? Wells were blocked adding 200 µl/well of Block & Sample buffer (B&S buffer), 
incubated at RT, for 1 hr, without shaking; then the plate was rinsed 
? The standard curve was prepared performing serial dilutions, using human rec- 
GDNF. The standard curve is linear between 15.6 and 1,000 pg/ml of hr-GDNF 
? Added 100 µl of the test samples/well, in triplicates and in serial dilutions. 
Incubated for 6 hours, at RT, with shaking 
? Washed 5 times with PBS+0.05% Tween-20 (PBS-T) 
Materials and Methods 
 
 
 69
? Incubated plate with 100 µl of anti-human GDNF pAb diluted in B&S buffer, O.N, 
at 4°C, without shaking. Next day, washed as above. 
? Added 100 µl of anti-chicken IgY, HRP-conjugate diluted in B&S buffer. 
Incubated 2 hr, shaking, at RT. Washed as above 
? Prepared the enzyme substrate by combining the same amount of TMB solution 
and peroxidase substrate and added 100 µl/well. Incubated at RT, for 15 min 
? The reaction was stopped by adding 100 µl of 1M phosphoric acid to the wells. The 
blue coloration changed to yellow upon acidification 
? The absorbance was recorded at 450 nm on a plate reader within one hour of 
stopping the reaction 
Some samples were treated with acid (HCl, 1N) for 15 min in order to separate the ligand 
(GDNF) from its receptors, thus the specific epitope could be detected by the capture mAb 
(Okragly and Haak-Frendscho, 1997). 
5.4.2. ELISA - TNF-α 
(PharMingen) 
? Samples were the following: PBMCs (2x106 cells/ml) were seeded in a 24 well-
plate, activated either with LPS+IFN-γ or with ConA, and cultured during different 
time points; then cells were incubated 24 hr or longer with of GDNF or NTN (100 
ng/ml). SN were collected, spun down and stored at -20 °C until the assay was 
performed. Samples were tested in triplicates and with two serial dilutions 
? Coated wells with 100 µl/well of capture Ab: mouse anti-human TNF-α in coating 
buffer. Sealed plate and incubated ON, at 4°C 
? Aspirated content of wells and washed 3 times with PBS-T 
? Wells were blocked adding PBS+10% FCS, 200 µl/well. Incubated at RT, 1 hr 
? Standard curve and samples were prepared in assay diluent 
? Added 100 µl of diluted samples/well. Sealed the plate, incubated 2 hr, at RT 
? After washing, added 100 µl/well of biotinylated mouse anti-human TNF-α mAb + 
avidin-HRP conjugate in PBS+10% FCS, and incubated 1 hr, at RT 
? Added 100 µl/well of substrate solution (TMB and hydrogen peroxide). Incubated 
maximal 30 min, at RT, in the dark 
? Aspirated and washed the contents 
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? Stopped the reaction by adding 100 µl/well of 1 M H3PO4 
? Read absorbance at 450 nm within 30 min of stopping reaction. 
5.4.3. ELISA - IL-10 
(PharMingen) 
? The procedure is similar to ELISA-TNF-α, antibodies are different. 
? Capture Ab: mouse anti-human IL-10, diluted in coating buffer 
? Detection Abs: biotinylated-mouse α-human IL-10 + avidin-horseradish peroxidase 
conjugate. 
 
 
 
5.5. WESTERN BLOTTING  
Proteins have a net positive or negative charge that reflects the mixture of charged amino 
acids they contain. If an electric field is applied to a solution containing a protein molecule, 
the protein will migrate at a rate that depends on its net charge and on its size and shape; 
this technique is called electrophoresis. Sodium dodecyl sulfate (SDS) polyacrylamide-gel 
electrophoresis (SDS-PAGE) uses a highly cross-linked gel of polyacrylamide as the inert 
matrix through which the proteins migrate. Proteins are released from their associations 
with other proteins or lipids and are soluble in the negatively charged detergent solution. In 
addition, a reducing agent (β-mercaptoethanol) is added to break any S-S linkages in the 
proteins so that all polypeptides in multi-subunit molecules can be analyzed separately. As 
a result, a mixture of proteins is fractionated into a series of protein bands with the same 
size, arranged in order of molecular weight (Molecular biology of the cell, 1999). 
General Protocol: Once the gel is ready, separated proteins were transferred to a 
nitrocellulose membrane, which was then incubated with a primary Ab. To avoid 
unspecific binding, the membrane was blocked by incubation in 10% milk powder in PBS-
T, ON, at 4°C. The first Ab was incubated for 1 hr, at RT, on a shaker and then, washed 
with PBS-T. When the Ab bound to the membrane, a secondary-HRP-linked Ab (diluted in 
skim milk+PBS-T) in combination with chemiluminescence was used to detect it. 
Chemiluminescence was visualized by exposing the membrane to a Kodak film. 
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5.5.1. Cell lysates 
Cells were spun down to discard medium and debris, and then washed in PBS. They were 
pelleted and lysed in RIPA buffer, passed through a needle several times and incubated on 
ice for 30 min. Cell nuclei were eliminated by centrifugation 14,000 rpm, at 4°C, for 20 
min. Total protein lysates were kept in small aliquots at -20 °C. 
5.5.1.1. Protein concentration determination: 
a) Lowry method: Tyr residues of the soluble protein react with Folin-Ciocalteu 
reagent to form a protein-dye complex with a maximal absorption at 600 nm. The assay 
was performed according to manufacturer’s instructions (Sigma) with different 
dilutions of protein. A calibration curve was established using bovine serum albumin 
(BSA) and concentration of the test sample was calculated from the absorption value. 
b) Bradford method: The Coomassie brilliant blue G250 forms a protein/dye 
complex with arginine residues of proteins, with a maximal absorption at 595 nm. 1-10 
µl of the protein lysate were incubated with 1 ml Bradford reagent (1/5 from the stock 
solution), 10-30 min, at RT. A calibration curve was established using BSA and the 
sample concentration was calculated from the absorption value. The method can be 
used for final concentrations of 1-10 µg/ml, and it is faster than method a). 
5.5.2. Polyacrylamid-Gel electrophoresis (PAGE) 
5.5.2.1. Precast NuPAGE® Bis-Tris gels: 
The NuPAGE® Bis-Tris System (Novex®) is based upon a Bis-Tris-HCl buffered 
polyacrylamide gel (gel matrix) available in different concentrations. Gels were used in 
conjunction with the recommended NuPAGE® denaturing SDS running buffers. Protein 
samples were loaded in 4xLDS buffer and gels were run for different times at 200 V, 
depending on which buffer was used. Separated proteins were transferred from the gel to a 
nitrocellulose membrane: Semidry Western transfer method (NuPAGE® Booklet, 1999). 
5.5.2.2. Semidry Western transfer protocol: 
? After wetting the surface of the gel with transfer buffer and position the pre-soaked 
transfer nitrocellulose membrane on the gel, all air bubbles were removed 
? Placed the 3 pre-soaked anode filter papers on top of the membrane 
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? Placed the gel-membrane assembly in the same sequence, so that the gel was closest to 
the cathode plate. Pressed the anode onto the top and applied constant current. 
 
5.5.3. Antibodies used in Western blot 
5.5.3.1. Western blot: GDNF monoclonal Ab: 
Monoclonal antibody against human GDNF (R&D Systems) 
? Loaded protein lysate inside the wells of a 4-12% Bis-Tris gel 
? Running in 1xMES buffer: 200 V, 35 min 
? Transferred proteins to a nitrocellulose membrane: 50 mA, 50 V, 90 min 
? Blocked O.N, 4°C, 10% skim milk powder in PBS-T 
? Washed 3 times with PBS-T 
? 1° Ab: mAb-αhuman GDNF+2% skim milk in PBS-T, incubated for 2 hr, at RT 
? Washed 3 times 
? 2° Ab: Goatαmouse-HRP+2% skim milk in PBS-T, incubated for 30 min, at RT 
? Washed 3 times. Developed with ECL (Amersham). 
5.5.3.2. Western blot: GDNF polyclonal Ab: 
Polyclonal antibody against human GDNF-biotinylated (R&D Systems) 
? Same procedure as described above, changing antibodies 
? 1° Ab: Goatαhuman GDNF-biotin+2% skim milk PBS-T, incubated for 2hr, at RT 
? Washed 3 times with PBS-T 
? 2° Ab: STP-HRP+2% skim milk powder in PBS-T, incubated for 45 min, at RT 
? Washed 3 times. Developed with ECL. 
5.5.3.3. Western blot: RET - short isoform: 
Ret (SC-19) (Sta. Cruz Biotechnology) 
? Loaded protein lysates on 4–12% Bis-Tris gel 
? Running in 1xMOPS: 200 V, 55 min 
? 10 min gel pre-incubation in 0.02 % SDS in 2x transfer buffer 
? Transfered proteins to nitrocellulose membrane: 100 mA, 50 V, 90 min 
? Blocked 2 hr, at RT, with 10% skim milk in PBS-T. Washed 3 times 
? 1° Ab: RabbitαRET pAb + 5% milk in PBS-T, incubated ON, 4°C, shaking 
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? Washed 3 times with PBS-T 
? 2° Ab: Goatαrabbit-biotin + 2% skim milk in PBS-T, 50 min, at RT 
? Washed 3 times with PBS-T 
? 3° Ab: STP-HRP + 0.5% milk powder in PBS-T, incubated for 40 min, at RT 
? Washed 3 times. Developed with ECL. 
5.5.3.4. Western blot: RET - long isoform:  
Ret (SC-20) (Sta. Cruz Biotechnology) 
? Molecular weight: 2 bands of 170 and 150 kDa can be detected, but also other 
bands of 100 and 120 kDa could be seen, corresponding to non-glycosylated forms. 
? The six first steps were similar to those described for the short isoform of c-RET 
? 1° Ab: GoatαRET pAb + 5% skim milk in PBS-T, incubated ON, at 4°C, shaking 
? Washed 3 times with PBS-T 
? 2° Ab: Rabbitαgoat-biotin+2% skim milk in PBS-T, incubated for 30 min, at RT 
? Washed 3 times 
? 3° Ab: STP-HRP + 0.5% skim milk in PBS-T, incubated for 40 min, at RT, shaking 
? Washed 3 times with PBS-T. Developed with ECL.  
 
 
5.6. IMMUNOFLUORESCENCE 
5.6.1. Staining for adherent cells 
? HeLa cells were grown in a slide-chamber in RPMI + 10% FCS, at 37°C, 5% CO2, 
until they were 80% confluent 
? Medium was removed and the plastic chamber was taken off 
? After washing with 1xPBS, slides were incubated 10 min, in 4% PFA in PBS 
? Staining with primary antibody was performed as following: 
o Incubated mouse-anti human NTN (IgG2b), dilution 1:100, ON, at 4°C 
o Isotype control: mouse IgG2b, equal concentration, ON, at 4°C  
? Washed 3 times with 1xPBS 
? Stained with secondary Ab: goat-αmouse IgG-Cy3, 2 hr, at RT. Washed 3 times 
? Slides were dried at RT and then examined using fluorescence microscopy. 
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5.6.2. Staining for cells in suspension 
? 100 µl of cells in suspension (PBMCs) were taken and placed on to glass slides in 
the cytospin device, then spun down at 600 rpm, 5 min, at RT 
? Slides were dried and fixed with cold acetone, 10 min, at RT 
? Incubated with first Ab and isotype IgG as described above 
? Next day, incubated with secondary-labeled Ab, 2 hr, at RT, then washed with PBS 
? Added mouse serum, concentration (1:100), 1 hr, at RT, to block unspecific 
binding or cross-reaction with the first antibody 
? Washed slides with PBS 
? Added anti-CD-FITC labeled antibodies, 45 min, at RT. Washed slides with PBS 
? DAPI staining was added to show nuclei in blue 
? Slides were dried and then examined using fluorescence microscopy. 
 
 
 
5.7. FACS ANALYSIS 
Fluorescence Assisted Cell Sorting/counting is a method used to assess the surface 
presentation of Ags. In a FACS instrument, cells are passed through a thin cuvette; at 
concentrations such that only one cell passes at a time. Using a laser a single excitation 
wavelength (488 nm) is utilized to illuminate cells; the forward scattered light (FSC) is a 
measure of the size of the cells. Light scattered perpendicular to the laser direction (side 
scatter, SSC) indicates the cell granularity. Fluorescent dyes bound to the cells through Ag-
specific Abs are excited to emit light at specific wavelengths, i.e., FITC (fluorescein 
isothiocyanate), R-PE (R-phychoerythrin), Cy-Chrome, PrCP. 
Cells can be counted; percentages of cell populations fitting certain criteria (gates) can be 
calculated, as well as changes in the expression of surface Ags under different conditions. 
When two or more staining are used on the same sample, compensation is necessary.  
Reagents that block Fc receptors may be useful for reducing non-specific staining. 
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5.7.1. Extracellular Immunostaining 
5.7.1.1. Protocol 
? Transfer 1–2x105 cells/well (96 conic bottom well plate, NUNC) 
? Spin down at 1,200 rpm, 5 min, at 4°C. Discard SN 
? Wash the cells twice, adding 200 µl FACS staining buffer to each well, resuspend 
and spin down at 1,200 rpm, 5 min, at 4°C. Discard SN 
? Incubation with first Ab diluted in 100 µl FACS staining, 30 min, at 4°C 
? Spin down at 1,200 rpm, 5 min, at 4°C. Discard SN and wash cells twice 
? If the first Ab is not fluorochrome-labeled, a secondary-labeled Ab (anti-first 
primary Ab) is used to stain the cells indirectly. Incubate secondary Ab as above 
? Cells can be double stained using Abs labeled with different fluorochromes 
? Add Via-Probe (B-D) 10 µl, incubate 10 min, at 4°C and spin down 
? Resuspend the pellet in 200-300µl of PBS 
? Analyze samples during the next 2 hours. Fluorescence, as well as FSC and SSC 
are determined for at least 10,000 cells in a Becton Dickinson FACSCalibur. 
5.7.1.2. Antibodies used for extracellular FACS 
(a) GFRα-1: 
1° Ab: Mouse anti human-GDNFR-α mAb (non-labeled) (Transduction Lab.) 
2° Ab: Goat anti mouse-FITC (DAKO)  
(b) GFRα-2: 
1° Ab: Goat anti human-GFRα-2 pAb (non-labeled) 
2° Ab: Donkey anti goat-PE (Jackson Immunores) 
(c) HLA-DR: 
Mouse anti human-HLA-DR-PE (Transduction Laboratories) 
(d) Anti-CD molecules: 
Mouse anti human-CD25-FITC (PharMingen)  
Mouse anti human-CD38-FITC (ImmunoTech) 
Mouse anti human-CD69-FITC (PharMingen) 
Mouse anti human-CD86-PE (Serotec) 
Isotype controls were described in Section 5.1.4 “Purity of selected sub-sets”. 
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5.7.2. Intracellular Immunostaining 
5.7.2.1. Protocol 
? Incubate cells with Monensin (Sigma) (2 µM final conc.), for 3 hr, at 37°C 
? Next three following steps are similar as described in FACS Extracellular Staining 
? Cell fixation: with 4% PFA in PBS, 20 min, at 4°C, in the dark 
? Spin down at 1,200 rpm, 5 min, at 4°C. Discard SN 
? Wash 2x with permeabilization buffer, adding 200 µl/well, pipetting, spin down 
? Incubation with first Ab in 100 µl permeabilization buffer, for 30 min, at 4°C 
? Wash twice. Add labeled secondary Ab and incubate in the dark 
? Wash twice, and add 200 µl PBS to analyze the samples 
? Isotypes controls should be included 
5.7.2.2. Antibodies used for Intracellular FACS 
(a) GDNF (mAb): 
1° Ab: Mouse anti human-GDNF mAb (non-labeled) (R-D Systems) 
2° Ab: Goat anti mouse-FITC (DAKO) 
(b) GDNF (pAb): 
1° Ab: Goat anti human-GDNF biotinylated pAb (R-D Systems) 
2° Ab: Streptavidine-PE (DAKO) 
(c) RET: 
1° Ab: Rabbit anti human RET pAb (Sta. Cruz Biotech.) 
2° Ab: Goat anti rabbit-Cy3 (Jackson Immunoresearch) 
(d) IL-4: 
Mouse anti human-IL-4-PE mAb (PharMingen) 
(e) IFN-γ: 
Mouse anti human-IFN-γ-PE mAb (PharMingen) 
(f) TNF-α: 
Mouse anti human-TNF-α-FITC mAb (B&D) 
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5.8. RT-PCR 
The polymerase chain reaction (PCR) allows single-stranded cDNA to be amplified one 
billion-fold, if part of its nucleotide sequence is known. This sequence is used to design 
two synthetic DNA oligonucleotides, one complementary to each strand of the DNA 
double helix and residing on opposite sites of the region to be amplified. They serve as 
primers for in vitro DNA synthesis, which is catalyzed by a DNA polymerase. 
Each reaction cycle requires a brief heat treatment to separate the two complementary 
DNA strands. A subsequent cooling of the DNA in the presence of primers allows them to 
hybridize to complementary sequences. The annealed mixture is incubated with DNA 
polymerase and the four-dNTP. When the procedure is repeated, the newly synthesized 
fragments in turn serve as templates, and after a few cycles the predominant product is a 
single DNA fragment. 
 
5.8.1. RNA extraction  
5.8.1.1. RNAzol method 
? To prepare RNA from 1 to 10x106 cells, washed cells in PBS and spun down 
? Dissolved the pellet in 1 ml RNAzol, and centrifuged 10 min, 14,000 rpm, at 4°C 
? Transferred the SN and added CHCl3 (1/10 of SN volume) 
? Centrifuged at 14,000 rpm, 20 min, at 4°C 
? Put SN in a new tube and added same volume of Isopropanol (2-propanol) 
? Kept 30 min, at -20°C, then centrifuged 10 min, 14,000 rpm, at 4°C 
? Washed the pellet with 1 ml of ethanol-75%. Vortex 
? Centrifuged 10 min, at 14,000 rpm. Dried pellet by air 
? Added 34 µl DEPC water to solve the RNA 
? Measured RNA concentration and digest genomic DNA with DNAse enzyme 
5.8.1.2. Qiagen method 
RNA extraction was performed following the manufacture’s protocol. After total RNA 
was isolated, the genomic DNA contamination is higher using this method as compared 
with others. It is necessary to digest contaminating DNA with DNAse. 
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5.8.1.3. DNA digestion 
One unit of RQ1 RNAse-Free DNAse is defined as the amount required to completely 
degrading 1 µg of λDNA, at 37°C, in 50 µl of a buffer containing: 40mM Tris-HCl, 
10mM NaCl, 6mM MgCl2 and 10mM CaCl2. The protocol used was the following: 
? 10 µl RNA (1-5 µg) 
? 12 µl distillated water 
? 6 µl 5x transcription buffer (Promega) 
? 2 µl RQ1 RNAse-free DNAse (Promega) 
? Heat at 37°C, for 60 min 
? Use the “Clean-up RNA Protocol” from Rneasy-mini handbook (Qiagen) 
following the manufacturer’s instructions 
? Measure amount of total RNA and continue with the cDNA synthesis 
5.8.1.4. RNA concentration 
RNA concentration was determined by measuring the absorption at 260 nm and at 280 nm. 
A280 can be used as a measure of impurity of RNA (A280/A260 should be approx. 1.7). 
 
5.8.2. First-strand cDNA synthesis 
A DNA copy (cDNA) of a mRNA molecule can be produced by the enzyme reverse 
transcriptase, which is an unusual DNA polymerase that synthesizes a DNA chain from 
RNA template; forming a DNA/RNA hybrid helix. Treating the DNA/RNA hybrid with 
alkali degrades the RNA strand into nucleotides. The enzyme requires a small oligo-(dT) 
primer, which is annealed with the long poly-A tail at the 3’-end of most mRNAs. In this 
way, the single-stranded cDNA can be copied into double-stranded cDNA molecules. 
5.8.2.1. Protocol: 
? 1 µl Oligo(dT)12-18 (500 µg/ml) 
? Total RNA (from 1 ng to 5 µg) 
? 1 µl dNTP mix (10mM each dATP, dGTP, dCTP and dTTP, at neutral pH) 
? Sterile, distilled water to 12 µl 
? Heat mixture to 65°C for 5 min and quickly chill on ice.  
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? Collect the contents of the tube by brief centrifugation and add: 
- 4 µl 5x first-strand buffer (250mM tris-HCl, pH 8.3; 375mM KCl; 15mM MgCl2) 
- 2 µl 0.1 M DTT 
- Mix contents of the tube gently and incubate at 42°C, for 2 min 
- Add 1 µl (200 U) of SuperScriptII Rnase reverse transcriptase (Gibco BRL) 
- Incubate 50 min, at 42°C.  
- Inactivate the reaction by heating to 70°C for 15 min 
 
5.8.3. RT-PCR reaction 
To prepare a final reaction volume of 50 µl: 
? 5 µl 10x PCR Buffer (200mM Tris-HCl, pH 8.4, 500mM KCl) 
? 1.5 µl of 50 µM MgCl2 
? 1 µl of 10 µM dNTP mix 
? 1 µl primer 1: forward (10 µM) and 1 µl primer 2: reverse (10 µM) 
? 0.25 µl Taq DNA polymerase (5 U/µl) 
? 2 µl cDNA (from first-strand reaction) 
? 38 µl distilled water. 
Perform 25 to 40 cycles of PCR. Annealing and extension conditions are primer and 
template dependent. 
5.8.3.1. Agarose gel electrophoresis 
PCR products were analyzed on 1.7% agarose gels. Agarose was boiled in TAE buffer, 
then 20 µl of diluted ethidium bromide were added and the gel was cast. The solidified gel 
was inside the running chamber that was filled with 1xTAE. PCR products were mixed 
with 6x loading buffer and loaded into the wells. Gels were run at 80 V, 40 min. Amplified 
PCR products were visualized by UV light (302 nm) and photographs were taken. 
5.8.3.2. DNA purification 
To remove contaminants (agarose, buffers) and primers from DNA, PCR products were 
purified using QIAGEN PCR purification kit (Qiagen) according to the manufacturer′s 
instructions. 
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5.8.3.3. PCR-product sequencing 
Sequencing of PCR products (purified DNA) were performed by Toplab, Martinsried. 
 
 
 
5.9. PRIMER SEQUENCES 
5.9.1. β-Actin 
Human housekeeping gene used as internal control. 
5.9.1.1. Actin EM 
Forward primer: 5’-CGG GAA ATC GTG CGT GAC AT-3’ (bp 689-708) 
Reverse primer: 5’-GAA CTT TGG GGG ATG CTC GC-3’ (bp 1381-1400) 
PCR product: 729 base pairs 
5.9.2. GDNF 
5.9.2.1. GDNF - A 
Forward primer: 5’-TTC GCG CTG AGC AGT GAC-3’ (Exon 2, bp 133-150) 
Reverse primer: 5’-TAC ATC CAC ACC TTT TAG CGG-3’ (Exon 3, bp 611-632) 
PCR product: 498 base pairs 
5.9.2.2. GDNF - B 
Using GDNF-B primers, the spliced isoform and the FL of GDNF can be amplified. 
Forward primer: 5’-ATG AAG TTA TGG GAT GTC GT-3’ (Exon 2, bp 9-29)  
Reverse primer: 5’-TCA GAT ACA TCC ACA CCT TT-3’ (Exon 3, bp 510-530) 
PCR product: 521 base pairs (FL) and 460 base pairs (short isoform) (Hishiki et al., 1998) 
5.9.3. NEURTURIN 
5.9.3.1. NTN - 2 
Forward primer: 5’-CCT CAG TGC TCT GCA GCT C-3’ (Exon 1, bp 29-47) 
Reverse primer: 5’-TCG TGC ACC GTG TGG TAG-3’ (Exon 2, bp 546-563) 
PCR product: 535 base pairs 
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5.9.4. PERSEPHIN 
5.9.4.1. PSP - 1 
Forward primer: 5’-CTG GGC TCT CTG CTG CTC-3’ (Exon 1, bp 22-39) 
Reverse primer: 5’-CAT CAC CGA CGT GGC CTT-3’ (Exon 2, bp 384-401) 
PCR product: 389 base pairs 
5.9.4.2. PSP - C 
Forward primer: 5’-TCT CTG CTG CTC CTG TCC CTG CA-3’ (Exon 1, bp 28-50) 
Reverse primer: 5’-CGC ACC CAG CAT GGC CTG-3’ (Exon 2, bp 304-321) 
PCR product: 294 base pairs 
5.9.5. RET 
Multiple isoforms of the c-RET proto-oncogene can be amplified at the 5’-end or at the 3’-
end regions of the mRNA sequence. The 5’-end region encodes for the NH2 segment and 
the extracellular domain of the protein; the 3’-end region encodes for the COOH and the 
intracellular domain (see Figure 5). 
5.9.5.1. RET (ex6) 
Primers located between exons 2-3 and exon 6 used to amplify isoforms at the 5’-end. 
Forward primer: 5’-TGT CCG CAA CCG CGG CTT TC-3’ (Exon 2-3, bp 262-281) 
Reverse primer: 5’-CTG ACC GGC AGC ACC GAC ACG TT-3’ (Exon 6, bp 1327-1351) 
PCR product: 873 base pairs (full length) 
5.9.5.2. RET - 9-b 
To detect the short isoform, RET-9 (Myers et al., 1995; Ivanchuck et al., 1998): 
Forward primer: 5’-AAA CCC CTA TCC TGG GAT TCC T-3’ (Exon 19, bp 2996-3017) 
Reverse primer: 5’-ATC ACA GAG AGG AAG GAT AGT-3’ (Intron 19, bp 3326-3337) 
PCR product: 446 base pairs  
5.9.5.3. RET - 51-b 
To detect the long isoform, RET-51 (Myers et al., 1995; Ivanchuck et al., 1998). 
Forward primer: 5’-AAA CCC CTA TCC TGG GAT TCC T- 3’ (Exon 19, bp 2996-3017) 
Reverse primer: 5’-TCA GCT CTC GTG AGT GGT-3’ (Exon 20, bp 4762-4779) 
PCR product: 430 base pairs  
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5.9.5.4. RET-43 
To detect the middle isoforms, RET-43 (Ivanchuck et al., 1998). 
Forward primer: 5’-AAA CCC CTA TCC TGG GAT TCC T- 3’ (Exon 19, bp 2996-3017) 
Reverse primer: 5’-GGG GTA CCT ATC AGT GCT TTA AGT CTG- 3’ (Exon 21, bp 
6256-6282) 
PCR product: 354 base pairs 
5.9.5.5. RET 9 – 18 
To amplify other probable isoforms located upstream of exon 19 (Fluge et al., 2001)  
Forward primer: 5’-ACT TCT CCA CCT GCT CTC C- 3’ (Exon 9, bp 1592-1610) 
Reverse primer: 5’-GCT GAT GTC GCG AAA CAC C- 3’ (Exon 18, bp 2909-2927) 
PCR product: 1335 base pairs. 
5.9.6. GFRα-1 
5.9.6.1. Rec-Alpha1(2) 
Forward primer: 5’-ATG TTC CTG GCG ACC CTG T- 3’ (Exon 1, bp 1-18) 
Reverse primer: 5’-CTG GTA CAT GCT CCA GTA-3’ (Exon 2, bp 324-307) 
PCR product: 325 base pairs (Eng et al., 1998). 
5.9.6.2. ALPHA-1 
To amplify the splice isoform that lacks exon 5 (15 bp) (Hishiki et al., 1998): 
Forward primer: 5’-TAC CAA CTG CCA GCC AGA GT- 3’ (Exon 4, bp 777-796) 
Reverse primer: 5’-GGT AGT GGC AGT GGT GGT CTG TA- 3’ (Exon 7, bp 1086-1064) 
PCR product: 310 base pairs. 
5.9.7. GFRα-2 
Three variants due to exon skipping have been described. They are generated when either 
exon 2 or exon 3 are spliced out, or when exons 2 + 3 are lacking (Wong et al., 1998). 
5.9.7.1. GFRa2 
Forward primer: 5’-CGT CCT CTT CTT CTT TCT AG-3’ (Exon 1, bp 20-40) 
Reverse primer: 5’-TGG TAA TTG TCC GCA GGG CA-3’ (Exon 5, bp 850-870) 
PCR products: 
851 bp: Full Length (GFRα-2a) 
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537 bp: exon 2 spliced out (GFRα-2b) 
453 bp: exon 2 and exon 3 spliced out (Exon 1-4 mRNA) 
 
 
 
 
5.10. STATISTICAL ANALYSIS  
 
Data are represented as the mean (or average) of at least three values (n=3 or n=6), which 
correspond to each bar in the graphics. Always “n” was indicated in the figure legend. 
Error bars represent standard error of the mean (SEM), calculated as following: 
 
SEM=   SD 
 /n 
 
SD: standard deviation 
 
The Student`s t-test was used as a test of significance for cytokine production (ELISA for 
TNF-α and IL-10) and proliferation assays, because independent values from two sample 
groups with normal distribution was compared. 
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6 RESULTS 
6.1. PURITY OF CELLS 
The purity of each sub-set of immune cells was assessed by FACS analysis using specific 
directly labeled-mouse mAb against human CD4, CD8, CD14 and CD20 surface 
molecules. Analyses were performed 24 or 48 hours after immunomagnetic selection. 
 
 
 
Figure 11: FACS analysis to assess the purity of cells after separation: CD4+ and CD8+-T lymphocytes, 
B lymphocytes. Positively isolated cells were incubated O.N and labeled after removed the beads. The purity 
of each sub-type was assessed by double staining with two different fluorochrome Abs. Each row of dot-blots 
represents each cell type, starting from the left side: a) CD4+-T cells, b) CD8+-T cells and, c) B lymphocytes. 
Each column represents the α-CD Ab: Column 1: isotype control: Neg-PE/Neg-FITC. Column 2: α-CD14-
PE/α-CD20-FITC. Column 3: α-CD4-PE/α-CD8-FITC.The percentage of CD4+ and CD8+-T cells was 95% 
for both cell types. 98% was the purity for B cells. (Monocytes are not shown).  
a) 
b) 
c) 
1 2 3 
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6.2. PROLIFERATION ASSAYS 
Total PBMCs or a sub-set of immune cells were activated with different mitogens and 
cultured at 2x105 cells/well in a 96-round bottom plate, in triplicates for each activator. 
Cells were labeled with 3H-thymidine at different times points, and harvested after 18-
hours of incubation. When cells are not well activated, they did not uptake 3H-thymidine; 
and were discarded. Next graphic shows one example of lymphocytes proliferation: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: CD8+-T cell proliferated after 24, 48, 72 and 96 hr of activation with PMA+Ionomycine. 
CD8+-T lymphocytes were positively selected using immunomagnetic beads. 3H-incorporation is expressed 
in counts per minute (c.p.m). Each bar represents the mean of three values, n=3, + Error bar= SEM (standard 
error of the mean). 
This graphic Figure 13represents proliferation of PBMCs after different activators: 
 
Figure 13: Representative proliferation assay of non-activated and activated PBMCs. Cells were either 
untreated or treated with PHA, ConA or PMA+Ion. 3H-incorporation was measured after 24, 72 and 120 hr in 
culture. The best stimulation was observed after 72 hr. Representative results, mean of n=3, + SEM. 
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6.3. GDNF EXPRESSION 
6.3.1. RT-PCR: GDNF 
Two sets of primers were utilized to amplify GDNF transcripts from immune cells (both 
intron-spanning primers): GDNF-A primers: forward: 5’-TTC GCG CTG AGC AGT 
GAC-3’ (exon 2, bp 133-150); reverse: 5’-TAC ATC CAC ACC TTT TAG CGG-3’ (exon 
3, bp 611-632), that amplify only the large isoform (Woodbury et al., 1998). GDNF-B 
primers: forward: 5’-ATG AAG TTA TGG GAT GTC GT 3’ (exon 2, bp 9-29); reverse: 
5’-TCA GAT ACA TCC ACA CCT TT-3’ (exon 3: bp 510-530), which detect both 
isoforms (Hishiki et al., 1998). 
Non-activated and activated PBMCs (either with PHA, ConA, LPS+IFN-γ or PMA+Ion), 
non-activated and activated CD4+-T cells, CD8+-T cells, B cells, and monocytes did not 
express GDNF mRNA. A few representative samples are shown in Figure 14. 
 
 
 
 
 
 
Figure 14: Immune cells did not express GDNF. A) RT-PCR using primers-A. Amplifications were 
observed neither in activated PBMCs (PBMCs+) nor in monocytes (Mo+). B) RT-PCR using GDNF-B 
primers, which detect both spliced isoforms Any of the immune cells studied expressed GDNF. PCR 
products: 521 base pairs: large isoform; 460 base pairs: short isoform (lacking 78 bp). 293 cells expressed 
both, full and truncated isoforms. (+RT): plus reverse transcriptase. (-RT): without reverse transcriptase. 
A) 
B) 
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RT-PCR using β-actin primers, as house keeping gene was performed with all cDNAs to 
test their quality.   
Prior to the cDNA synthesis, total amount of RNA was divided into a two tubes, only one 
of them was incubated in the presence of the reverse transcriptase enzyme (+RT), the other 
part was incubated in its absence (-RT), to avoid the inclusion of samples containing 
genomic DNA. 
 
 
6.3.2. ELISA-GDNF 
6.3.2.1. ELISA: GDNF in immune cells 
GDNF protein was not detected in the supernatant from cultured immune cells, even after 
activation with different mitogens and at different stimulation times, using ELISA 
detection kit for GDNF and following the manufacture’s instructions. The acidic treatment 
was performed in some samples to separate bound GDNF from its receptors. In Table 2 
treated and non-treated samples are indicated. 
Cells were isolated from 24 different Buffy-coats. Different sub-types of immune cells 
were separated as described. T lymphocytes (both, CD4+ and CD8+-T lymphocytes), B 
lymphocytes, and monocytes were obtained and activated with diverse mitogens or 
activators, depending on the cell type. After different time-points (12, 24, 48, 72, 96 or 120 
hours) in culture, supernatants were collected; spun down and stored at -20°C until the 
assay was performed. Samples were collected from the wells in triplicates. 
As positive control, human recombinant GDNF (also for the standard curve) and 
supernatant from 3T3-GDNF transfected fibroblasts were used. 15p  
As a negative control, supernatant from NGF-transfected fibroblasts was tested. 
In a few SN of immune cells, the amount of GDNF detected was very low, close to the 
limit of detection. 
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Table 2: Summary of results obtained from different GDNF-ELISA. Supernatants taken from sub-types 
of immune cells isolated from 24 different Buffy-coats. Samples in triplicates were stimulated for up to 120 
hours. After collection, supernatants were stored at -20°C until the assay was performed. As positive control, 
human recombinant GDNF and supernatant from 3T3-GDNF transfected fibroblasts were used. In a few 
samples, the amount of GDNF detected was very low, close to the limit of detection (15 pg/ml), those values 
cannot be taken as positive results. 
 
Buffy Coat Cell sub-type Activation Results Acidic treatment 
1 Mo (-), LPS Negative Non-treated 
2 CD4, CD8, Bcells, Mo (-), PHA, LPS Negative Acidic 
3 CD4, CD8, Bcells (-), ConA Limit of detection Acidic 
4 CD4, CD8, Bcells, Mo (-), PHA, LPS Negative Non-treated 
5 CD8 (-), PMA/Ion Limit of detection Non-treated 
6 CD4, CD8, Mo (-), PHA, LPS Negative Non-treated 
7 B cells (-), PWM Negative Non-treated 
8 Mono (-), LPS Limit of detection Acidic 
9 CD4, B cells (-), PHA Negative Non-treated 
10 B cells (-), PWM Limit of detection Non-treated 
11 PBL, Bcells, Mo (-), ConA, LPS Negative Non-treated 
12 PBMC; B cells (-), PHA, PWM Negative Non-treated 
13 PBMC, B cells (-), PHA, PWM Negative Non-treated 
14 Mo (-), LPS Negative Non-treated 
15 Mo (-), LPS Negative Non-treated 
16 B cells, Mo (-), α-IgM, LPS Negative Non-treated 
17 Mo (-), LPS Negative Non-treated 
18 Mo (-), LPS Negative Non-treated 
19 PBMC, Mo (-), PMA/Ion, LPS Negative Acidic 
20 PBMC, Mo (-), PMA/Ion, LPS Limit of detection Acidic 
21 PBMC, Mo (-), ConA, LPS Negative Acidic 
22 PBMC, Mo (-), ConA, LPS Limit of detection Acidic 
23 PBMC, Bcells, Mo (-), ConA, LPS Negative Acidic 
24 CD4, CD8, Bcells, Mo (-), ConA, PHA, LPS Negative Acidic 
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6.3.2.2. ELISA: GDNF in human sera 
Sera from healthy donors (HD), multiple sclerosis patients (MS) and COP-treated (CopT) 
MS patients were also tested in the GDNF-ELISA. 
In most of the samples, 17 out of 22 sera, GDNF was detected at different concentrations, 
ranging from 15 to 230 pg/ml. Thirteen samples, including the negatives, were treated with 
HCl (1 N), before GDNF was measured. In all negative samples, GDNF was detected; see 
Figure 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Concentration of GDNF protein (pg/ml) in sera from healthy donors (HD), multiple 
sclerosis patients (MS) and Cop-treated MS patients (CopT) detected by ELISA. 15-A) In 4 out of 22 
samples, GDNF was undetectable. Each sample was tested in triplicates, with 2 serial dilutions. Each value 
represents the mean of n=6 wells, + SEM. 15-B) Some samples shown in Fig. 15-A were treated with 1 N 
HCl for 15 min (red bars). ELISA was performed afterwards and it was possible to detect GDNF protein in 
A. 
B. 
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all samples, even in those, which were negative. The amount of protein detectable in acidic-treated samples 
(red bars) was always higher than in non-treated ones. Each bar represents the mean of n=6, + SEM on each 
bar. 
6.3.3. Western blot-GDNF 
In order to identify GDNF protein in the studied immune cells, Western blot was 
performed using 2 different antibodies, a monoclonal antibody (Ab) and a biotinylated 
polyclonal antibody from the rabbit (pAb) against human GDNF. 
Immunoprecipitation was also performed using pAb on total cell lysate with Protein G 
sepharose beads and mAb-anti GDNF was used for detection.  
As shown in the following Western blots GDNF was not present in any of the immune 
cells tested. 
 
6.3.3.1. Western blot: pAb anti-GDNF 
pAb was used to perform Western blot using total lysate from human separated immune 
cells under different conditions. The secondary antibody was a donkey anti-rabbit-HRP. 
Human recombinant GDNF homodimer was loaded as positive control and has a molecular 
weight of 30 kDa, which was detected in this blot. 
 
 
 
 
Figure 16: GDNF protein was not present in immune cells by Western blot. Using as primary antibody a 
biotinylated pAb α-human GDNF and as secondary antibody a donkey anti-rabbit-HRP, the Western blot 
was performed. Human recombinant GDNF = hrGDNF (10 ng/lane) was used as positive control (lane 1) and 
LPS-activated monocyte lysate is shown as immune cell (100 µg of protein lysate/lane) (lane 2). 
1 2
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As shown in Figure 16 no GDNF polypeptide was found in 100 µg of monocyte lysate, 
although 10 ng of hrGDNF gave a very strong signal. Other protein lysates from T and B 
cells, both un-stimulated and stimulated were tested with pAb as well; however GDNF 
protein could not be detectable (data not shown). 
6.3.3.2. Western blot: mAb anti-GDNF 
A monoclonal Ab, mouse against human GDNF, was used in Western blot.  
All sub-types of immune cells, both, non-activated and activated for 72 hours, were 
included in different blots; however, none of the lysates was stained with the mAb.  
 
 
 
 
 
 
Figure 17: GDNF protein was not found in the immune cells by Western blotting using a mouse anti-
human GDNF monoclonal antibody. The amount of protein lysate of each immune cell was ~50 µg/lane. 
The secondary antibody was a goat anti-mouse-HRP. The reaction was detected with ECL detection kit. As 
positive control: hrGDNF (10 ng/lane) showing a unique band approx. at 30 kDa. TGW: neuroblastoma cell 
line; PBMCs-: non-activated peripheral blood mononuclear cells; PBMCs+: PHA-activated PBMCs; Bc -: 
resting B cells; Bc+: SAC-activated B cells; Mo–: non-activated monocytes; Mo+: LPS-activated 
monocytes.  
Also immunoprecipitation did not provide evidence that GDNF is expressed or can be 
induced in lymphocytes and monocytes (data not shown). These experiments performed in 
order to immunodetect GDNF protein (either by GDNF – ELISA or by Western blotting) 
were in agreement with the RT-PCR experiments, in which GDNF was not expressed at 
mRNA level in any human immune cells studied. Immunofluorescence and FACS analysis 
(intracellular staining) were also performed using mAb and pAb; however, the results were 
always negative for immune cells (data not shown). 
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6.4. NEURTURIN EXPRESSION 
In contrast to the findings obtained for GDNF, the ligand Neurturin (NTN) was detected in 
both resting and activated human peripheral blood mononuclear cells as shown below. 
At the mRNA level, NTN expression was demonstrated using RT-PCR. At the protein 
level, NTN was detected by Western blot and by immunofluorescence. 
 
6.4.1. RT-PCR: NTN 
 
 
 
Figure 18: mRNA expression of NTN was studied in all immune sub-sets by RT-PCR. Cells were 
stimulated for 24 hrs. PCR was performed with the NTN primer pair binding to sequences encoded by exon 1 
and exon 2. The large product could correspond to the full length mRNA (535 bp), the short fragment is 330 
bp. As positive control: HeLa cell line. Next lanes: PBMCs-: non-activated peripheral blood mononuclear 
cells; PBMCs+: ConA-activated PBMCs; CD4-: non-activated CD4+-T cells; CD4+: PHA-activated CD4+-T 
cells; CD8-: non-activated CD8+-T cells; CD8+: PHA-activated CD8+-T cells; Bc-: resting B cells; Bc+: 
SAC-activated B cells; Mo–: non-activated monocytes; Mo+: LPS-activated monocytes. To control the 
cDNA quality a PCR for β-actin mRNA was also performed. 
In the reactions two different PCR fragments were obtained using primers spanning exons 
1 and 2. The large product corresponds to the full length mRNA (535 bp), the short one 
(330 bp) could be a new splice variant, in which 207 bp were lacking. No alternative 
splicing has been described for the human NTN gene; therefore the shorter fragment was 
sequenced. The 207 bp missing in the smaller PCR product (exactly 328 bp) corresponded 
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to a region consisting of 80 % GC and cannot be explained by alternative splicing. For this 
reason, the possibility that this amplification would be an artifact was tested changing 
diverse conditions to the PCR reaction to allow faithful amplification of GC-rich 
templates. 
 
The addition of DMSO (5% final concentration) to the PCR master mix resulted only in 
the fragment of 535 bp. As the second band at 328 bp was not detected anymore, the 328-
bp product must be an artifact.  
 
 
 
 
 
Figure 19: mRNA expression of NTN in immune cells after addition of DMSO to the PCR reaction. See 
legend to Figure 18. HeLa and HL-60: as positive controls. PBMCs++: LPS+IFN-γ activated PBMC. The 
PCR contained 5% DMSO.  
PCR products from non-activated CD4+-T lymphocytes and from LPS+IFN-γ-activated-
PBMCs (PBMCs++) were sequenced and they showed 100% homology to the human 
NTN mRNA. 
Resting and activated lymphocytes (all subpopulations) and monocytes express NTN 
mRNA. 
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6.4.2. Western blotting - NTN 
Western blot analyses using a polyclonal antibody against human NTN was used to 
immuno-detect NTN in the various human immune cells.  
 
 
 
Figure 20: Detection of NTN in immune cells by Western blot. Protein was detected in 50 µg lysate of 
non-activated and PHA-activated PBMCs after 24 and 48 hour of activation. The positive control was 1 
µg/lane human recombinant NTN (hr-NTN) ~ 19 kDa, which is not glycosylated. A band around 25 kDa is 
shown, corresponding to a monomer of NTN. The second band of 50 kDa size could correspond to dimers. 
The gel was run under non-reducing conditions. First Ab, a goat anti-human NTN polyclonal antibody (Sta. 
Cruz Biotechnology) was used; the secondary Ab was a donkey anti-goat-biotin, and then a STP-HRP 
(Jackson Immunoresearch) The enzymatic reaction of HRP was developed using ECL kit. TE671: 
rabdomyosarcoma cell line. PBMCs-: non-activated peripheral blood mononuclear cells. PBMCs+ 24 h: 
PHA-activated PBMCs during 24 hours. PBMCs+ 48 h: PHA-activated PBMCs during 48 hours. The 
molecular marker was unstained and is drawn.  
In the cell analyzed two proteins of about 25 kDa and 50 kDa were detected. Differences in 
the band sizes are due to the fact that NTN is secreted as a glycosylated dimer (around 50 
kDa), for that reason the molecular weight of the monomer is higher than the recombinant 
protein, which is a non-glycosylated. 
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6.4.3. Immunofluorescence - NTN 
Neurturin protein was also demonstrated by immunofluorescence staining intracellular 
NTN in human immune cells. 
The following fluorescence micrographs show the positive control cell line (HeLa cells, 
see also Figure 19) and non-activated and activated PBMCs using diverse activators. 
 
 
 
Figure 21: Neurturin is present in the cytoplasm of HeLa cells. Permeabilized HeLa cells were stained 
with the first Ab mouse anti-human NTN (mouse IgG2b) in A), or with the isotype control mouse IgG2b in B) 
and the secondary Ab goat anti mouse IgG-Cy3 labeled. Cells were grown in slide-chambers until they were 
80% confluent, then fixed with paraformaldehyde and incubated O.N. with primary Abs. Magnification 40x. 
 
 
 
Figure 22: NTN is present in PBMCs. Non-activated and activated PBMCs were fixed and the same Abs 
were used to stain intracellular NTN as described above. A) Few non-activated PBMCs stained weakly for 
NTN, showing lower amounts inside their cytoplasm (red cells). B) 72 hrs ConA-activated PBMCs (T cell 
B)A) 
Non-activated 
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activation) showed that most of the cells were positively stained. C) In LPS+IFN-γ-activated PBMCs most of 
the cells stained for NTN, some cells showed a higher amount of NTN. D) PWM-activated PBMCs showed 
fewer cells but strongly positive in comparison with the others. Nuclei are shown in blue after DAPI staining. 
In non-stimulated PBMCs only few mononuclear cells stained positive for cytoplasmic 
NTN. All activations significantly increased the NTN-staining. Stimulation with ConA 
(mainly T cells) and LPS+IFN-γ (mostly monocytes and less lymphocytes) induced similar 
numbers of NTN+ cells, whereas PWM (B cells) stimulated fewer cells which very 
strongly NTN positive. 
To define clearly the NTN positive cells after the various stimuli, non-activated and 
activated PBMCs were stained for intracellular NTN, and additionally, double stained with 
a second directly labeled mAb to mark CD surface molecules, which are specific for each 
immune cell type. Thus, cells expressing NTN can be phenotypically characterized due to 
the present CD molecules. Examples are shown in the next pictures (Figure 24, 26 and 27). 
To be sure that no cross-reactivity with a second labeled mouse anti-CD antibody could 
occur a control staining was performed with IgG2a-FITC. As shown in the next figure 
(Figure 23) no cross-reactivity between the consecutively applied mice mAbs was found 
(anti-NTN and anti CDs antibodies). 
 
 
 
Figure 23: Cross-reactivity was not observed in this double immunostaining control. ConA-activated 
PBMCs were intracellularly stained with mAb against NTN (A) or IgG2a (B) + gαm-Cy3. After this step the 
slides were incubated one hour with mouse serum (1:100), and then IgG2a-FITC was added. A) Cy3 staining. 
B) FITC staining. C) Cy3 + FITC staining. Nuclei are stained in blue with DAPI (40x). 
 
C)A) B)
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Figure 24: Double staining: CD4/FITC (CD4+-T lymphocytes) and NTN/Cy3 in non-activated PBMCs. 
Non-activated PBMCs were double stained with mAb against NTN, indirectly labeled with goat α-mouse-
Cy3 (intracellular staining), and then with a mouse anti-human α-CD4-FITC. Pictures were taken for both 
fluorescences (A and B) and then an overlaid in C), in order to detect whether double stained cells were 
present. Nuclei are stained in blue with DAPI. Magnification of big micrographs was 40x. Small pictures: 
100x. 
Many non-activated PBMCs were CD4+ T cells as shown by their surface green staining. 
But only few PBMCs stained weakly for NTN (Figure 24). Pictures overlaid showed that 
some resting PBMCs expressed both molecules: NTN and CD4. NTN seems to be 
accumulated in small patches (spots), as it was seen previously in Figure 22. 
Another example of NTN expression in CD8+ T cells of LPS+IFN-γ-activated PBMCs is 
given in Figure 25. Few CD8+-T lymphocytes were stained double positive for intracellular 
A) 
C) 
B)
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Neurturin and for surface CD8 molecule. The majority of the activated CD8+ T cells are 
NTN negative. 
 
 
 
 
 
Figure 25: Double staining: CD8/FITC (CD8+-T lymphocytes) and NTN/Cy3 in LPS-IFN-γ-activated 
PBMCs. A) Photograph taken to see only green fluorescence, meaning CD8/FITC positive cells. Some cells 
were positively stained for CD8+-T cells on this preparation (LPS+IFN-γ-activated PBMCs). B) Picture 
showing cells intracellularly stained with mAb anti-NTN (red colored cells). Fewer cells were NTN positive 
in this part of the slide. C) This picture shows the overlaid images from A) and B). Nuclei are stained in blue 
with DAPI. 
 
 
C) 
A) B)
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Similarly monocytes and B lymphocytes were tested by intracellular staining for NTN 
expression. Both unstimulated monocytes and B cells express NTN protein in the 
cytoplasm in some cells (Figure 26 and Figure 27). 
 
 
 
 
 
 
Figure 26: Double staining: CD14/FITC (monocytes) and NTN/Cy3 in non-activated PBMCs. Non-
activated PBMCs were double stained as indicated. A) Cells stained with α-CD14-FITC Ab are monocytes 
(green cells). B) Few cells were weakly stained intracellularly with NTN (red cells), probably because they 
are resting cells. C) Overlaid images from A) and B). In the magnification, a representative example of two 
monocytes, only one expressing NTN is shown. In all pictures, arrows with different colors indicate another 
NTN+ monocyte. Nuclei were stained in blue with DAPI.  
 
 
C)
A) B)
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Figure 27: Double staining: CD19/FITC (B cells) and NTN/Cy3 in non-activated PBMCs. A) Resting 
PBMCs stained with α-CD19-FITC Ab identifying B cells (green cells, in low amounts). B) Few cells were 
stained intracellularly with NTN (red cells). C) Overlaid images A) and B) indicated in yellow the B cells 
expressing NTN. A pair of B cells is enlarged with only one cell expressing NTN. The nuclei are seen in blue 
(stained with DAPI). 
 
 
 
 
 
 
 
C) 
A) B)
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6.5. PERSEPHIN EXPRESSION 
6.5.1. RT-PCR: PSP 
Similarly, Persephin mRNA was investigated by RT-PCR on the human immune cells. As 
the PSP gene also contains a rich-GC region, addition of DMSO to the PCR was useful to 
amplify the right product. Without DMSO a smaller band was amplified (approx. 88 bp) in 
all reactions. This product was eliminated after DMSO addition. The best results were 
obtained with 2% DMSO and 60°C of annealing temperature (Figure 28). 
 
 
 
Figure 28: mRNA expression of PSP by human immune cells. Different concentrations of DMSO and two 
different annealing temperatures were tested in order to find the best amplification condition. These pictures 
show TE671: as negative control. 293 cells: as positive control (human embryonary kidney cells). Act. PBMC: 
ConA-activated PBMCs. Mono+: LPS-activated monocytes. Neg: no cDNA.  
These preliminary results with the forward primer: exon 1, base pairs 22 - 39 and reverse 
primer: exon 2, base pairs 384 - 401 demonstrated that PSP mRNA is expressed in ConA-
activated PMBCs and monocytes. Another set of primer pair: forward primer: exon 1 (base 
pairs 28 - 50) and reverse primer: exon 2 (base pairs 304 – 321) was also used for RT-
PCR. The signals were not so clear, however, but the subsets of immune cells were also 
positive (data not shown). 
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6.6. RET EXPRESSION 
The expression of the transmembrane receptor RET was assessed at the mRNA level using 
RT-PCR, and at the protein level performing Western blot using pAbs against the 
intracellular part of the protein, and with FACS analysis, using a mAb directed to the 
extracellular domain of RET (extracellular staining). 
6.6.1. RT-PCR: RET 
The RET mRNA is large and extensive alternative splicing. The isoforms have been 
reported for the exons encoding the extracellular portion and the intracellular enzymatic 
active domain respectively. mRNA expression of the RET transmembrane receptor 
tyrosine kinase was detected in all subsets of immune cells studied. Multiple splice 
isoforms were expressed, depending on the cell type and activation state. Specific sets of 
primers were used in this work to detect the alternatively splice variants of the RET gene 
by RT-PCR. These splice variants are located either at the 5’-end or at the 3’-end region. 
6.6.1.1. Multiple splice variants at the 5’-end region of RET gene 
An outline of the extracellular domain of the RET protein relative to the exon organization 
was presented in the introduction (see Figure 3). Most of the splice variants will encode 
proteins with deletions in the CLD-x, where the binding of ligand and the co-receptor 
GFRα take place, generating a truncated extracellular ligand-binding domain. The 
isoforms described in this region were found in fetal human brain and adult kidney (see 
Lorenzo et al., 1995). Exon 1 codes the initiator codon and 24 aa at the N-terminus, the 
signal sequence starts in exon 2 (aa 24 – 28). 
 
6.6.1.1.1. RET (ex6) primers 
First a primer pair (forward primer: exon 2 and 3 (base pairs 260 - 281) and reverse primer: 
exon 6 (base pairs 1327 - 1351)) was employed amplifying the full length (FL) RET cDNA 
(873 bp) and the alternative transcripts 5-RET lacking exon 5 (677 bp) and 3-RET missing 
exon 3 (585 bp).  
The results for all different subpopulations, unstimulated or activated cells, is given in 
Figure 29 and will be explained individually. 
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Figure 29: Multiple isoforms at the 5’-end region of RET were expressed by immune cells. RT-PCR 
showing cDNA from different sub-sets of immune cells, which amplified three isoforms of RET located at 
the 5’-end tail. First lane: pUC 8 marker. TGW (neuroblastoma cell line): positive control. CD4-: non-
activated CD4+-T cells. CD4+: PHA-activated CD4+-T cells. CD8-: non-activated CD8+-T cells. CD8+: 
PHA-activated CD8+-T cells. B cell-: resting B cells. B cell+: SAC-activated B cells. Mono-: non-activated 
monocytes. Mono+: LPS-activated monocytes. Tc blasts: ConA-activated T cell blasts. cDNA were tested 
with β-actin primers as shown. Cell fractions were isolated by immunomagnetic selection and then activated 
with mitogens; total RNA was extracted using RNAzol method. 1 µg of total RNA was reverse-transcribed in 
a 20 µl reaction mix containing oligo-dT primers. 2 µl of cDNA were amplified using specific primers for 
RET located in exon2/3 (forward) and exon 6 (reverse). After 38 cycles of amplification, 15 µl of the 
amplified products were loaded on 1.7% agarose gel stained with ethidium bromide. The RET protein figures 
located at the right side represent predicted proteins encoded with deletions (small circles) in the extracellular 
domain, mainly in the cadherin-like domain (CLD). The protein portion encoded by the 3’-half of the 
transcript that was not analyzed with the primers is marked by the dotted line. 
6.6.1.1.2. PCR products amplified in human immune cells: 
* Full length mRNA: Exon 2 linked to exon 3 (873 base pairs) was detected in RNA of 
the control cell line TGW, in T cell blasts (ConA-activated T cells), unstimulated and 
activated CD8+-T cells and monocytes and B cells+, but only a very weak signal was seen 
-   → non-activated cells 
+  → activated  cells
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in non-activated B cells. In CD4+-T cells, both non-activated and activated as well as in 
activated B cells no FL sequence was amplified (data from 3 different PCR reactions). 
The PCR fragments from the full-length mRNA of activated PBMCs+ (data not shown) 
and activated monocytes were verified by sequencing and showed 99% identity to the 
published RET mRNA. 
* 5-RET mRNA: exon 5 is spliced out (exon 4 linked to exon 6). A PCR product of 677 bp 
was obtained for both non-activated and activated CD8+-T cells, and non-activated B cells. 
This size could correspond to the isoform, which lacks exon 5. The predicted amino acid 
sequence would have a deletion in the CLD-3 (amino acids 273 to 387). This isoform has 
not been yet described.  
* 3-RET mRNA: exon 3 spliced out (exon 2 linked to exon 4). The third PCR product 
obtained was a band of 585 bp, corresponding to the isoform in which exon 3 is spliced 
out. A strong signal was observed in resting T and B cells, but not in monocytes. This 
variant encodes a protein lacking 68 amino acids in the CLD-1 (aa 28 to 156) and in CLD-
2 (aa 166 to 272). 
Surprisingly in contrast to stimulated T cells, in activated B cells no 5’-RET mRNA 
sequences were amplified, probably because exon 6, where the reverse primer was located, 
could be spliced out, since new isoforms at the 5’-end were published recently, some of 
them lacking exon 6 (Fluge et al., 2001). 
 
Interestingly, CD4+ and CD8+-T cells expressed different RET isoforms, although they 
have the same origin; both are T lymphocytes. The main difference is that CD8+-T cells 
expressed the full length, 3-RET mRNA and 5-RET mRNA; whereas CD4+-T cells 
expressed only the shortest 3-RET mRNA. Experiments were performed at least four times 
for each cell type and activation (Figure 30).  
In T cell blasts (PBMCs activated for 6 days with ConA) only the full length mRNA in this 
region was amplified. The results demonstrate differential regulation of alternative splicing 
in T cell subsets but not upon stimulation. In B cells and to a lower degree in monocytes 
activation influences the RET mRNA expression.  
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Figure 30: Comparison between the RET isoforms expressed by CD4+ and CD8+-T cells analyzing the 
5’-end region. For details see Figure 30. 
All RT-PCR reactions were performed at least three times with different PBMCs; always 
the same fragments were amplified. Results obtained by RT-PCR from different human 
immune cells and the isoforms expressed at the 5’-end region of RET mRNA are 
summarized in the following table: 
 
 
Table 3: Alternative spliced RET transcripts varying at the 5’-end expressed in different subtypes of human 
immune cells.  + : c-RET mRNA expression. -  : mRNA not detected. CD4-: resting CD4+-T cells. CD4+: 
PHA-activated CD4+-T cells. CD8-: resting CD8+-T cells. CD8+: PHA-CD8+-T cells. T cell blasts: ConA-
activated PBMCs after 6 days in culture. B cells-: resting B cells. B cells+: SAC-activated B cells. 
Monocytes-: non-activated monocytes. Monocytes+: LPS-activated monocytes. 
 
ISOFORMS at  
5’ –end region of 
c-RET gene 
     CD4 -      CD4 +       CD8 -      CD8 + T cell blasts    B cells -    B cells + Monocytes- Monocytes+
Full Length 
873 bp      -      -       +       +       +      -      -       +       + 
Exon 5 spliced out 
677 bp      -      -       +       +      -       +      -      -      - 
Exon 3 spliced out 
585 bp       +       +       +       +      -       +      -      -      - 
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In summary: 
 Resting and activated CD4+-T cells expressed only the 3-RET mRNA isoform. 
 Resting and activated CD8+-T cells expressed the full length, the 3-RET mRNA 
and the 5-RET mRNA isoforms. 
 Activated T cell blasts expressed only the full length RNA. 
 Resting B cells expressed 3-RET mRNA and 5-RET mRNA isoforms, but not the 
full length mRNA. Activated B cells do not express RET mRNA in this region. 
 Resting and activated monocytes express only the full length. 
Additional possible alternatively spliced transcripts lacking more that 1 exon sequence 
were not observed: 3,4-RET mRNA and 3,4,5-RET mRNA were not detected in any of the 
immune cells studied. However, one splicing variant, which has not been described, was 
found. This PCR product of 677 base pairs of size could correspond to the skipping of 
exon 5. This novel splice variant was only detected in CD8+-T cells and in resting B cells. 
 
6.6.1.2. Multiple splice variants located at the 3’-end region of the RET gene 
The 3’-end region codes for the intracellular domain of the RET protein. At least three 
spliced isoforms differing in the presence of intron 19 or the absence of exon 20 were 
described in human tissues: RET-9 or short isoform, RET-51 or long isoform and RET-43 
or middle isoform (see Introduction, Figure 5). The encoded polypeptides differ in the 
length and in the sequence of the carboxyterminus. 
Short isoform (RET-9) is generated when intron 19 is not removed. The ORF of exon 19 
continues with nine further codons, which lie within intron 19. 
Long isoform (RET-51) is expressed when exon 19 is spliced to exon 20, which encodes 
51 amino acids at the carboxyl terminus in the protein. 
Middle isoform (RET-43) occurs when exon 19 is spliced to exon 21. In this transcript, 
exon 21 codes for unique 43 amino acids. 
 
6.6.1.2.1. RET-B primers 
All 3’-end variants can be detected using a primer pair RET-B: forward primer: exon 16 
(base pairs: 2701 - 2722) and reverse primer: exon 19 (base pairs: 3072 - 3102) with a PCR 
product of 402 bp (Figure 31). 
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Figure 31: Expression of 3´-end RET with primers RET-B. Marker: pCU8; TGW: neuroblastoma cell 
line; PBMCs-: non-activated PBMCs; SHSY-5Y (+RT): neuroblastoma cell line (in the presence of reverse 
transcriptase); SHSY-5Y (-RT): neuroblastoma cell line (in the absence of reverse transcriptase); Mo+: LPS-
activated monocytes; Neg: no DNA control.  
A weak fragment of the expected size was detected in non-activated PBMCs; a stronger 
one in LPS-stimulated monocytes. Both PCR products from PBMCs and monocytes were 
sequenced and showed 99% identities to the human RET mRNA. 
 
6.6.1.2.2. RET-9-b primers 
Primers used to amplify specifically the short isoform of RET (RET–9) were: forward 
primer: exon 19 (base pairs: 2996 - 3017) and reverse primer: intron 19 (base pairs: 3326 - 
3337) resulting in a PCR product of 446 bp. 
These primers are specific for RET-cDNA with intron 19, because the reverse primer is 
located at the 5’-end of intron 19, which is not translated in any other isoform of RET. 
 
 
Figure 32: Several subtypes of immune cells expressed the short isoform of c-RET (RET-9), which 
encodes the short RET protein containing 9 unrelated amino acids at the C-terminus. PBMCs-: non-activated 
PBMCs; Marker: pCU8; TGW (+RT): as positive control, cDNA containing reverse transcriptase; TGW (-
RT): cDNA without reverse transcriptase. PBMCs-: non-activated PBMCs; PBMCs+: LPS+IFN-γ-activated 
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PBMCs; T cell+: ConA-activated T cells blasts. CD4 -: resting CD4+-T cells; CD4 +: PHA-activated CD4+-
T cells; CD8 -: resting CD8+-T cells; CD8 +: PMA/Ion-activated CD8+-T cells; B cell -: non-activated B 
cells; B cell +: SAC-activated B cells; Mo-: non-activated monocytes; Mo+: LPS-activated monocytes; Neg: 
no cDNA. β-actin transcripts for each cDNA were not included in this figure because they are shown in 
Figure 36, Figure 38, Figure 40, Figure 42, and Figure 44, in which RT-PCR results were separated 
depending on the cell type analyzed. 
PCR products (446 bp) from activated PBMCs and TGW were sequenced and showed 
100% identities to the RET mRNA short isoform.  
Differential expression of RET-9 was observed in the subsets of immune cells analyzed. 
CD8+-T cells did not have the short isoform. Otherwise, all activated cells expressed RET-
9 (PBMCs+, B cell+, Mo+, T cell+). A RT-PCR product for the short isoform was also 
obtained with RNA of non-stimulated PBMCs and monocytes.  
 
6.6.1.2.3. RET-51-b primers 
The long isoform of RET (RET–51) was amplified using these pair of primers: forward 
primer: exon 19 (base pairs: 2996 - 3017) and reverse primer: exon 20 (base pairs: 4762 - 
4779) resulting in a PCR product of 430 bp. 
 
 
 
Figure 33: mRNA expression of the long isoform of RET (RET-51). PBMCs-: non-activated PBMCs; 
PBMCs+: LPS+IFN-γ-activated PBMCs; T cell+: ConA-activated T cells blasts. CD4 -: resting CD4+-T 
cells; CD4 +: PHA-activated CD4+-T cells; CD8 -: resting CD8+-T cells; CD8 +: PHA-activated CD8+-T 
cells; B cell -: non-activated B cells; B cell +: SAC-activated B cells; Mo-: non-activated monocytes; Mo+: 
LPS-activated monocytes; Neg: no cDNA. β-actin transcripts for each cDNA were not included in this figure 
because they are shown in Figure 36, Figure 38, Figure 40, Figure 42, and Figure 44, in which RT-PCR 
results were separated depending on the cell type analyzed. 
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PCR products of 430 bp obtained from the cDNA of activated PBMCs and activated 
monocytes were sequenced and showed 99% identity to the published RET sequence, 
corresponding to the RET-51 (long isoform). 
Again, no cDNA fragment was isolated of unstimulated and activated CD8+-T cells. Also 
resting B cells did not express the long isoform of RET. All the other sub-types of immune 
cells expressed the long isoform even without activation. 
 
6.6.1.2.4. RET-43 primers 
The middle isoform of RET (RET-43) is generated when exon 19 is spliced directly to 
exon 21, skipping exon 20 and was detected with the forward primer: exon 19 (base pairs: 
2996 - 3017) and reverse primer: exon 21 (base pairs: 6256 - 6285) as PCR product of 354 
bp. 
 
 
 
Figure 34: mRNA expression of the middle isoform RET-43 by RT-PCR in immune cells. PCR product 
of 354 bp was amplified from subsets of immune cells. PBMCs-: non-activated PBMCs; PBMCs+: 
LPS+IFN-γ-activated PBMCs; T cell+: ConA-activated T cells blasts. CD4 -: resting CD4+-T cells; CD4 +: 
PHA-activated CD4+-T cells; CD8 -: resting CD8+-T cells; CD8 +: PHA-activated CD8+-T cells; B cell -: 
non-activated B cells; B cell +: SAC-activated B cells; Mo-: non-activated monocytes; Mo+: LPS-activated 
monocytes; Neg: no cDNA control.  
PCR products from non-activated PBMCs and activated monocytes were sequenced and 
showed 100% identity to the published RET sequence, corresponding to the RET-43 
isoform (middle isoform).  
Yet another picture was observed for the expression of the middle isoform in the immune 
cells. Again CD8+-T cells were negative. In activated B cells this transcript was lost. All 
other cell types expressed this isoform. 
 
Results 
 
 
 110
Next table summarizes the results obtained by RET-RT-PCR at the 3’-end region of RET 
mRNA from different subsets of immune cells and the isoforms: 
 
Table 4: Spliced isoforms at the 3’-end of RET gene expressed in human immune cells. Results and PCR 
pictures were compiled from different PCR reactions, in which cDNAs from several donors were analyzed. 
+ : RET mRNA expression. - : mRNA non-detected. CD4-: resting CD4+-T cells. CD4+: PHA-activated 
CD4+-T cells. CD8-: resting CD8+-T cells. CD8+: PHA-activated CD8+-T cells. T cell blasts: ConA 
activated PBMCs after 6 days in culture. B cells-: resting B cells. B cells+: SAC-activated B cells. 
Monocytes-: non-activated monocytes. Monocytes+: LPS-activated monocytes. 
In summary: 
 Resting CD4+-T cells expressed RET-51 and RET-43 but not the short isoform 
RET-9. Activated CD4+-T cells expressed all isoforms. 
 Resting and activated CD8+-T cells did not express any of these isoforms. 
Nevertheless, these cells expressed the isoforms located at the 5’-end. 
 Activated T cell blasts expressed the three isoforms. 
 Resting B cells expressed RET-43, but neither RET-9 nor RET-51. Activated B 
cells expressed both, RET-9 and RET-51 isoforms, but not the middle isoform RET-43. 
 Resting and activated monocytes expressed the three isoforms. 
 
As described above, RT-PCR reactions were performed using different set of primers 
(described in Materials and Methods) to detect all the spliced isoforms expressed from 
RET. To understand better the expression pattern of the RET isoforms at both, the 5’-end 
and 3’-end regions of the gene, a summary and schematic description for each cell type is 
presented below: 
 
ISOFORMS at  
3’ –end region of 
c-RET gene 
     CD4 -      CD4 +       CD8 -      CD8 + T cell blasts    B cells -    B cells + Monocytes- Monocytes+
RET – 9 
SHORT ISOFORM      -       +      -      -       +      -       +       +       + 
RET – 51 
LONG ISOFORM       +       +      -      -        +      -       +       +       + 
RET – 43 
Exon 20 spliced  
out 
      +       +      -      -       +       +      -       +       + 
Results 
 
 
 111
CD4+-T CELLS: 
 
At the 5’-end region of the RET gene coding for the extracellular domain of the mature 
RET protein only one isoform was detected, 3-RET lacking exon 3. No difference was 
observed in CD4+ T cells activated with PHA (see Figure 29). The derived mature protein 
will have a truncated CLD-1 and CLD-2 domain. This deletion might interfere with the 
ligand binding properties of the RET receptor. 
 
 
 
 
Figure 35: Both, non-activated and activated CD4+-T cells expressed only one isoform of RET located 
at the 5’-end region of the gene. A product of 585 bp specific for a transcript lacking exon 3 is shown in 
both lanes. TGW: as positive control. ( - ) represents non-activated CD4+-T cells; ( + ) represents PHA-
activated CD4+-T cells. PCR for β-actin as housekeeping gene using 28 cycles of amplification was always 
performed in all samples to test the cDNA quality. 
 
Alternative transcripts were detected in CD4+-T cells at the 3’-end region of the RET gene 
encoding the intracellular domain of the mature RET protein. The long and the middle 
isoform were synthesized in both non-activated and PHA-activated T lymphocytes, 
whereas the short transcript RET-9 is not present in non-stimulated CD4+-T cells, but is 
induced by PHA stimulation.  
 
 
 
5’-end region of 
the RET gene 
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Figure 36: Summary of the splice isoforms of RET located at the 3’-end region of non-activated and 
activated CD4+-T cells. Non-activated (-) and activated (+) CD4+-T cells; cell line TGW as control. The 
quality of the cDNA was assessed by amplification of a β-actin cDNA fragment (below). The translated RET 
protein variants are shown on both sides. They differ in the carboxyl terminal sequence and the fourth 
tyrosine residue, which is only present in the middle and long RET proteins.  
Upon PHA stimulation of CD4+-T lymphocytes alternative splicing results in a RET-
transcript encoding a carboxyl-terminal shortened RET receptor. 
CD8+-T CELLS 
In contrast to CD4+-T cells, all alternatively spliced transcripts at the 5’-end region of the 
RET gene were detected in CD8+-T cells.  
 
 
 
 
Figure 37: Both, non-activated and activated CD8+-T cells expressed all isoforms of RET at the 5’-end. 
The full length of 873 bp, the product of 677 bp (5-RET mRNA) when exon 5 is spliced out and a product of 
5’-end region of 
the c-RET gene 
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585 bp due to the absence of exon 3 (3-RET mRNA). TGW (human neuroblastoma cell line) is shown as 
positive control. (+): PHA-activation. β-actin for all cDNA was amplified and is shown below. 
CD8+-T lymphocytes (activated and non-activated cells) expressed the full length mRNA 
located at the 5’-end region of the gene, as well as the 3-RET mRNA and the 5-RET 
mRNA isoforms. The weakest signal in CD8+-T cells was detected at 873 bp 
corresponding to the full length. It seems that the 5-end mRNA lacking exon 3 is the 
strongest expressed isoform in CD8+-T lymphocytes, although the differences might also 
be explained by preferential amplification of the shortest fragment. No differences were 
seen after lymphocyte activation with PHA or PMA+Ionomycin (Data not shown).  
Primers amplifying 3’-end cDNA fragments gave no results for CD8+-T 
lymphocytes even after PHA activation. Surprisingly, although RET-transcripts were 
detected using primers for the 5’-end region of the gene and the cDNA quality was tested 
with β-actin primers, the RT-PCR for the 3’-end were negative. Presumably, RET mRNA 
expressed in resting or activated CD8+-T cells lack either exon 19 or/and 20, 21. A simple 
explanation would be a premature termination of the RET transcript in CD8+-T cells. 
 
 
Figure 38: CD8+-T cells did not express any of the three splice isoforms of RET located at the 3’-end. 
Three different RT-PCR reactions were performed in order to detect the spliced isoforms located in this 
region using as template cDNA from non-activated and PHA-activated CD8+-T cells, and as forward primer 
a oligonucleotide binding to exon 19 sequence and different reverse primers annealing to sequences present 
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in intron 19, exon 20 and exon 21. None of the samples expressed any of the isoforms. β-actin amplifications 
are included to test the cDNA quality. 
Other primer pairs were tested to find out the site where the intracellular domain stops in 
CD8+-T cells (activated and non-activated cells). Primers pair was as follows: forward 
primer: exon 9 (base pairs: 1592 – 1610) and reverse primer: exon 18 (base pairs: 2909 – 
2927). Results were not conclusive, and data not shown. 
 
T CELL BLASTS: 
Peripheral blood mononuclear cells were isolated from healthy donors and activated with 
ConA, cultured during 6 or 7 days. At that time almost 100% of the cells are activated 
CD3+-T cells blasts (verified by FACS analysis; data not shown). These cells are a mixture 
of CD4+ and CD8+-T cells. RNA was prepared and analyzed by RT-PCR to detect 
alternative splice variants at both the 5’-end and the 3’-end region of RET. 
 
 
 
Figure 39: RET mRNA expression of the full length 5’-end mRNA in ConA activated T cell blasts. 
There is one signal at 873 bp corresponding to the full-length size. TGW: positive control. (+): activated T 
cell blasts after 7 days in culture with ConA. 
ConA-activated T cells expressed only the full length of the RET transcript in the analyzed 
5’-sequence. The expressed protein contains all four CLDs.  
With regard to the intracellular domain, the T cell blasts should synthesize all three 
carboxy terminal receptor variants, as the RT-PCR analyses were positive for short RET-9, 
long RET-51 and middle RET-43 (see Figure 40). 
 
 
5’-end region of 
the RET gene 
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Figure 40: Activated T cell blasts after 7 days in culture with ConA expressed the three isoforms of 
RET located at the 3’-end of the gene. Predicted proteins encoded by the short (RET-9), long (RET-51) and 
middle (RET-43) isoforms are represented at the right side. ( + ) represents ConA-activated-T cells. 
Although T cell blasts consist of activated CD4+ and CD8+-T lymphocytes, differences in 
the expressed RET splice variants were observed. Activated T cell blasts had the three 
isoforms located at the 3’-end region. These transcripts might be present in the CD4+ 
fraction, as the CD8+-T cells (activated and non-activated cells) were negative in the RT-
PCR. T cell blasts in contrast to resting and PHA-activated CD4+- and CD8+-T cells only 
expressed the full length 5’-end RET mRNA sequence. The different isoform expression 
pattern observed in T cell blasts might be explained by the influence of cytokines induced 
in the population by the stimulation. 
 
B CELLS: 
In B cells the expression of the RET isoforms was found to be strongly regulated by 
activation. Resting B cells expressed the full length and the two shorter isoforms at the 5’-
end, but only the middle sequence for the cytoplasmic domain. In contrast, SAC-activated 
B cells (and PWM-activated B cells, data not shown) did not contain any of these isoforms. 
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Figure 41: Multiple splice variants located at the 5’-end of RET were expressed in resting B cells. 5-
RET mRNA (677 bp), 3-RET mRNA (585 bp) and very low expression of the full length (873 bp). In 
contrast, SAC-activated B cells did not express any of these RET isoforms.  
As RET mRNA was detected in the RT-PCR with primers amplifying 3’-sequences, one 
explanation could be that the exon 6 is spliced out in B cells upon activation. Activation 
also changes the splicing pattern in the 3’-sequences, where either intron 19 is retained or 
intron 19 and exon 20 are removed.  
 
 
Figure 42: RET spliced isoforms located at the 3’-end region were differently expressed in non-
activated and SAC-activated B cells. RT-PCR pictures show that activated B cells (+) expressed RET-9 
and RET-51 but not RET-43. On the contrary, non-activated B cells (-) expressed only RET-43. The 
reactions were performed at least three times for each sample, from several donors. β-actin was amplified in 
28 cycles to ensure the quality of the cDNAs and RNAs were tested for genomic contamination. 
5’-end region of 
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MONOCYTES: 
Monocytes expressed RET constitutively and LPS activation had no effect on the 
expression pattern. 
 
 
 
Figure 43: Both, non-activated (-) and LPS-activated monocytes (+) expressed only the full length at 
the 5’-end region of the RET gene by RT-PCR. Only a fragment for the full length 5’-end mRNA of 873 
bp was amplified. β-actin is shown. 
Non-activated (-) and activated (+) monocytes expressed only the full length RET mRNA 
at the 5’-end, whereas all splice isoforms were detected for the 3’-end.  
 
 
Figure 44: All spliced isoforms of RET at the 3’-end region were detected in non-activated and in 
activated monocytes by RT-PCR. RET-9 (short isoform: 446 base pairs), RET-51 (long isoform: 430 base 
pairs) and RET-43 (middle isoform: 354 base pairs) are shown. TGW as positive control for RET. β-actin is 
also shown. 
5’-end region of 
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Both, non-activated and activated monocytes express the normal extracellular RET protein 
that differ at the COOH-terminus. 
 
 
6.6.2. Western blot - RET 
At the protein level, the expression of RET receptor was assessed by Western blot and 
FACS analysis using mAb for extracellular staining. 
6.6.2.1. Western blot – RET Short isoform 
To detect the short isoform of RET (RET-9) Western blot using non-labeled rabbit anti-
human RET directed against the short isoform of the intracellular domain (Sta. Cruz 
Biotechnology) was performed. The secondary antibody was a goat anti-rabbit-biotin, and 
then streptavidine-horse peroxidase.  
Several immune cells expressed the short isoform as 150-kDa polypeptide (Figure 45), 
with the exception of CD8+-T lymphocytes, which did not express the short isoform 
mRNA (data from W.B. not shown).  
 
 
 
 
 
Figure 45: Detection of RET protein (short isoform) in human immune cells. Lysates from TGW 
neuroblastoma cell line (20 µg of protein/lane). From non-activated PBMCs (PBMCs-), ConA-activated T 
cell blasts (T cell), non-activated (Mo -) and LPS-activated monocytes (Mo +), SAC-activated B cells (Bc +) 
and LPS+IFN-γ-+αCD40-activated PBMCs (PBMCs+) were loaded approximately 80-100 µg/lane. Proteins 
were separated on 4-12% Bis-Tris gels and analyzed by Western blotting with anti-RET pAb that recognizes 
the intracellular domain of the short form of the protein.  
Non-activated and activated PBMCs (LPS + IFN-γ + α-CD40), non-activated and LPS-
activated monocytes, SAC-activated B cells; and ConA-activated T cell blasts showed a 
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strong band at 150 kDa and a weaker signal at 170 kDa. Unstimulated PBMCs had only 
little amounts of this RET protein. The highest level was found in T cell blasts and in the 
control cell line TGW. 
6.6.2.2. Western blot – RET Long isoform 
To detect the long carboxy-terminal isoform of RET (RET-51), Western blot using a goat 
pAb antibody against RET was performed. In immune cells, only the 150-kDa band was 
stained. With regard to the amount of RET polypeptides similar results were obtained as 
with the “RET-9”-specific antiserum.  
 
 
 
 
 
Figure 46: Detection of RET protein (long isoform) in several human immune cells. Lysates from TGW 
cells (20 µg of protein/lane), and from mononuclear cells: non-activated PBMCs (PBMCs-), activated T cell 
blasts (Tc +), non-activated (Mo -), activated monocytes (Mo +) and SAC-activated B cells (Bc +), 
approximately 100 µg/lane were separated on 4-12% Bis-tris gels, transferred to a nitrocellulose membrane, 
stained with anti-RET pAb that recognizes the long form of the protein and analyzed whit ECL kit. TGW 
cells showed two bands, 150 and 170 kDa RET proteins.  
 
 
 
6.7. GFRα-1 EXPRESSION 
The expression of the surface receptor GFRα-1 was studied at mRNA level using RT-
PCR, and at the protein level using extracellular FACS staining and Western blot. 
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6.7.1. RT-PCR - GFRα-1  
RT-PCR using specific primers for GFRα-1 was performed to analyze the message in 
immune cells. GFRα-1 mRNA expression was present in both CD4+ and CD8+-T 
lymphocytes, in B cells and monocytes. 
In most of the cases, a weak signal was observed in different samples. The PCR reactions 
with cDNA from T and B cells had to be amplified for 38 or 40 cycles to obtain the signal 
indicating low transcript levels. When cDNA from monocytes was amplified, the PCR 
product was seen with a lower number of cycles. 
To analyze GFRα-1 mRNA expression two different primer pairs were employed:  
1) Rec-Alpha1(2) with the forward primer: Exon 1 (bp 1-18) and the reverse primer: Exon 
2 (bp 307-324) resulting in a PCR product of 325 base pairs. 
 
 
 
Figure 47: GFRα-1 mRNA expression was detected by RT-PCR in non-activated and in activated 
PBMCs. All reactions were performed at 40 cycles. As positive controls: TGW and SHSY5Y (with (+RT) and 
without (-) reverse transcriptase). 293 cells: human embrionary kidney cell line. PBMCs-: non-activated 
peripheral blood mononuclear cells. PBMCs+: peripheral blood mononuclear cells activated with LPS, IFN-γ 
and α-CD40. CD4-: resting CD4+-T cells. CD8-: resting CD8+-T cells. B cell-: resting B cells. Mono-: non-
activated monocytes. 
Sequenced products were 99% identical to GFRα-1 mRNA in activated PBMCs and in 
SHSY-5Y. The mRNA expression of GFRα-1 is low in immune cells, for that reason the 
bands were visualized very weak on the gels. When the quality of cDNA was not good 
(i.e., no β-actin amplification was obtained after 30 cycles), signals from GFRα-1 PCR 
were not visible. 
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2) The primer pair ALPHA-1 with the forward primer: exon 5 (bp 777-796) and the 
reverse primer: exon 7 (bp 1064-1086) amplifying a fragment of PCR product of 310 base 
pairs. 
 
 
 
 
 
 
Figure 48: Amplification of GFRα-1 mRNA by immune cells using RT-PCR. This picture shows a very 
weak band at 310 base pairs in activated PBMCs, and in both, CD4+ and CD8+-T cells. cDNA from B cells 
was the weakest. SHSY-5Y: neuroblastoma cell line cDNA in the presence of reverse transcriptase, as 
positive control. (-RT): in the absence of reverse transcriptase. 
As well as the reactions preformed with Rec-Alpha1 (2), the PCR products observed with 
these primer pairs were very weak. Also, the reactions were amplified 38 or 40 cycles to 
obtain the signal on immune cells. The positive control, SHSY-5Y, always showed higher 
expression. 
PCR product from LPS-activated PBMCs was sequenced and the homology to the human 
GFRα-1 mRNA was 99%. 
 
6.7.2. FACS-GFRα-1 
FACS analysis using extracellular staining for GFRα-1 was performed to stain the surface 
receptor on immune cells. For this experiment living cells were carefully taken, then 
washed 2 times and incubated for 30 min with a primary, non-labeled monoclonal 
antibody, a mouse anti-human GFRα-1, which was posterior labeled with a secondary 
FITC-labeled goat anti-mouse pAb. 
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As positive control, TGW cell line was used. These cells expressed higher amounts of 
GFRα-1 mRNA, and therefore they should express also the protein in their surface. 
 
 
Figure 49: TGW cells are positive control for GFRα-1 protein detected by FACS. A percentage of TGW 
cells were positively stained with a mouse mAb against human GFRα-1 as non-labeled primary Ab, using as 
secondary Ab a goat-anti mouse-FITC labeled showed in FACS histograms. Green line represents the isotype 
control. Blue filled histograms show labeled cells with Ab against GFRα-1. First histogram showed 16% of 
positive cells, the second showed 18% of positive stained cells. Less than 20% of the TGW cells expressed 
GFRα-1 on the surface. 
A negative cell line for GFRα-1 mRNA was found by RT-PCR, because they did not 
express GFRα-1 mRNA. These cells are the HL-60 cell line, which were stained with 
similar concentrations of mAb anti human-GFRα-1 for extracellular FACS. They did not 
stain their surface with GFRα-1 antibody:  
Fresh non-activated PBMCs were stained using the same protocol to determine whether 
they express GFRα-1 protein on the surface as it was found at mRNA level, Figure 47: 
When fresh isolated and non-activated PBMCs were stained for GFRα-1, the lymphocytic 
population was not stained, only monocytic population; about 14% of the total amount of 
cells was stained positively for GFRα-1, this population corresponded to monocytes. 
M1
M1
TGW 
16% 
TGW 
18% 
Figure 50: HL-60 cell line used as negative control for FACS 
analysis using a mAb α-GFRα-1, secondary labeled with gαm-
FITC. Blue histogram represents cells stained with GFRα-1-FITC. 
Green line represents isotype control. No cells were positively 
stained with the Ab, meaning that they do not express GFRα-1 on 
their surface. 
HL-60 
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When non-activated PBMCs were cultured during 3 days without activation, a small 
population of lymphocytes was stained for GFRα-1 (~20%), as well as monocytes. 
Probably, after 3 days in culture, lymphocytes got a weak activation, which was enough to 
induce higher surface expression of GFRα-1 on their surface (data not shown). 
After 72 hours of activation (LPS + IFN-γ), PBMCs were taken to perform flow cytometry, 
using a mAb against-human GFRα-1 and secondary labeled goat α-mouse-FITC. The 
extracellular staining showed that activated PBMCs expressed GFRα-1 on their surface; 
mainly positive cells were located on the monocytic population. A small sub-population of 
non-activated lymphocytes was also stained, next dot-plots (Figure 52). 
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Figure 52: FACS analysis for GFRα-1 using extracellular staining on activated PBMCs. Dot-plot 
showing 72 hours activated PBMCs (with LPS and IFN-γ) and stained with mAb-GFRα-1 (non-labeled) and 
the secondary Ab goat anti mouse-FITC. Mainly monocytes were stained on the surface with GFRα-1 Ab. 
Isotype control    GFRα-1 mAb 
FL1 
81% 
M1
Figure 51: Fresh non-activated PBMCs expressed on their 
surface the receptor GFRα-1. Living cells were stained with mAb 
mouse against human GFRα-1, secondary labeled with goat anti-
mouse-FITC. Most of the positively stained cells were located on 
the monocytic population. Almost non-lymphocytic cells were 
stained at day 1. Cells were treated with human Igs to block Fc 
receptors. 
PBMCs 
14 % 
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A population of ~10% in the upper left quadrant was also stained. These were small cells 
with granularity similar to lymphocytes (SSC <10). The identity of this subset could be 
addressed by double staining for GFRα-1 and different CD antigens (not done). 
The population of large cells (macrophages, upper right quadrant) also showed staining for 
GFRα-1, giving an increase of 15 folds between isotype and specific staining. To prove the 
identity of these cells, a double staining for CD14 and GFRα-1 could be performed. 
Activated PBMCs were gated for lymphocytic (small size) and for monocytic (big size and 
high granularity) sub-populations. Then, the statistical analysis was better applied. 
14 % of lymphocytic cells were positively stained for GFRα-1. 89% of monocytic cells 
were positive stained for GFRα-1 secondary labeled with FITC. A mixture of human Ig 
was added to the cells and incubated for 10 min, at 4°C, in order to block Fc receptors on 
monocytes, which can bind unspecific any antibody. 
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Figure 53: Histograms showing gated lymphocytes (on the left side) and gated monocytes (on the right 
side). PBMCs were 72 hours activated with LPS + IFN-γ; then were stained with GFRα-1 mAb, secondary 
labeled with FITC. Isotype control (mouse IgG1) is represented in gray color. Ab-FITC is represented as a 
black line. Fluorescence-1 intensity was higher in monocytes (more than 102), approximately 80% of gated 
cells stained positive for this antibody. 
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Figure 54: FACS analysis using extracellular staining for GFRα-1 surface receptor on ConA-activated 
PBMCs. Dot plots showing a population of ConA-activated T cell (72 hours in culture); approximately 9% 
of these cells expressed GFRα-1 on their surface. 
 
 
  
 
 
 
 
 
 
 
Figure 55: FACS analysis of T cell blasts after GFRα-1 surface staining. Dot-plots showing that after 6 
days of ConA activation, a low percentage of T cells are positively stained with GFRα-1 mAb; the amount of 
positive cells was lower than 3 days before. Left dot plot represents the isotype control (mouse IgG1). Right 
dot-plot shows the GFRα-1-FITC labeled stained activated T cell blast. 
It seems that along ConA activation time, T cell blasts loose GFRα-1 from their surface. 
Probably, it is cleaved from the cell and liberated to the medium as soluble protein.  
GFRα-1 mAb Isotype control     
FL1 
Isotype control GFRα-1 mAb 
5 % 
Results 
 
 
 126
 
Table 5: This table shows the summary of Flow Cytometry analysis using extracellular staining for GFRα-1 
and blocking Fc receptors, which was done in groups of PBMCs, non-activated or activated with different 
mitogens.  
These data suggest that the GFRα-1 receptor is mainly expressed on the surface of 
activated monocytes, and that a small sub-population of lymphocytes also expresses it. 
After 96 hours of ConA activation, those positive stained lymphocytic cells did not express 
the receptor anymore; however, mRNA transcripts from activated T cells were found in 
RT-PCR. 
 
 
6.7.3. Western blot- GFRα-1  
Western blot using the same monoclonal antibody against human GFRα-1 gave a positive 
and unique band at the expected size: between 55 – 60 kDa in all tested samples, even 
those, which were negative by RT-PCR, see Figure 57. 
For that reason, the results obtained in these experiments cannot be taken as reliable. 
 
CULTURE 
CONDITIONS 
Lymphocytic cells Monocytic cells 
Non-activated PBMCs 
 
- / + + 
Activated PBMCs 
+ ConA (24 hours) 
+ + 
Activated PBMCs 
+ LPS, IFN-γ (72 hours) + ++ 
ConA-activated T cells  
(5 days) 
- / 
TGW  
(Positive control) 
+ 
HL-60  
(Negative control) 
- 
K562 
(Negative control) 
- 
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Figure 56: GFRα-1 protein expression in subtypes of peripheral mononuclear cells. Western blot was 
performed using a mouse mAb- anti human GFRα-1. The secondary antibody was a goat α-mouse-HRP. 
Different protein concentrations of each cell lysate were loaded/well (from 30 to 100 µg/lane). A unique 
band approx. at 60 kDa was seen on the stained nitrocellulose membrane. The detection system used was 
ECL. All immune cells and both positive controls (TGW and A431 cell lines) stained positively for GFRα-1. 
 
 
 
 
Figure 57: Western blot using mAb might give false positive results. Non-activated and ConA- activated 
T cells, and myoblasts stained positive for GFRα-1, but also the HL-60 and K562 cell lines, which were 
negative controls by RT-PCR, meaning that they did not express GFRα-1 mRNA. These experiments were 
performed four times, obtaining similar results. 
B. 
Western blot
RT-PCR
A. 
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A. Western blot performed with mAb against GFRα-1 showed a unique band at the right size: 60 kDa in all 
samples, even in the negative controls (K562 and HeLa cells). 
B. Expression of GFRα-1 mRNA by RT-PCR in the TGW cell line (as positive control) and in the K562 
and HeLa cells (as negative controls). Activated T cell blasts and myoblasts also expressed GFRα-1 
mRNA. 
Some monoclonal antibodies could give false positive signals, as shown in Figure 57, 
thereby, always the protein findings should be compared with mRNA results. 
 
 
 
6.8. GFRα-2 EXPRESSION 
GFRα-2 surface receptor for NTN was studied at the mRNA level using RT-PCR.  
For protein detection, Western blot using two different antibodies were not useful for this 
approach (data not shown). On the contrary, FACS analysis using a goat α-human GFRα-2 
pAb, secondary labeled with donkey anti-goat-PE was done in immune cells.  
 
6.8.1. RT-PCR: GFRα-2 
Pair of primers used to amplify GFRα-2 were as following; with them all spliced isoforms 
described can be amplified. Forward primer: Exon 1 (20 – 40 bp) and reverse primer: Exon 
5 (853 – 872 bp). 
 
PCR products: 
851 bp: GFRα-2a (full length)  
537 bp: GFRα-2b (exon 2 spliced out) 
453 bp: Exon 1-4 mRNA (exon 2 and exon 3 spliced out) 
280 bp: Unspecific 
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Figure 58: GFRα-2 mRNA expression by immune cells. RT-PCR was performed using primers spanning 
exons 1 to 5 that can detect all splice isoforms described. Sub-sets of immune cells amplified different 
isoforms. Non-activated CD8+-T cells and B cells, both resting and activated, expressed low levels of GFRα-
2. TGW: human neuroblastoma cell line, as positive control showing all isoforms. HL-60 (+RT): human 
leukemia cell line, + reverse transcriptase. PBMCs-: resting PBMCs. PBMCs++: LPS+IFN-γ-activated 
PBMCs. CD4-: resting CD4+-T cells. CD4+: ConA-activated CD4+-T cells. CD8-: resting CD8+-T cells. 
CD8+: PHA-activated CD8+-T cells. Tc+: ConA-activated T cell blasts. B cells-: resting B cells. B cells+: 
PWM-activated B cells. Mo-: non-activated monocytes. Mo+: LPS-activated monocytes. β-actin for all 
samples is shown on the bottom. 
The full length of GFRα-2 (GFRα-2a) was expressed in TGW, in non-activated and LPS-
activated monocytes and in LPS+IFN-γ-activated PBMCs. 
GFRα-2b isoform (537 bp) was amplified in low amounts by TGW, in activated PBMCs 
and in non-activated monocytes. 
Exon 1-4 mRNA isoform (453 bp, lacking exons 2 and 3) was the most frequently 
expressed in all immune cells studied, as shown in Figure 58, it was present in activated 
and non-activated PBMCs, in activated and non-activated CD4+-T cells, activated CD8+-T 
cells, ConA-activated T cell blasts and in the positive control TGW. The expression of 
GFRα-2 in non-activated B cells was very low. 
The PCR product of 851 bp from activated PBMCs was sequenced and showed 100% 
homology to the human GFRα-2 sequence. 
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6.8.2. FACS - GFRα-2 
Protein levels of GFRα-2 were detected using extracellular staining for FACS analysis. 
As positive control, TGW cells were stained on the surface with GFRα-2 pAb, secondary 
labeled with a donkey anti-goat PE labeled Ab. Histogram is shown in Figure 58. 
 
 
 
Non-activated PBMCs were also stained with the same antibodies. In freshly isolated cells 
without activation approximately 9% of lymphocytes (Figure 60) and 8% of monocytes 
(Figure 61) expressed GFRα-2 on their surface by FACS analysis using extracellular 
staining: 
 
 
 
 
 
 
 
 
 
 
Figure 60: Fresh isolated PBMCs, gated for lymphocytes showed that 8% of cells were positively 
stained in their surface with GFRα-2 pAb. Non-activated PBMCs were isolated and stained with goat-anti 
human GFRα-2 pAb (1:50), secondary PE- labeled. Left dot-plot represents the isotype control (Goat IgG – 
PE). Right dot-plot shows gated lymphocytes stained with pAb GFRα-2 - PE labeled. 
TGW 
24% 
Figure 59: TGW cell line as positive control for 
GFRα-2 in FACS. TGW cell line stained positively for 
GFRα-2 using a pAb, secondary labelled with donkey-
anti-goat-PE in extracellular staining and FACS. The 
histogram shows 24% of positive cells. Green line: 
isotype control. Blue: pAb α- GFRα-2. 
8 % 
GFRα-2 - PE Isotype control 
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Figure 61: A percentage of the gated monocytes were stained positively for GFRα-2 with extracellular 
staining in FACS. Fresh isolated PBMCs from the above experiment were gated for monocytes showing that 
~ 9% of monocytes expressed GFRα-2 on their surface. Non-activated PBMCs were stained in the same 
manner as described in Figure 60. Left dot-plot: isotype control (Goat IgG – PE). Right dot-plot: GFRα-2 – 
PE labeled cells. 
Some experiments were done using double staining, means pAb anti-GFRα-2, secondary 
labeled with PE plus mAb anti-CD molecules, to know which sub-sets of immune cells 
express higher amounts of GFRα-2 (data not shown). 
 
6.8.3. Indirect immunofluorescence – GFRα-2 
Unstimulated and PWM-activated PBMCs were incubated during 1 hour, at 37°C, in the 
presence of mAb anti-NTN (1:100). Then, cells were washed in PBS, attached to glass 
slides (cytospin), fixed with paraformaldehyde and stained with a secondary Ab goat 
anti mouse-Cy3 labeled.  
Positive cells are stained in red, showing that Neurturin is present or attached on the cell 
surface. The ligand NTN has to bind to the surface receptor GFRα-2 (located on the 
cellular membrane); otherwise it is free in the medium.  
This method was an indirect way to show that the receptors are expressed on the surface 
and they are functional because they could bind the NTN, which is secreted either for the 
same cell or for neighboring cells. 
9 % 
GFRα-2 - PE Isotype control  
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Figure 62: Surface staining of NTN on resting and PWM-activated PBMCs indicates the presence of 
the surface receptor GFRα-2. Non-activated and activated PBMCs were compared on their capacity to bind 
NTN, indicating indirectly the presence of the GFRα-2 coreceptor on their surface. This figure shows a big 
difference in the amount of positive stained cells after activation with pokeweed mitogen (PWM) in picture 
C), when compared with resting cells in A). After activation the majority of cells were stained in red 
(NTN+). Isotype controls are shown in B) and in D). 
 
PBMCs+PWM
Non-activated PBMCs
C) 
A) B)
D)
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Figure 63: Double staining: anti-NTN/Cy3 and anti-CD/FITC antibodies on the surface of resting 
PBMCs to demonstrate the presence of the receptor GFRα-2, which binds with high affinity NTN. 
After to have incubated PBMCs with monoclonal antibody against human Neurturin, cells were fixed and 
stained with secondary Ab (goat anti-mouse-Cy3), then double stained using monoclonal and labeled 
antibodies against the surface molecules: CD4 (A), CD8 (B), CD14 (C) and CD19 (D). Yellow regions from 
overlaid micrograph show the presence of both molecules on the surface of these cells (NTN + CD 
molecules), yellow arrows indicate them. Even that few cells were positively stained for NTN because they 
were non-activated PBMCs, a difference between each sub-type could be seen: CD4+-T cells (A) and CD14 
monocytes (C) stained stronger for surface NTN than CD8+-T cells (B) and B cells (D). 
CD4+-T and CD14+ monocytes were the immune cells that stained stronger with anti-NTN 
Ab than CD19 (B cells), which expressed lower amounts of NTN. In contrast, in CD8+-T 
lymphocytes the amount of NTN was very low, almost not seen in this picture  
C) D)
A) B)
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6.9. GDNF and RECEPTORS IN HUMAN MYOBLASTS 
 
6.9.1. GDNF 
GDNF was not expressed by human myoblasts, neither at the mRNA level nor at the 
protein level.  
 
6.9.1.1. RT-PCR GDNF: 
Same primers used to detect GDNF on immune cells were used to perform PCR reactions 
with myoblast’s cDNA. Samples were prepared either with non-stimulated or with IL-1β 
or IFN-γ–stimulated cells. All reactions were negative, indicating that human myoblasts 
did not express GDNF mRNA (data not shown). 
 
6.9.1.2. ELISA - GDNF 
To measure GDNF protein, myoblasts were either non-treated or treated 48 hours with 100 
pg/ml of IL-1β or 100 U/ml of IFN-γ. After 48 hours, the supernatants were analyzed using 
the same ELISA kit used for GDNF detection on immune cells supernatants. 
We used as positive control NIH-3T3 cells transfected to produce GDNF. 
Non-stimulated and stimulated myoblasts did not produce GDNF protein (data not shown).  
 
6.9.1.3. Proliferation: 
We did not find any effect on the induction of myoblasts proliferation after GDNF 
treatment using different GDNF concentrations (ranging from 0.1 to 500 ng/ml of human 
recombinant GDNF).  
 
6.9.2. GFRα-1 
6.9.2.1. RT-PCR GFRα-1: 
Human myoblasts in culture expressed GFRα-1 mRNA, as shown in Figure 64. We used 
SHSY-5Y cells as positive control and HL-60 cell line as negative control.  
Primers used to amplify GFRα-1 were already described for immune cells. 
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A PCR product of 324 bp was sequenced showing 100% homology to GFRα-1 mRNA. 
 
 
 
Figure 64: RT-PCR showing the mRNA expression of the GFRα-1 receptor in human myoblasts. 
Positive control: SHSY-5Y. Negative control: HL-60 cell line. Myoblasts expressed transcripts of GFRα-1. 
β-actin is shown to verify the cDNA quality. RT+: cDNA in the presence of reverse transcriptase. RT –: 
cDNA in the absence of reverse transcriptase. 
 
6.9.3. RET 
RET was also studied on human myoblasts. These cells expressed the long and the short 
isoform of RET. 
6.9.3.1. RT-PCR RET: 
c-RET large (430 bp) and short isoforms (446 bp) were expressed by SHSY-5Y cells used 
as positive control and also by myoblasts, as shown in the next picture:  
 
 
 
Figure 65: Human myoblasts expressed RET mRNA by RT-PCR. Both isoforms, long and short RET 
were detected. As positive control: SHSY-5Y; as negative control: K562 cells. All samples were prepared 
with (RT+) or without reverse transcriptase (RT-). β-actin was used as housekeeping gene. 
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6.9.3.2. Western Blotting - RET: 
Western blot to stain RET protein in human myoblasts is shown in Figure 66. The Ab used 
was: as primary, a rabbit anti human RET pAb that detects the short isoform, and as 
secondary: a goat anti-rabbit biotinylated pAb; to catalyze the reaction, a streptavidine – 
HRP was used. 
 
 
 
 
 
Figure 66: RET protein was also detected in myoblasts performing Western blotting. Two bands at 150 
and 170 kDa were seen in the positive control SHSY-5Y; the upper band of 170 kDa is very weak. In 
myoblasts and in activated T cell blasts RET protein was also detected, but in lower amounts. The negative 
control K562 did not show signals at the right size.  
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6.10. FUNCTIONAL EXPERIMENTS 
6.10.1. Proliferation Assays 
3H-Thymidine incorporation was assessed in order to find an effect of GDNF and NTN on 
the proliferation of immune cells. PBMCs or separated subtypes of cells were activated as 
it was described in Materials and Methods, then after 24, 48, 72, 96 and 120 hours of 
activation, GDNF or NTN was added to the wells. Immune cells were Thymidine-labeled 
at different time-points and were harvested 18 hours later. Samples were always were 
measured in triplicates. Different concentrations of GDNF and NTN were tested. Neither 
GDNF nor NTN had an effect on lymphocyte proliferation (data not shown). 
 
6.10.2. ELISA-TNFα 
TNF-α ELISA was performed using supernatants from non-activated PBMCs or PMBCs 
that had been stimulated with either LPS+IFN-γ to activate monocytes or with ConA to 
activate T cells.  
Results obtained from these experiments indicated that the amount of TNF-α measured in 
the supernatant of 24 hours GDNF- or NTN-treated cells after some days in activation was 
significantly reduced in comparison with non-treated cells.  
The strongest difference was detected when activated cells (either with ConA or with LPS 
+ IFN-γ) were cultured during 5 or 6 days and then treated for 24 hours with GDNF or 
NTN. By contrast, if the cells were treated from day 0 with mitogens plus GDNF or NTN, 
no effect of GDNF or NTN on the TNF-α content of the supernatant obtained at day 4 was 
observed. 
Results are shown in the following graphics, first ConA-activated PBMCs (T cell+ or 
activated T cell blasts) and then, LPS+IFN-γ-activated PBMCs (PBMCs++): 
An example of 7 days ConA-activated PBMCs (activated T cell blasts) is shown in Figure 
67, in which after 6 days in culture (ConA added at day 0) cells were treated for 24 hours 
with GDNF or NTN (100 ng/ml). SN were taken and afterwards measured, observing a 
significant difference between treated and non-treated samples (p<0.005 or **).  
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Figure 67: TNF-α ELISA was performed using supernatants from 6 days ConA-activated PBMCs and 
24 hours treated with GDNF or NTN. A significant reduction in the TNF-α concentration (pg/ml) was 
found in 6 days ConA-activated-PBMCs and then treated 24 hours with either GDNF or NTN. Supernatants 
were taken at day 7. In this graphic Tc+: activated T cell blasts. Each bar represents the mean of triplicates, 
+/- SEM (standard error of the mean). Statistical analysis was calculated with the Student’s t- test. ∗∗ : p< 
0.005. 
Similarly, a significant difference was observed when cells were activated at day 0 for 5 
days with ConA and then 4 days treated with GDNF or NTN. In Figure 68 this difference 
is less evident than in the previous one:  
 
 
 
 
 
 
 
 
 
 
Figure 68: TNF-α ELISA was performed using supernatants from 5 days ConA-activated PBMCs, 
treated 4 days with GDNF or NTN. A significant reduction in the TNF-α concentration (pg/ml) was found 
in PBMCs activated during 5 days and treated 4 days with either GDNF or NTN (100 ng/ml). Tc+: ConA-
activated T cell blasts: Each bar represents the mean of triplicates (n-3), +/- SEM. ∗∗ : p< 0.005. p was lower 
than in Figure 67. 
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When PBMCs were activated and treated with NTN or GDNF from the first day of culture 
and incubated during 4 or 5 days, no difference in the TNF-α concentration was observed 
between treated and non-treated samples, Figure 69 shows only NTN-treated and non-
treated ConA-activated PBMCs:  
 
 
 
 
 
 
 
 
 
 
Figure 69: No differences were detected in TNF-α concentration when PBMCs were activated with 
ConA and treated with NTN from the first day and then cultured during 4 days. Each bar represents the 
mean of n=3, +/- SEM. Results were analyzed with the Student’s t-test. ∅ : Non-statistically significant. 
Examples of LPS+IFN-γ stimulated PBMCs in the absence or presence of GDNF and NTN 
are the following: 
 
 
 
 
 
 
 
 
 
Figure 70: TNF-α ELISA was done using SN from LPS+IFN-γ-activated PBMCs (PBMCs++). A 
significant reduction in the TNF-α concentration was found when GDNF or NTN was added to activated 
PBMCs 6 days after activation with LPS+IFN-γ for 24 hours. Each bar represents the mean of triplicates, +/- 
SEM. Results were analyzed with the Student’s t- test. ∗∗ : p< 0.005. 
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Figure 71: TNF-α ELISA performed with the supernatants from LPS+IFN-γ-activated PBMCs 
(PBMCs++). This graphic shows that the amount of TNF-α was similar after 4, 5 or 6 days in the medium of 
activated-PBMCs. In contrast, when LPS+IFN-γ-activated PBMCs were treated at day 5 with 100 ng/ml of 
either GDNF or NTN during 24 hours, a statistically significant reduction was seen in TNF-α concentration. 
∅: not statistically significant. p< 0.005 or ∗∗  
When PBMCs were cultured from day 0 in the presence of GDNF / NTN plus activators 
(LPS + IFN-γ) and kept in culture during 4 days, neither GDNF nor Neurturin had an 
effect on the TNF-α content Figure 72: 
 
 
 
 
 
 
 
 
 
 
 
Figure 72: LPS+IFN-γ-activated PBMCs treated at the same time (day 0) with NTN and cultured 
during 4 days, no difference was found in the TNF-α production. p=0.67. ∅: Non-statistically significant 
(p> 0.05). 
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When a blocking Ab against GDNF was added to GDNF-treated and activated PBMCs, the 
amount of TNF-α was similar to the non-GDNF treated cells, indicating that the Ab (15 
µg/ml) could block the effect of GDNF, see next figure: 
 
 
 
 
 
 
 
 
 
 
 
Figure 73: Blocking antibody was added to the GDNF-treated sample. After 5 days in culture with 
LPS+IFN-γ, activated PBMCs were 24 hours treated with GDNF (100 ng/ml), then supernatants were 
collected and TNF-α concentration was measured. There was a significant reduction in the soluble TNF-α 
from treated sample (second bar). p<0.005 (∗∗). After addition of GDNF plus 15 µg/ml of blocking antibody, 
the amount of TNF-α did not change (p=0.15). Each bar represents the mean of triplicates, +/- SEM. Results 
were analyzed with the Student Test. ∅: Not statistically significant (p> 0.05). Statistically significant 
∗: p<0.05. 
 
In order to understand whether the reduction of TNF-α concentration after treatment with 
GDNF or NTN was due to an increase in its consumption, an increase in the uptake, or due 
to a reduction of its production, the following experiment was performed: LPS+IFN-γ-
activated PBMCs were cultured during 5 days, then cells were washed with PBS and 
cultured again with fresh medium in the presence or absence of 2,000 pg/ml of human 
recombinant TNF-α, as well as in the presence or in the absence of 100 ng/ml of GDNF. 
After 24 hours, supernatants were taken and TNF-α concentration was measured.  
These data indicated that GDNF had the capacity of reducing TNF-α from the medium; 
see Figure 74: 
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Figure 74: Increased uptake or consumption by LPS+IFN−γ-activated PBMCs? After 6 days in culture 
with LPS+IFN−γ, activated PBMCs were washed and 2,000 pg/ml of human recombinant TNF-α were added 
to the fresh medium in the presence (green bar) or in the absence (second blue bar) of GDNF (100 ng/ml), 
after 24 hours supernatants were collected and measured TNF-α concentration. GDNF treatment resulted in a 
statistically significant reduction in the soluble TNF-α. Each bar represents the mean of triplicates from two 
different wells. +/- SEM. ∗ : p< 0.05. 
 
6.10.3. ELISA-IL-10 
PBMC were stimulated with LPS+IFN-g or with ConA for 6 days and then GDNF or NTN 
was added at a concentration of 100 ng/ml. The supernatants were collected 24 h later and 
the IL-10 content was measured by ELISA. It seems that there was a slight reduction of the 
IL-10 concentration in the supernatants taken from GDNF or NTN-treated cells.  
However, 3 out of 6 experiments did not show any difference (data not shown). 
 
6.10.4. FACS for IL-4 and IFN-γ 
FACS analysis using fluorochrome labeled-mAbs against IL-4 and IFN-γ was performed in 
order to find an effect of GDNF and NTN on the cytokine production of immune cells. 
Non-activated PBMCs, 24 hours and 72 hours LPS+IFN-γ-activated PBMCs were treated 
with either 100 ng/ml or 1 ng/ml of GDNF or NTN, during 2 or 24 hours. Cells were taken 
and processed as described in intracellular staining protocol, and analyzed by FACS.  
All samples were tested in duplicates.  
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Treatment with GDNF or NTN did not change the percentage of cells stained with the anti 
IL-4 or anti-IFN-γ mAbs (data not shown). 
 
6.10.5. FACS: Expression of surface molecules 
The expression of surface molecules that are present in activated lymphocytes or in 
monocytes was measured by FACS analysis using the extracellular staining protocol 
(concentration of isotype controls and mAbs were described in Materials and Methods). 
Specificity of the labeled-Abs tested: HLA-DR, CD25, CD38, CD40, CD69 and CD86. 
GDNF or NTN (100 ng/ml) was added to resting PBMC and to PBMC that had been 
activated with LPS+IFN-g or ConA. FACS analysis performed 24 h later showed that 
GDNF or NTN did not alter the expression of the above mentioned surface markers (data 
not shown). 
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7 DISCUSSION 
 
 
Recent studies have demonstrated that the four members of the GDNF family ligands 
(GFLs) represent the ligands for RET tyrosine kinase receptor, although they do not bind 
RET with high affinity when a ligand binding component, the GFRα receptor, is not 
present (Treanor et al., 1995; Baloh et al., 1997; Trupp et al., 1998). GDNF and NTN play 
crucial roles in the survival and differentiation of various types of neurons, as well as in the 
development of kidneys and the enteric nervous system. 
Few reports have been published about the expression of GFLs and their receptors in 
human immune and hematopoietic cells.  
A putative role of RET in the functional regulation of hematopoietic cells was suggested 
by the presence of RET in lympho-hematopoietic tissues (fetal liver, thymus, spleen and 
lymph nodes) of mice and rats (Tahira et al., 1990; Avantaggiato et al., 1994; Tsuzuki et 
al., 1995), and in two human leukemia cell lines (Takahashi et al., 1985; Tahira et al., 
1990; Takahashi et al., 1991). Subsequently, RET mRNA expression was shown in some 
myelomonocytic, B and T cell leukemia/lymphoma cell lines, although the expression 
levels appear to be higher in myelomonocytic leukemia cells than in T and B cell lines. 
RET mRNA expression increased at later stages of myelomonocytic maturation, suggesting 
that RET may be involved in terminal differentiation of these cells (Gattei et al., 1997). 
Nevertheless, these results were in contrast with another study (Nakayama et al., 1999), 
where the findings suggested that RET may play a role at an intermediate stage of 
myelomonocytic maturation rather than at its terminal stages. This study showed that 
promyelocytes and myelocytes highly expressed RET in comparison to mature neutrophils 
and monocytes, although RET mRNA was also detected in these mature cells.  
However, most of the RET positive leukemia/lymphoma cell lines examined did not 
express GFRα-1, GFRα-2 and GFRα-3, and neither GDNF nor NTN induced RET 
tyrosine-phosphorylation in these cells (Gattei et al., 1997; Nakayama et al., 1999). 
Bone marrow (BM) hemopoietic cells expressed only RET whereas BM adherent cells (or 
stromal cells) expressed GFRα-1, GFRα-2 and GDNF. Soluble GFRα receptors are able to 
mediate GDNF or NTN signaling in cells that express RET but not GFRα. Therefore, it has 
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been speculated that GFRα on the surface of BM stromal cells functions like soluble 
GFRα. Thus, the interaction between BM and stromal cells may induce the formation of 
functional GDNF/RET receptors and may be involved in GDNF signaling and maturation 
of myelomonocytic cells in the BM microenvironment. 
In addition, RET and GFRα-1 mRNAs were also studied in some purified human cell 
populations from healthy donors (Gattei et al., 1997). RET transcripts were amplified from 
CD34+ hematopoietic progenitors taken from peripheral blood and cord blood; higher 
levels were found in circulating neutrophils and adherent CD14+ monocyte/macrophages, 
being further increased upon GM-CSF stimulation. In contrast, circulating eosinophils and 
different T cell sub-sets from peripheral blood, thymus and tonsils did not express RET-
specific mRNA. Cell lines of mature T cell phenotype displayed higher levels of RET 
mRNA than cell lines of post-thymic phenotype, whereas no RET transcripts were found in 
cell lines of the thymic phenotype.  
Similarly, tonsil and peripheral blood CD19+B cells did not express RET mRNA. Most 
tumor B-cell lines encompassing early pre-B to plasma cell differentiation stages were 
either negative or displayed low levels of RET mRNA. No RET expression was detected in 
cell lines derived from erythroid precursors. 
As opposed to RET, transcripts specific for GFRα-1 were never found in any of the normal 
cell types analyzed. Expression of GFRα-1 was very infrequent, being confined to cell 
lines of myelomonocytic type, T cell and B cell phenotype.  
Despite these few preliminary indications, which mostly concerned the expression of RET 
in human lymphohematopoietic cells, and human tumor cell lines, no further reports have 
been published, that examined the expression and/or functions of GDNF family ligands 
and GFRα receptors on immune-hematopoietic cells. This question was analyzed in this 
thesis. 
Discussion 
 
 146
7.1. EXPRESSION OF GDNF 
 
 
The ligand GDNF was not detected in any of the immune cells studied. 
Many attempts were made to search for GDNF in immune cells; however, GDNF was not 
found either at the mRNA (RT-PCR) or at the protein level (Western blot, 
immunoprecipitation, ELISA, intracellular staining and FACS). 
The presence of all the receptors necessary for GDNF/NTN signaling on immune cells 
suggests that also the ligand would be expressed, as it was demonstrated for almost all 
neurotrophins (see Introduction). However, the GDNF family ligands are a different family 
of neurotrophic factors, having different functions on each cell type. In this work, receptors 
for GDNF and NTN were found on immune cells, nevertheless only the ligands NTN 
(mRNA and protein) and PSP (mRNA, preliminary data) were expressed but not GDNF. 
On the other hand, GDNF protein was found in all human sera studied (after acidic 
treatment) and since immune cells are also circulating in the serum, receptors for GFLs on 
immune cells have probably some function after binding GDNF from the surrounding 
environment, such as endothelial cells or other tissues. 
Our present data showing that immune cells do not express GDNF, excludes the possibility 
of a RET/GFRα-1 - GDNF autocrine loop. The presence of the GDNF receptors and the 
absence of ligand could suggest that functional c-RET activation in human mononuclear 
cells could be mediated by the ligand NTN instead of GDNF, since NTN is produced by 
blood mononuclear cells, and it is known that GFRα-1 is able to bind NTN in the absence 
of GDNF under certain conditions. 
In addition, exogenous GDNF can be provided by different microenvironment cell types, 
for example, GDNF and GFRα-1 are produced by bone marrow stromal cells (Gattei et al., 
1997; Gattei et al., 1999), by brain endothelial cells (Igarashi et al., 1999), by normal and 
damaged muscles, and by Schwann cells after nerve inflammation (Yamamoto et al., 
1998). 
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7.2. EXPRESSION OF NEURTURIN 
 
 
This is the first report demonstrating that NTN is expressed at mRNA and at protein levels 
in human immune cells. Some studies have reported that NTN was present in neonatal 
mouse blood and in spleen using Northern blot analysis (Creedon et al., 1997). 
In this work, NTN mRNA expression was detected in all immune cells studied, as shown 
in Figure 19. It was found in PBMCs, activated and non-activated CD4+ and CD8+-T cells, 
activated B lymphocytes and monocytes expressed NTN mRNA.  
NTN protein was detected by Western blot analysis using a polyclonal Ab against human 
NTN, thus confirming the presence of the protein in mononuclear cells, as shown in Figure 
20. 
Also, immunofluorescence using a mouse mAb against human NTN was performed to 
stain intracellular NTN in blood mononuclear cells. The Ab stained intracytoplasmic NTN 
present in non-activated PBMCs as well as in PBMCs activated with different mitogens, 
such as: ConA, LPS+IFN-γ, GM-CSF and PWM. It was possible with this method to 
demonstrate that the amount of NTN was up-regulated markedly after activation in 
comparison to resting states (See Figure 22). 
 
 
 
7.3. EXPRESSION OF PERSEPHIN 
 
Preliminary results from RT-PCR using intron-spanning primers showed that PSP mRNA 
is expressed by PBMCs and activated monocytes. Other sub-types of immune cells will be 
studied in the near future. 
PSP protein expression will be also investigated. 
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7.4. EXPRESSION OF RET RECEPTOR 
 
The transmembrane tyrosine kinase receptor RET, a component of the receptor-complex 
for GFLs was detected at the mRNA and protein level in T cells, B cells, and monocytes. 
The human RET gene contains at least 21 exons and generates several isoforms through 
alternative splicing at the 5’-end and at the 3’-end regions. The 5’-end region encodes the 
extracellular domain of the protein, and the 3’-end region encodes the intracellular domain. 
In this work, a detailed study about all mRNA variants, in each subtype of immune cells 
was performed using RT-PCR with specific primers that were able to amplify each 
isoform. Several already described isoforms of RET were detected in different patterns in 
each subtype of human immune cells. 
At the 5’-end coding region of RET mRNA: 
Three alternatively spliced isoforms due to exon skipping in the 5’-region of the RET gene 
have been described (Lorenzo et al., 1995). 
Full length mRNA (FL): exon 2 linked to exon 3  
3-RET mRNA: exon 3 spliced out 
3,4-RET mRNA: exons 3 and 4 spliced out  
3,4,5-RET mRNA: exons 3, 4 and 5 spliced out 
The full length mRNA is expressed 3 times more abundantly than 3-RET and 3,4-RET 
mRNAs. The 3,4,5-RET mRNA isoform is the least abundantly expressed, only 10% of the 
amount of FL have been found in human fetal kidney (Lorenzo et al., 1995). 
All of them have been expressed in a range of normal human adult tissues: thyroid, adrenal 
glands, kidneys and brain, none of them are tumor-specific variants. 
3-RET and 3,4,5-RET mRNA isoforms adhere to the published open reading frame (ORF) 
and are predicted to encode RET proteins with deletions in the extracellular domain within 
the ligand-binding domain, because part or the entire cadherin domain is removed. 
However, the 3,4-mRNA does not adhere to the published ORF, if this message is 
translated from the initiating ATG codon as published, exon 5 is translated in another 
frame that reaches a stop codon within exon 5 and the translated protein terminates before 
the transmembrane domain, encoding a soluble form of c-RET. 
Recently, new isoforms with variations at the 5’-end of the gene were reported (Fluge et 
al., 2001): 
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Ret 1-8 mRNA: exons 2, 3, 4, 5, 6 and 7 are spliced out 
Ret 2-8 mRNA: exons 3, 4, 5, 6 and 7 are spliced out 
Ret 3-8 mRNA: exons 4, 5, 6, and 7 are spliced out 
Ret 2-3 mRNA: exon 3 is spliced out (already described) 
In the central RET mRNA region encoding the cysteine-rich, transmembrane, and the main 
tyrosine kinase domains no alternative splicing has been detected. 
The results obtained in this work are the following: 
 Resting and activated CD4+-T cells expressed only the 3-RET mRNA isoform 
(exon 3 spliced out, PCR product: 585 base pairs). 
 Resting and activated CD8+-T cells expressed the full length (PCR product: 873 
bp), and two isoforms: 3-RET mRNA (PCR product: 585 base pairs) and 5-RET mRNA 
(PCR product: 677 base pairs). 
 Activated T cell blasts expressed only the full length mRNA. 
 Resting B cells expressed 3-RET mRNA and 5-RET mRNA isoforms, but not the 
full length mRNA. Surprisingly, activated B cells did not express RET mRNAs that 
contained the extracellular domain of the mature RET protein. 
 Resting and activated monocytes expressed only the full length. 
It is important to emphasize the evident difference found between CD4+, CD8+ and 
activated T cell blasts, since all of them are T lymphocytes, but they expressed different 
RET isoforms. Blast cells expressed only the full length; in contrast, mature CD4+ and 
CD8+-T cells are able to express other isoforms, which, when translated, would give rise to 
a different extracellular domains, probably having the capacity to bind different ligands. 
The second largest PCR product, the 5-RET mRNA isoforms (677 base pairs) could be a 
new splice variant, which has not been described. The size could correspond to an isoform 
lacking exon 5. The predicted amino acid sequence would lack 65 amino acids belonging 
to the cadherin-like domain-3 (CLD-3). 
The third PCR product obtained was a band of 585 base pairs, corresponding to the 
isoform in which exon 3 is spliced out (3-RET mRNA). A high number of these transcripts 
were expressed in resting T and B cells, but not in monocytes. This isoform will encode a 
protein lacking 96 amino acids between CLD-1 (aa 28 to 156) and CLD-2 (aa 166 to 272) 
(Anders et al., 2001). The deleted part of the protein does not contain the Ca2+ binding site, 
which is necessary to linearize and rigidify the structure of the entire extracellular domain, 
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and also to promote dimerisation of cadherins, increasing their adhesivity, required for 
RET/GDNF interaction. 
The functional consequences of deletions of each CLD are the following: 
CLD-1 is important for the stabilization and folding of this domain due to the presence of 
hydrogen bonds and a hydrophobic core. Mutations that disrupt RET folding result in 
accumulation of a lower molecular mass isoforms, which is only partially glycosylated and 
does not reach the membrane but is retained in the endoplasmic reticulum, resulting in the 
accumulation of partially processed RET at the expense of the fully matured species. 
Deletion of CLD-1 would induce alterations in the ligand-binding and in receptor 
activation. 
CLD-2 has three Cys residues that form disulfide-bridges. If it is deleted, it could affect the 
stability of the protein, because an unfolded domain would be generated. 
CLD-3 interferes with the folding of this domain, after its disruption decreases the 
structural stability. 
CLD-4 contains two disulfide bonds and they stabilize the folding of this domain. 
The expression of spliced isoforms that vary at the 5’-end indicates that part of the 
extracellular domain of the RET protein is not encoded, therefore interfering with ligand 
interactions. The 3-RET mRNA (exon 3 spliced out) would encode a protein lacking 96 aa 
in the cadherin domain; probably, CD8+-T and B lymphocytes would have differences in 
the ligand binding in comparison with monocytes and activated T cell blasts, which 
expressed the full length transcript (Anders et al., 2001). 
Surprisingly, in activated B cells no PCR product that contained exons from the 5’-end 
region was amplified, probably because exon 6 (or exon 2), where the reverse (or forward) 
primer was located, can also be spliced out. After this part of the study was finished, a 
report describing three new isoforms at the 5’–end region of RET gene was published 
(Fluge et al., 2001): Ret 1-8 mRNA, Ret 2-8 mRNA and Ret 3-8 mRNA. These isoforms 
were expressed in human thyroid carcinoma and in normal thyroid tissue. This finding 
could explain why activated B cells did not express any product. For this reason, new 
primers were designed for exon 2 (forward) and exon 8 in order to detect these recently 
described isoforms. 
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3,4-RET mRNA and 3,4,5-RET mRNA variants, which have been detected in low amounts 
in some human tissues (Ivanchuck et al., 1998), were not expressed in any of the immune 
cells studied. 
 
At the 3’ end coding region of RET gene: 
The RET gene may encode 10 different 3’ termini reflecting three different coding variants 
and four polyadenylation sites (Tahira et al., 1990; Myers et al., 1995; Ivanchuck et al., 
1998). This region encodes the intracellular domain and the COOH terminus of the RET 
protein. The isoforms are the following:  
Short isoform (RET-9) is generated when exon 19 is not spliced to any other exon and 
continues directly downstream with nine further codons, which lie within intron 19. RET-9 
will encode a protein having 9 unrelated amino acids at the C-terminus. 
Long isoform (RET-51) is expressed when exon 19 is spliced directly to exon 20, 
encoding 51 completely different amino acids at the carboxyl terminus. 
Middle isoform (RET-43) occurs when introns 19 and 20, in addition to exon 20 are 
absent, so that exon 19 is directly spliced to exon 21. In this transcript, exon 19 is followed 
by additional 43 codons downstream until a stop codon in exon 21 is reached. RET-43 
encodes a completely different COOH sequence from the first two isoforms described. 
The functional differences between these three isoforms at the C-terminus of RET proteins 
have not yet been well characterized, probably because it depends on the tissue and cell 
type studied, and on the developmental time when they have been investigated.  
During development, RET-9 is essential for development of normal kidneys and normal 
ENS (de Graaff et al., 2001), and probably RET-51 is most important later to induce 
shaping and differentiation of cells (Ivanchuck et al., 1998). 
Another difference is that the long RET-51 but not the shorter RET-9 isoform becomes 
phosphorylated upon stimulation of NGF. Probably, both isoforms may be localized 
differently and that NGF-dependent RET activation occurs specifically in subcellular 
compartments (Weiss et al., 1997).  
RET-9 and RET-51 have different signaling properties in vivo and might define specific 
temporal and spatial requirements of RET functions, which are currently not well 
understood (Myers et al., 1995; de Graaff et al., 2001).  
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In this work, the 3’-end RET mRNA variants described are: the short (RET-9), long (RET-
51) and middle isoform (RET-43) that were amplified by RT-PCR using several primer 
pairs. The identity of each amplified PCR product was confirmed by sequencing. 
The results obtained for each cell type and activation state are the following: 
 Resting CD4+-T cells expressed RET-51 and RET-43 but not the short isoform 
RET-9. Activated CD4+-T cells expressed all isoforms. 
 Resting and activated CD8+-T cells did not express any of the isoforms with 
variations at the 3’-end region. Nevertheless, these cells expressed three isoforms with 
variations at the 5’-end region. 
 Activated T cell blasts expressed all three isoforms. This group of cells contains 
CD4+ and CD8+-T cell blasts. 
 Resting B cells expressed RET-43, but neither RET-9 nor RET-51. Activated B 
cells expressed both, RET-9 and RET-51 isoforms, but not RET-43. 
 Resting and activated monocytes expressed all three isoforms. 
Based on these results, a surprising difference was detected between T lymphocytes, due to 
the fact that CD8+-T cells (both, resting and activated cells) did not express any of the 
isoforms at the 5’-end, in contrast to activated T cells blasts and activated CD4+-T cells, 
which expressed all of them. Probably, the functional responses of CD4+ and CD8+-T 
lymphocytes to GFLs and perhaps to other ligands could be completely different. 
 
Summary of the RET splice isoforms for cell type:  
CD4+-T cells: 
The 3-RET mRNA spliced isoform lacking exon 3 is expressed in both, non-activated and 
activated CD4+-T cells, predicting a deletion in part of the cadherin motif (part of CLD-1 
and part of CLD-2) located in the extracellular domain of the mature protein. Probably, it 
could interfere with the ligand-binding properties of this receptor (Anders et al., 2001). 
From the 3’-end region that codes for the C-terminus, resting and activated CD4+-T cells 
expressed the three isoforms, with the exception of RET-9 in non-activated CD4+-T cells. 
CD8+-T cells: 
Both, non-activated and activated CD8+-T cells expressed the FL and two other isoforms 
that encode for the extracellular domain of the RET protein, indicating that CD8+-T cells 
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are able to bind any of the GFLs because the extracellular domain is intact. Due to 
deletions in the CLD, these cells could confer additional ligand specificities. 
In contrast, they do not express any of the 3 splice isoforms generated at the 3’-end region, 
which encodes for the intracellular domain (probably exons 19 to 21 are spliced out). 
Primers spanning exon 9–18 provided indeed evidence for transcription of the intracellular 
part of c-RET in CD8+-T cells. Studies are on the way to characterize whether there are 
presumably novel splice variants in CD8+-T lymphocytes. 
B cells: 
B cells did not express the full length version of RET from the 5’-end terminus; resting B 
cells expressed the isoforms lacking either exon 3 or exon 5.  
Activated B cells did not express any transcript containing exons from the 5’-end. One 
explanation for this finding could be that exon 6 is not present. If exon 6 is spliced out, no 
PCR product could be amplified with the reverse primer used in this work, which was 
located in exon 6. Also, new primers will be tested on these samples. 
At the COOH-terminus, non-activated B cells expressed only RET-43 (middle isoform); 
however, activated cells expressed both, the short RET-9 and the long RET-51 isoforms. 
Monocytes:  
Both, non-activated and activated monocytes translate the complete extracellular domain at 
the N-terminal because they expressed the FL mRNA. Monocytes can bind any of the 
GFLs through the RET receptor and GFRα. They did not express any alternative variant. 
Monocytes are also able to generate three proteins that differ from each other at the C-
terminus, probably having different functions, which until now have not been described. 
In all RT-PCR reactions using as a template cDNA from human immune cells, RET was 
reliably detected after 35 cycles; this indicates that low levels of RET mRNA are present in 
immune cells, results that are in agreement with other reports, where RET was found in 
human normal monocytes (Gattei et al., 1997; Nakayama et al., 1999; Gattei et al., 1999) 
and in neutrophils (Nakayama et al., 1999), at lower levels when compared with 
myelocytic leukemia cells. Nevertheless, Gattei and colleagues could not detect RET 
mRNA in T or in B lymphocytes taken from normal human peripheral blood using RT-
PCR with primers in exon 7 and 12. These primers amplify a 790 base pairs region 
spanning from the extracellular domain upstream of the cysteine-rich domain to the kinase 
domain downstream of the ATP binding site. 
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In this work, however, using different primers for both end regions, it was demonstrated 
that T and B cells transcribed RET and generated a spectrum of splice variants. Further 
studies have to be done to clarify whether splice variants lacking exon 7 and/or 12 can 
account for the negative results of Gattei (Gattei et al., 1997; Gattei et al., 1999). 
CD8+-T cells expressed very low levels of RET full length; the highest expressed isoforms 
were 3- and 5-RET mRNAs. If exons 6 or 7 are spliced out in these cells, the product 
probably could not be amplified with Gattei’s primers because the length of the amplified 
region is too short to be detected. 
In CD4+-T cells only the variant 3-RET mRNA was detected with our primers (from exons 
2-3 to exon 6): if other alternative splicing occurs, for example, if RET 3-8 mRNA is 
generated (exons 4, 5, 6 and 7 deleted), this isoform would not be amplified and therefore, 
similarly to Gattei et al., was not seen in these cells. But at the C-terminus, the three 
isoforms were present, indicating that RET mRNA was expressed in CD4+-T cells but not 
the full length version. A similar explanation for B cells, in this work B cells did not 
express the FL mRNA, only resting B cells expressed two isoforms which stopped before 
exon 7. If exon 6 and 7 are spliced out our primers would not amplify it as was the case for 
other variants that were not detected by Gattei et al. 
 
At the protein level, Western blotting was performed. RET antibodies used in W. B. 
stained almost all immune cells studied, with the exception of non-activated B cells and 
CD8+-T lymphocytes, because they express only the RET-43 isoform, and the available 
antibodies (pAbs) are directed against the carboxy terminus of either the short (RET-9) or 
the long (RET-51) proteins, but not against the middle form (RET-43). 
There was a notable difference in the signal obtained from neuroblastoma cells (TGW and 
SHSY-5Y) and from immune cells. Larger amounts of protein from immune cells had to 
be loaded (more than 100 µg/lane) in order to detect only a weak signal in comparison with 
neuroblastoma cells (20 µg/lane), shown in Figure 45 and Figure 46. This means that the 
amount of RET protein in immune cells is much lower than in neuroblastoma cell lines, 
which served as positive controls.  
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7.5. EXPRESSION OF GFRα-1 RECEPTOR 
At the mRNA level, GFRα-1 transcripts were present in low amounts in all immune cells 
studied. The PCR products were seen only after 38–40 amplification cycles, indicating 
indirectly that the number of GFRα-1 mRNA transcripts is relatively low. 
In agreement with our results, Yamamoto (Yamamoto et al., 1998) has reported that 
mRNA levels of GFRα-1 were elevated to variable extents (in addition to RET and 
GDNF) in various nerve biopsies from patients with peripheral neuropathies, and they 
found that there is a significant correlation between the extent of inflammatory cell 
invasion, such as T cells and macrophages infiltrates, and levels of GFRα-1 mRNA. 
Honda et al. (Honda et al., 1999) have found GFRα-1 mRNA and protein in rat cultured 
microglia. GFRα-1 was able to phosphorylate RET in the presence of GDNF. Because 
microglia in the CNS is related to monocytes in the peripheral blood, it is probable that 
both cell types express similar receptors.  
On the contrary, another publication (Gattei et al., 1997) did not find GFRα-1 mRNA 
expression in human peripheral T and B lymphocytes using RT-PCR. They used only 35 
cycles for their RT-PCR reactions, which may not be sufficient to amplify low numbers of 
GFRα-1 transcripts. 
One spliced isoform of this gene has been described, lacking 15 base pairs in exon 5. Even 
though the primers used were located in the appropriate region of the gene, this small 
difference between both isoforms would not have been detected on agarose gels. 
Nevertheless, no functional differences have been described between them. 
 
At the protein level, the GFRα-1 receptor was detected using extracellular staining and 
FACS with a primary non-labeled mAb. The surfaces of small lymphocyte sub-populations 
of non-activated and activated PBMCs, mainly after LPS+IFN-γ activation were positively 
stained, and the strongest expression was seen in monocytes (activated and non-activated). 
In ConA-activated PBMCs, a reduction in the percentage of GFRα-1 expressing cells over 
time was found. Nevertheless, a low mRNA expression in these cells was observed in 
different experiments. 
The positively stained lymphocytic population expressing GFRα-1 on the surface (~ 10%) 
in Figure 52 disappeared after ConA stimulation (Figure 55). After 96 hours of ConA 
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activation, more than 95% of the PBMCs are activated T cell blasts (CD3+-T cells). Since 
GFRα-1 is a GPI-linked receptor that can be cleaved from the cell surface by the action of 
the PI-PLC enzyme, the receptor may remain in a soluble form in the medium or may bind 
to the extracellular matrix or to the surface of neighboring cells, which happen to bind 
GFLs as well. This theory could explain why activated T cells are positive for GFRα-1 
mRNA but not the receptor protein on the cell surface, as the receptor may rapidly be 
cleaved (Paratcha et al., 2001). 
Because of this, it would be interesting to detect GFRα-1 protein in the supernatant of 
activated- and non-activated T cells in culture, e.g. with an ELISA for GFRα-1. 
 
 
 
7.6. EXPRESSION OF GFRα-2 RECEPTOR 
GFRα-2, the specific receptor for NTN, was studied at the mRNA level by RT-PCR. 
In this work, amplification reactions were performed using primers spanning exons 1 to 5, 
which can detect all spliced isoforms described. 
In our experiments, only the full length and two spliced variants were detected in immune 
cells. The following PCR products were obtained: 
GFRα-2a: full length (PCR product: 851 base pairs) 
GFRα-2b: exon 2 spliced out (PCR product: 537 base pairs). It has a deletion of 315 bp 
(entire exon 2), the deduced amino acid sequence is identical to GFRα-2a (full length) 
except for the 105 amino acid deleted at the N-terminus of the protein, that contains eight 
Cys residues and a single glycosylation site. 
Exon 1-4 mRNA: exon 2 and exon 3 spliced out (PCR product: 453 base pairs) generating 
a deletion of 399 base pairs from the full length GFRα-2a. The resultant transcript is 
predicted to encode a protein of 331 amino acids that would not contain the N-terminal 
Cys-rich domain of the protein and one N-glycosylation site. The deleted protein region is 
not critical for binding of NTN and RET to GFRα-2 and does not determine the specificity 
of interactions of GFRα and GFLs (Scott and Ibanez, 2001). 
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The mammalian GFRα-4 completely lacks the corresponding Cys-rich domain (Masure et 
al., 1998), suggesting functional similarities between GFRα-4 and the shortened form of 
GFRα-2 (Exon 1-4 mRNA) (Lindahl et al., 2000; Scott and Ibanez, 2001). 
The results obtained from immune cells are the following:  
- The full length GFRα-2a (851 bp) was expressed in non-activated and in LPS-
activated monocytes, as well as in LPS+IFN-γ-activated PBMCs. 
- The GFRα-2b isoform (537 bp) was expressed at low levels in TGW cells, in 
activated PBMCs and in non-activated monocytes. 
- The isoform Exon 1-4 mRNA (453 bp) was found in all immune cells studied. This 
isoform was expressed in activated and non-activated PBMCs, in activated and non-
activated CD4+-T cells, PHA-activated CD8+-T cells, ConA-activated T cell blasts and in 
TGW. In non-activated B cells, the expression was very low, i.e. almost undetectable with 
35 cycles of amplification.  
Other reports (Wong et al., 1998; Wong et al., 2002) have shown that in mouse brain the 
most abundant isoform of GFRα-2 mRNA was the full length GFRα-2a, but probably the 
differences are due to the different tissues investigated. The authors detected GFRα-2 
variants in human and murine whole brain tissue and found that the most prominent 
mRNA transcripts were the GFRα-2a full length and the least abundant isoforms detected 
was the Exon 1-4 mRNA variant, but this isoform is designated by them as GFRα-2c, 
because they did not find mRNA transcripts in which exon 3 is spliced out.  
In this work, GFRα-2c is referred to as the spliced isoform lacking exon 3 (Vanhorne et 
al., 2001). 
 
At the protein level, it was at first difficult to clearly demonstrate the presence of the 
GFRα-2 receptor by Western blot using two different pAbs against human GFRα-2. 
Subsequently, a goat anti-human GFRα-2 was used to stain the extracellular surface of 
fresh PBMCs, followed by FACS analysis. The results demonstrated that approx. 8% of 
lymphocytes and 9% of monocytes stained positively for GFRα-2 (see Figure 60 and 
Figure 61, respectively). 
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7.7. FUNCTIONAL EXPERIMENTS 
To investigate whether GFLs receptors (GFRα-1, GFRα-2 and c-RET) are functional on 
human immune cells, several assays were performed in non-treated and GDNF- or NTN-
treated cells. Most of them did not show any difference in proliferation assays, IL-4 and 
IFN-γ production and modulation of surface molecules (HLA-DR, CD40, CD69, and 
CD83). 
On the contrary, GDNF and NTN did have an effect on the TNF-α concentration of 
supernatants from activated immune cells.  
Supernatants from ConA activated T cell blasts and LPS+IFNγ-activated PBMCs cultured 
for 5 or 6 days, followed by treatment with GDNF or NTN (100 ng/ml) for 24 hours 
induced a significant reduction of the TNF-α concentration when compared with non-
treated cells, as measured by ELISA. Whether the reduction of TNF-α after the treatment 
was due to an increase in its consumption, an increase in the uptake, or a reduction of 
production was addressed by the following experiment: to PBMCs, which had been 
activated for 5 days before being washed with fresh medium, a constant amount of human 
recombinant TNF-α (2,000 pg/ml) was added. Then, cells were incubated either in the 
presence or in the absence of GDNF or NTN for 24 hours. After this time, TNF-α levels 
were measured. The result was that GDNF and NTN were able to reduce the amount of 
TNF-α from the SN of treated samples, suggesting that an increase in the uptake or in the 
consumption, instead of a reduced production was caused by GDNF and NTN. Further 
experiments should be done to fully understand which mechanisms underlie this finding.  
 
 
 
7.8. MYOBLASTS 
In collaboration with Dr. G. Chevrel, we have examined the presence of GDNF, GFRα-1 
and c-RET on human normal myoblasts in culture. We report that GDNF is not expressed 
by myoblasts contrary to its receptors GFRα-1 and RET. GDNF was not expressed by 
myoblasts even after stimulation by inflammatory cytokines such as interleukin-1β or 
interferon-γ. We did not find any effect of GDNF on the induction of the proliferation of 
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myoblasts. GDNF could be a factor implicated in muscle repair but its action on myoblasts 
is still unknown. 
Results from RT-PCR analysis of myoblast cDNA showed the expression of GFRα-1, see 
Figure 64.  
RET large and short isoforms were also expressed by human myoblasts, shown in Figure 
65. The presence of RET protein in myoblasts was also confirmed by Western blot 
analysis, Figure 66. 
No effect of GDNF was found on the proliferation of myoblasts (data not shown). 
The classical concept suggests that GDNF is involved in the survival of the motoneurons, 
which have established contact with their target muscles. RT-PCR analyses have shown 
that GFRα−1  mRNA is expressed in the ventral horn of human spinal cord, but not in the 
skeletal muscles. In contrast, GDNF mRNA was detected in normal skeletal muscles, but 
not in the ventral horn, and its expression was up-regulated in regenerating muscle fibers 
(Suzuki et al., 1998) of two different muscle diseases, namely inflammatory PM and 
degenerative DMD. 
In order to avoid contamination by other cells, we studied the expression of GDNF and its 
receptors, GFRα−1 and RET  on normal human myoblasts. Indeed, the preparation of 
muscle tissue that is not contaminated by nerve and other cell types is difficult, and it 
cannot be excluded that cell types other than muscle cells, such as blood vessels or 
Schwann cells that also express GDNF. We found that GFRα-1 and RET are expressed on 
myoblasts but not GDNF. The presence of GDNF receptors indicates that human 
myoblasts may be a target for GDNF. The action of GDNF on myoblasts or muscles 
remains unclear. One possibility could be the induction of repair mechanisms in muscles 
after destruction or inflammation. Indeed, myoblasts derive from satellite cells of muscle 
tissue, which suggests their involvement in such repair processes. 
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8 CONCLUSIONS 
 
While GDNF, the prototype of this family, was not expressed by any of the studied human 
immune cells, the related molecule Neurturin (NTN) was found to be expressed by T and 
B cells and monocytes as seen by RT-PCR, Western blot and immunofluorescence. NTN 
protein was up-regulated after cell activation.  
Additionally, Persephin (PSP), another member of the GFLs was also detected at the 
mRNA level in activated PBMCs, activated monocytes and CD4+-T lymphocytes 
(preliminary results). 
RET, the transmembrane receptor was expressed in all human immune cells studied. 
Several alternatively spliced RET transcripts are frequently present in immune cells. 
Different cells expressed distinct isoforms:  
- In T and B cells, the isoforms related the 3’-end region were regulated by activation. 
- Various RET spliced variants may affect the ligand-interacting and / or downstream 
signaling properties of the receptor. 
- Isoforms related to the 5’-end affects the ligand interaction sites in the extracellular 
domain of the predicted protein. 
- CD4+ and CD8+-T lymphocytes showed distinct expression patterns of RET isoforms. 
- A new isoform lacking exon 5 was detected (partial deletion of CDL-2 in the 
extracellular domain). 
- Monocytes expressed only the full length mRNA indicating their responsiveness to all 
GFLs. 
Immune cells also expressed the surface receptors GFRα-1 and GFRα-2 that 
preferentially bind NTN. The full length and one isoform of GFRα-2 were detected in 
different cell types by RT-PCR.  
The most abundant isoform in T cells and monocytes lacked exons 2 and 3 (Exon 1-4 
mRNA); the predicted protein lacks a region not critical for binding of NTN and 
interaction with RET. Additionally, GFRα-2 protein was detected on the surface of 
immune cells by FACS analysis (extracellular staining). 
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Functional finding: TNF-α was regulated in PBMCs by both GDNF and NTN, after 
activation by LPS+IFN-γ or by ConA. A reduced amount of TNF-α probably was due to 
an increased uptake or consumption rather than a reduced production. 
All components of the GDNF and NTN receptor complex (GFRα-1, GFRα-2 and RET), 
but not the ligand GDNF, are expressed by immune cells, indicating that these cells are 
receptive for GDNF and NTN mediated signaling, specifically for GDNF family ligands 
supplied by neurons that may be involved in neuro-immune communication, as well as 
GFLs derived from peripheral blood mononuclear cells, such as NTN and PSP, and bone 
marrow stromal cells. We could speculate that immune cells may communicate via NTN 
and PSP with other cells in a paracrine fashion, or within a restricted immune cell 
microenvironment using an autocrine loop.It might be possible that the up-regulation or 
down-regulation of these receptors on immune cells is important in some pathological 
situations, in which both, nervous and immune systems are in close relation (i.e., CNS 
inflammation, neuromuscular autoimmune diseases: demyelinating neuropathies, 
Myasthenia gravis, polymyositis, etc.). 
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10 APPENDICES 
10.1. ABBREVIATIONS 
aa amino acid 
Ab Antibody 
Ag Antigen 
ALL Acute Lymphoid Leukemia 
AML Acute Myeloid Leukemia 
ART Artemin 
BM Bone Marrow 
BMAC Bone Marrow Adherent Cells 
bp base pairs 
BSA Bovine Serum Albumin 
CLD-1/4 Cadherin Like Domain-1 to 4 
c-RET RET transmembrane receptor 
CNS Central Nervous System 
ConA Concanavalin A 
Cys Cysteine 
DA DopAmine 
DAPI DiAmino-2-PhenylIndole 
DMEM Dulbecco's Modified Eagle Medium 
DMSO DiMethylSulfOxide 
DRG Dorsal Root Ganglia 
DTT DiThioThreitol 
ECS ElectroConvulsive Seizures 
EDTA EthylenDiaminTetrAcetate 
ELISA Enzyme Linked ImmunoSorbent Assay 
ELISPOT ELISA SPOT assay 
ENS Enteric Nervous System 
FACS Fluorescence Assisted Cell Sorting 
FCS Fetal Calf Serum 
FITC Fluoresceine IsoThioCyanate 
F.L Full Length mRNA 
FL1 Fluorescence 1 
FSC Forward SCatter 
GDNF Glial cell line–Derived Neurotrophic Factor 
GFLs GDNF Family Ligands 
GFRα GDNF Family of Receptors alpha 
GFRα-1 GDNF Receptor α-1 
GFRα-2 GDNF Receptor α-2 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor 
GPI Glycosyl-PhosphatidylInositol 
HL-60 Promyelocytic leukemia cell line 
HRP HorseRadish Peroxidase 
HRSD Hirschsprung Disease 
IFN-γ Interferon-γ 
Ig Immunoglobulin 
IL-1 Interleukin-1 
IL-2 Interleukin-2 
IL-10 Interleukin-10 
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kb kilo base 
kDa kilo Daltons 
LPS LipoPolySaccharide 
mAb monoclonal Antibody 
MAP-K Mitogen-Activated Protein Kinase 
MES 2-(N-Morpholino) Ethane Sulfonic acid 
MN MotoNeurons 
MOPS 3-(N-Morpholino) Propane Sulfonic acid 
MPTP 1-Methyl-4-Phenyl-1,2,3,6-TetrahydroPyridine 
NGF Nerve Growth Factor 
NT NeuroTrophins 
NTN NeurTuriN 
O.N Over-Night 
pAb polyclonal Antibody 
PBMC Peripheral Blood Mononuclear Cells 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PD Parkinson’s Disease 
PE PhycoErythrin 
PFA ParaFormAldehyde 
PHA PhytoHemAgglutinin (from Phaseolus vulgaris red kidney bean) 
PI3-K Phosphatidyl-Inositol 3-Kinase 
PI-PLC Phosphatidyl-Inositol PhosphoLipase C 
PWM PokeWeed Mitogen 
PMA Phorbol 12-Myristate 13-Acetate 
PMSF PhenylMethylSulfonyl Fluoride 
PSP Persephin 
PTC Papillary Thyroid Carcinoma 
PTK Protein Tyrosine Kinase 
PVDF PolyVinylDeneFluoride 
RET-9 RET short isoform 
RET-43 RET middle isoform 
RET-51 RET long isoform 
rpm rounds per minute 
RT Room Temperature 
RT-PCR Reverse Transcriptase - PCR 
RTK Receptor Tyrosine Kinase 
SAC Staphylococcus Aurous Cowan A 
SCG Superior Cervical Ganglia 
SDS Sodium-DodecylSulfate 
SEM Standard Error of the Mean 
SHSY-5Y human neuroblastoma cell line 
SN SuperNatant 
SSC Side SCatters 
TBS Tris Buffered Saline 
TGF-β Transforming Growth Factor-beta  
TGW human neuroblastoma cell line 
THP-1 human monocytic leukemia cell line 
TMB 3,3',5,5'-TetraMethylBenzidine 
TNF-α Tumor Necrosis Factor-alpha 
Tyr Tyrosine 
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